Amendmen t
P ro toco l  Numbe r : 12C0074 -H
P r inc ipa l  Inves t iga to r :Jen  Kana k r y   NC I   ET IB   301 .451 .3787   jenn i fe r . kana k r y@n ih .go v
(N IH  Emp lo yee  Name ,  In s t i tu te /B ran ch ,  Te lephone  and  e -ma i l )Re fe rence  Numbe r : 373683
P ro toco l  T i t le :Mob i l i za t ion  and  Co l le c t ion  o f  Au to logou s  Hema topo ie t i c  P rogen i to r  Ce l l  (HPC )  fo r  T ran sp lan ta t ion  (AHCT )  fo r  P la sma  Ce l l  M ye loma
(PCM )
S IGNATURES
P r in c ipa l  In ve s t iga to r  ( * ) :  
Dan ie l  Fow le r  -  app l ied  s igna tu re  on  09 /22 /2017  2 :16  PM  EDT  
Jen  Kana k ry  -  a ppl ied  s i gna tu re  on  09 /22 /2017  11 :39  AM  EDT
A c coun tab le  In ve s t iga to r :
Rona ld  G re s s  -  appl ied  s i gna tu re  on  09 /22 /2017  12 :17  PM  EDT
B ran ch  Ch ie f /CC  Depa r tmen t  Head  ( * * ) :
Rona ld  G re s s  -  appl ied  s i gna tu re  on  09 /22 /2017  12 :18  PM  EDT
Med i ca l  Ad v i so r y  In ve s t iga to r  ( i f  app l i cab le ) :
N /A
Lead  A s so c ia te  In ve s t iga to r  s igna tu re :
N /A
Re fe r ra l  Con ta c t  s igna tu re s :
Jen  Kana k ry  -  a ppl ied  s i gna tu re  on  09 /22 /2017  11 :39  AM  EDT
A s so c ia te  In ve s t iga to r s  s igna tu re s :
N /A
Fo r  In s t i tu te /Cen te r  S c ien t i f i c  Re v iew  Comm i t tee :
N /A
O the r  IC  C l in i ca l  D i re c to r  s igna tu re s :
N /A
APPROVALS
IRB  Cha i r :
M i chae l  Ham i l ton  -  app l ied  s igna tu re  on  09 /23 /2017  1 :18  PM  EDT
C l in i ca l  D i re c to r :
N /A
CONCURRENCE
OPS  P ro to co l  Spe c ia l i s t :
S igna tu re P r in t  Name Da te
*  S igna tu re  s ign i f ie s  tha t  in ve s t iga to r s  on  th i s  p ro to co l  ha ve   been  in fo rmed  tha t  the  co l le c t ion  and  u se  o f  pe r sona l l y   iden t i f iab le  in fo rma t ion  a t
the  N IH  a re  ma in ta ined  in  a  s y s tem  o f  re co rd  go ve rned  unde r  p ro v i s ion s  o f  the  P r i va c y  A c t  o f  1974 .  The  in fo rma t ion  p ro v ided  i s  manda to r y  fo remp lo yee s  o f  the  N IH  to  pe r fo rm  the i r  a s s igned  du t ie s  a s  re la ted  to  the  adm in i s t ra t ion  and  repo r t ing  o f  in t ramu ra l  re sea r ch  p ro to co l s  andu sed  so le l y  fo r  tho se  pu rpo se s .   Que s t ion s  ma y  be  add re s sed  to  the  P ro t ra k  S y s tem  Owne r .
* *  I  ha ve  re v iewed  th i s  re sea r ch  p ro je c t  and  con s ide red  the  N IH  Po l i c y  fo r  In c lu s ion  o f  Women  and  M ino r i t ie s  in  C l in i ca l  Re sea rch .  Ta k ing  in to  
a c coun t  the  o ve ra l l  impa c t  tha t  the  p ro je c t  cou ld  ha ve  on  the  re sea r ch  f ie ld  in vo l ved ,  I  fee l  the  cu r ren t  p lan s  adequa te l y  in c lude s  bo th  se x /gende r ,  m ino r i t ie s ,  ch i ld ren ,  and  spe c ia l  popu la t ion s ,  a s  app rop r ia te .  The  cu r ren t  en ro l lmen t  i s  in  l ine  w i th  the  p lanned  en ro llmen t  repo r t  fo r  in c lu s ion  o f  ind i v idua l s  on  the  ba s i s  o f  the i r  se x /gende r ,  ra ce ,  and  e thn i c i t y  and  i s  app rop r ia te  and  o f  s c ien t i f i c  and  te chn i c a l  me r i t .  
IRB  Mee t ing  Da te : E xped i ted
DEC  C lea rance  Da te : 09 /22 /2017
P ro toco l  Ve rs ion  Da te :09 /14 /2017Lemue l  C la ybo rn                                                                              AM  H                                                      10 /04 /2017
A bb r e v i a t e d  T i t l e :  HPC  f o r  AHCT  in  PCM   
V e r s io n  d a t e :  S e p t em b e r  14,  20 17  
  
                                                                                                                                          P ag e  1 o f  38  Abb r e v ia t ed  T i t l e : HPC  f o r  AHCT  in  PCM 
CC P r o t o c o l  Numb e r :  1 2 -C - 0 0 7 4  NCT # :  NCT 0 1 5 4 7 8 0 6 
V e r s ion  D a t e :  S ep t emb e r  1 4 ,  2 0 1 7   
Am endm en t :  H 
 
P r o t o c o l  T i t l e:  Mo b i l i z a t io n  a n d  Co l l e c t io n  o f  A u to lo g o u s  H em a to p o i e t i c  P r o g e n i to r  C e l l  
( HPC)  f o r  T r a n sp l a n t a t io n  ( AHCT)  f o r  P l a sm a  C e l l  My e lom a  ( PCM)  
 
NC I  P r in c ipa l  Inv e s t ig a t o r :              J e n n i f e r  A .  K a n a k ry ,  M .D
 A -F 
          E xp e r im e n t a l  T r a n sp l a n t a t io n  a n d  Immu n o logy  B r a n c h           C e n t e r  f o r  C a n c e r  R e s e a r c h ,  NC I             1 0  C e n t e r  D r iv e ,  B u i ld in g  1 0 ,  Rm  4 - 3 1 3 2           B e th e sd a ,  MD  2 0 8 9 2            Ph o n e :  2 4 0 - 7 6 0 - 6 1 7 2                                                               F a x :  ( 3 0 1 )  4 5 1 - 5 6 6 7           Em a i l :  j e n n i f e r . k a n a k ry@ n ih . g o v  
 
N IH  A s so c ia t e  Inv e s t iga t o r s:  
D a n i e l e  A v i l a ,  C .R .N .P. ,  E T IB ,  CCR  
A- E D e n n i s  H i c k s t e in ,  MD. ,ET IB ,  CCR  A- F 
B a z e t t a   B l a c k lo c k   S c h uv e r ,   R .N. ,  OCD ,   CCR 
A -C  E l l e n  C a r r o l l ,  R .N . , OCD ,  CCR A- C 
T r a c ey  Ch in n ,  R .N. ,  ET IB ,  CCR  A- C  J e r emy  Ro s e ,  M .S,  ET IB ,  CCR  E- F 
Co n s t a n c e  Y u a n ,  M .D . ,  Ph .D ,  CCR  E- F J e n n i f e r  M a n n ,  C .R .N .P . ,  ET IB ,  CCR  A- E 
Ro n a ld  E .  G r e s s ,  M .D. ,  ET IB ,  CCR  A- F S t e v e n  P a v l e t i c ,  M .D. ,  ET IB ,  CCR  A- F 
F r a n  H a k im ,  Ph .D,  ET IB ,  CCR  E- F S e th  S t e in b e r g  Ph .D . , OCD ,  CCR B ,  E 
B r e n n a  H a n s e n ,  R .N . , OCD ,  CCR A- C M a ry a l i c e  S t e t l e r- S t e v e n so n ,  M .D . ,  PhD. , CCR 
B ,  E-F.4 
 S te p h a n i e  Co t to n ,  R .N . ,  OCD ,  CCRA- C D a v id  S t r o n c e k ,  M .D. ,DTM ,  CCRE- F 
 
R e f e r r a l  c on t a c t : J e n n i f e r  K a n a k ry ,  M .D .  
                             T e l e p ho n e :  2 4 0 - 7 6 0 - 6 1 7 2  
         Em a i l :  j e n n i f e r . k a n a k ry@ n ih .g o v  
 
                                 
S tudy  C o o rd ina t o r :   B a z e t t a  B l a c k lo c k  S c h u v e r,  RN  
                                        Ph o n e  n umb e r :  2 4 0 - 7 6 0 - 6 15 6  
                                     Em a i l :  b b l a c k lo c k@m a i l . n ih . g o v 
F o r  e a c h  p e r so n  l i s t e d  a bo v e ,  r o l e s  a r e  id e n t i f i e d  w i th  th e  a p p r o p r i a t e  l e t t e r  
A . O b t a in  in f o rm a t io n  by  in t e r v e n ing  o r  in t e r a c t ing  w i th  l iv in g  in d iv id u a l s  f o r  r e s e a r c h  p u r p o s e s  
B . O b t a in in g  id e n t i f i a b l e  p r iv a t e  in f o rm a t io n  a b o u t  l iv in g  in d iv id u a l s 
A bb r e v i a t e d  T i t l e :  HPC  f o r  AHCT  in  PCM   
V e r s io n  d a t e :  S e p t em b e r  14,  20 17  
  
                                                                                                                                          P ag e  2 o f  38  C . O b t a in in g  th e  v o lu n t a ry  in f o rm e d  c o n s e n t  o f  in d iv id u a l s  to  b e  su b j e c t s  
D . M a k e s  d e c i s io n s  a b o u t  su b j e c t  e l ig ib i l i ty 
E . S tu dy ing ,  in t e r p r e t ing ,  o r  a n a ly z ing  id e n t i f i a b l e  p r iv a t e  in f o rm a t io n  o r  d a t a / sp e c im e n s  f o r  
r e s e a r c h  p u r p o s e s  
F . S tu dy ing ,  in t e r p r e t ing ,  o r  a n a ly z ing  d e -id e n t i f i e d  d a t a  o r  sp e c im e n s  f o r  r e s e a r c h  p u r p o s e s  
G . Som e / a l l  r e s e a r c h  a c t iv i t i e s  p e r f o rm e d  o u t s id e  N IH 
 
Inv e s t ig a t iona l  A g en t s :  N o n e   
C omm e r c ia l  A g en t s : F i lg r a s t im  and  P l e r ix a fo r  
  
 
A bb r e v i a t e d  T i t l e :  HPC  f o r  AHCT  in  PCM   
V e r s io n  d a t e :  S e p t em b e r  14,  20 17  
  
                                                                                                                                          P ag e  3 o f  38   
PRÉC IS 
Ba c k g round :   
•  H ig h- d o s e  c h emo th e r a py  f o l low e d  by  a u to lo g o u s  h em a to p o i e t i c  c e l l  t r a n sp l a n t  
(A HCT )  r em a in s  a  c r i t i c a l  p a r t  o f  th e  P l a sm a  C e l l  My e lom a  (PCM )  t r e a tm e n t  in  
su b j e c t s  e l ig ib l e  f o r  th e  p r o c e d u r e .  T h e  t im in g  o f  th e  p r o c e d u r e  h ow e v e r ,  h a s  b e c om e  mo r e  c o n t r o v e r s i a l  r e c e n t ly .   T h i s  p r o to c o l  w i l l  a l low  c o l l e c t io n  o f  H em ato p o i e t i c  P r o g e n i to r  C e l l s  by  A p h e r e s i s  (HPC ,  A p h e r e s i s )  in  p o t e n t i a l  c a n d id a t e s  f o r  v a r io u s  PCM  p r o to c o l s  a t  th e  C l i n i c a l  C e n t e r . 
•  T h e  mo b i l i z in g  a g e n t  p l e r ix a f o r  (Mo zo b i l® ,  G e n z ym e )  h a s  b e e n  r e c e n t ly  ap p r o v e d  
by  th e  FDA  f o r  mo b i l i z a t io n  in  PCM .  H ow e v e r ,  th e  b e s t  a n d  mo s t  c o s t  e f f e c t iv e  s t r a t egy  f o r  i t s  u s e  r em a in s  to  b e  d e f in e d .  
O b j e c t i v e s : 
•  E v a lu a t e  th e  o v e r a l l  v a l id i ty  o f  a n  HPC  mo b i l i z a t io n  s t r a t e gy  (w i th  G-CSF  a lo n e  o r  in  
c omb in a t io n  w i th  p l e r ix a f o r )  u s ing  a  f o rmu l a  c a l cu l a t in g  th e  l ik e l ih o o d  o f  c o l l e c t in g  
≥ 5  x  1 0
6 CD 3 4+ c e l l s /k g  in  a  s in g l e  mo b i l i z a t io n  cy c l e .   
•  Co l l e c t  mo b i l i z e d  H em a to p o i e t i c  P r o g e n i to r  C e l l s  by  A p h e r e s i s  (HPC ,  A ph e r e s i s ) 
p r io r  to  AHCT f o r  PCM  
E l ig ib i l i t y : 
•  Su b j e c t s  w i th  a  p o s s ib l e  in d i c a t io n  f o r  AHCT f o r  th e  t r e a tm e n t  o f  n ew ly  d i ag n o s e d  
PCM . 
•  Su b j e c t s  w i th  r e c u r r e n t  o r  p e r s i s t e n t  e v a lu a b l e  d i s e a s e  w h o  h a v e  n o t  u n d e rg o n e  
AHCT f o r  th e  t r e a tm e n t  o f  th e  PCM .  
D e s ign:  
•  Su b j e c t s  w i l l  u n d e r g o  mo b i l i z a t io n  a n d  c o l l e c t io n  o f  HPC ,  A p h e r e s i s  f o r  su b s e q u e n t  
u s e  in  v a r io u s  c l in i c a l  p ro to c o l s .  
•  Mo b i l i z a tio n  w i l l  b e  p r o v id e d  by  a  5 - d a i ly  a dm in i s t r a t io n  o f  f i lg r a s t im  a c co r d in g  to  
s t a n d a r d  p r o c e d u r e .  
•  T h e  n e e d  f o r  a n  a d d i t io n a l  mo b i l i z in g  a g e n t  ( p l e r ix a f o r )  to  b e  g iv e n  o n  d ay  4 o f  
mo b i l i z a t io n  w i l l  b e  e v a lu a t e d  in  r e a l  t im e  in  e a c h  p a t i e n t ,  b a s e d  o n  th e  p e r iph e r a l  
b lo o d  CD 3 4  c o u n t  o n  th e  mo r n in g  o f  d ay  4  o f  f i lg r a s t im  a dm in i s t r a t io n .  
•  S tu dy  a c c r u a l  o v e r  a  3-y e a r  p e r io d :  7 0  su b j e c t s  
 
 
A bb r e v i a t e d  T i t l e :  HPC  f o r  AHCT  in  PCM   
V e r s io n  d a t e :  S e p t em b e r  14,  20 17  
  
                                                                                                                                          P ag e  4 o f  38   
TABLE  OF  CONTENTS 
PRÉC IS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  3  
TABLE  OF  CONTENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  4  
1 INTRODUCT ION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  7  
1 . 1 STUDY  OB JECT IVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  7  
1 . 1 . 1 P r im a r y  O b j e c t i v e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  7  
1 . 1 . 2 S e c o n d a r y  O b j e c t i v e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  7  
1 . 2 BACKGROUND  AND  RAT IONALE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  7  
1 . 2 . 1 O v e r v i ew  o f  T r e a tm e n t  o f  MM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  7  
1 . 2 . 2 AMD 3 1 0 0  (P l e r i x a fo r ,  Mo zo b i l™ ,  G e n z ym e )  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  8  
1 . 2 . 3 E v a lu a t e  th e  n e e d  fo r  s y s t em a t i c  u s e  o f  P l e r i x a fo r  o n  d a y  4  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  9  
1 . 2 . 4 E v a lu a t io n  o f  m in im a l  r e s id u a l  d i s e a s e  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 0  
1 . 2 . 5 La c k  o f n e e d  fo r  p u rg in g  o f  HPC ,  A p h e r e s i s  p ro d u c t  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 1  
1 . 2 . 6 U t i l i za t io n  o f  HPC  p ro d u c t s  in  NC I  p ro to c o l s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 1  
2 EL IG IB IL ITY  ASSESSMENT  AND  ENROLLMENT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 2  
2 . 1 EL IG IB IL ITY  CR ITER IA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 2  
2 . 1 . 1 I n c lu s io n  C r i t e r ia  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 2  
2 . 1 . 2 E x c lu s io n  C r i t e r ia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 2  
2 . 1 . 3 R e c ru i tm e n t  s t ra t e g y . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 3  
2 . 2 SCREEN ING  EVALUAT ION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 3  
2 . 2 . 1 H i s to r y  a n d  P h y s i c a l  e x am in a t io n  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 3  
2 . 2 . 2 La b o ra to r y  e v a lu a t io n  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 3  
2 . 3 REG ISTRAT ION  PROCEDURES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 3  
3 STUDY  IMPLEMENTAT ION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 3  
3 . 1 STUDY  OVERV IEW . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 3  
3 . 2 TREATMENT  SCHEMA  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 4  
3 . 3 DRUG  ADM IN ISTRAT ION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 5  
3 . 3 . 1 F i lg ra s t im  a dm in i s t ra t io n . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 5  
3 . 3 . 2 P l e r i x a fo r  A dm in i s t ra t io n . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 6  
3 . 3 . 3 A p h e r e s i s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 6  
3 . 3 . 4 I n a d e q u a t e  c o l l e c t io n  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 7  
3 . 3 . 5 S a l v a g e  c o l l e c t io n  r e g im e n  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 7  
3 . 4 DOSE  MOD IF ICAT IONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 7  
3 . 5 STUDY  CALENDAR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 8  
3 . 6 OFF  STUDY  CR ITER IA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 8  
3 . 6 . 1 C r i t e r ia  fo r  r em o v a l  f rom  p ro to c o l  th e ra p y . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 8  
3 . 6 . 2 O f f- S tu d y  C r i t e r ia  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 8  
3 . 6 . 3 O f f  P ro to c o l  Th e ra p y  a n d  O f f  S tu d y  P ro c e d u r e  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 9  
4 CONCOM ITANT  MED ICAT IONS /MEASURES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 9  
5 B IOSPEC IMEN  COLLECT ION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 9  
A bb r e v i a t e d  T i t l e :  HPC  f o r  AHCT  in  PCM   
V e r s io n  d a t e :  S e p t em b e r  14,  20 17  
  
                                                                                                                                          P ag e  5 o f  38  5 . 1 CORRELAT IVE  STUD IES  FOR  RESEARCH/PHARMACOK INET IC  STUD IES . . . . . . . . . . . . . . . . . . . . . . . . . .  1 9  
5 . 1 . 1 C l in i c a l  e n d  p o in t s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 9  
5 . 1 . 2 B io lo g i c  e n d  p o in t s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 9  
5 . 2 SAMPLE  STORAGE, TRACK ING  AND  DISPOS IT ION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 0  
5 . 2 . 1 C l in i c a l  HPC ,  A p h e r e s i s  P ro d u c t s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 0  
5 . 2 . 2 S to ra g e /T ra c k in g . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 0  
5 . 2 . 3 P ro to c o l  Com p l e t io n /S am p l e  D e s t ru c t io n  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 1  
6 DATA  COLLECT ION  AND  EVALUAT ION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 2  
6 . 1 DATA  COLLECT ION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 2  
6 . 2 TOX IC ITY  CR ITER IA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 3  
7 SAFETY  REPORT ING  REQU IREMENTS /DATA  AND  SAFETY  MON ITOR ING  
PLAN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 3  
7 . 1 DATA  REPORT ING  & RECORDS  TO  BE  KEPT  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 3  
7 . 2 DEF IN IT IONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 3  
7 . 2 . 1 A d v e r s e  E v e n t. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 3  
7 . 2 . 2 S u sp e c t e d  a d v e r s e  r e a c t io n  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 4  
7 . 2 . 3 U n e x p e c t e d  a d v e r s e  r e a c t io n . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 4  
7 . 2 . 4 S e r io u s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 4  
7 . 2 . 5 S e r io u s  A d v e r s e  E v e n t. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 4  
7 . 2 . 6 D i sa b i l i t y . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 5  
7 . 2 . 7 L i f e- th r e a t e n in g  a d v e r s e  d ru g  e x p e r i e n c e  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 5  
7 . 2 . 8 P ro to c o l  D e v ia t io n  (N IH  D e f in i t io n ) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 5  
7 . 2 . 9 No n - c om p l ia n c e  (N IH  D e f in i t io n )  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 5  
7 . 2 . 1 0 U n a n t i c ip a t e d  P ro b l em  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 5  
7 . 3 NC I- IRB AND  CL IN ICAL  DIRECTOR  REPORT ING. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 5  
7 . 3 . 1 NC I- IRB  a n d  NC I  CD  E xp e d i t e d  R e p o r t in g  o f  U n a n t i c ip a t e d  P ro b l em s  a n d  D e a th s
  2 5 
7 . 3 . 2 NC I- IRB  R e q u i r em e n t s  fo r  P I  R e p o r t in g  a t  Co n t i n u in g  R e v i ew  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 6  
7 . 3 . 3 E x c e p t io n s  to  r e p o r t in g :  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 6  
7 . 4 DATA  AND  SAFETY  MON ITOR ING  PLAN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 6  
7 . 4 . 1 P r in c ip a l  I n v e s t ig ato r /R e s e a r c h  T e am  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 6  
8 STAT IST ICAL  CONS IDERAT IONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 7  
9 HUMAN  SUBJECTS  PROTECT IONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 8  
9 . 1 RAT IONALE  FOR  SUB JECT  SELECT ION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 8  
9 . 2 PART IC IPAT ION  OF  CH ILDREN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 8  
9 . 3 PART IC IPAT ION  OF  SUB JECTS  UNABLE  TO  GIVE  CONSENT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 8  
9 . 4 EVALUAT ION  OF  BENEF ITS  AND  RISKS/DISCOMFORTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 8  
9 . 5 RISKS/BENEF ITS  ANALYS IS. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 8  
9 . 6 CONSENT  AND  ASSENT  PROCESS  AND  DOCUMENTAT ION. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 9  
9 . 6 . 1 T e l e p h o n e  r e - c o n s e n t  p ro c e d u r e . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 9  
9 . 6 . 2 S h o r t  fo rm  c o n s e n t  p ro c e s s  fo r  n o n -E n g l i sh  sp e a k in g  p a t i e n t s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 9  
9 . 7 SUB JECT  INFORMAT ION  AND  CONF IDENT IAL ITY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  3 0  
1 0 PHARMACEUT ICAL  INFORMAT ION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  3 0  
A bb r e v i a t e d  T i t l e :  HPC  f o r  AHCT  in  PCM   
V e r s io n  d a t e :  S e p t em b e r  14,  20 17  
  
                                                                                                                                          P ag e  6 o f  38  1 0 . 1 FILGRAST IM  (NEUPOGEN ® ,G -CSF ) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  3 0  
1 0 . 1 . 1 S o u r c e  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  3 0  
1 0 . 1 . 2 A d v e r s e  e f f e c t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  3 0  
1 0 . 1 . 3 F o rm u la t io n ,  S to ra g e ,  a n d  S ta b i l i t y . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  3 0  
1 0 . 1 . 4 A dm in i s t ra t io n. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  3 0  
1 0 . 2 PLER IXAFOR  (MOZOB IL®)  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  3 1  
1 0 . 2 . 1 S o u r c e  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  3 1  
1 0 . 2 . 2 A d v e r s e  e f f e c t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  3 1  
1 0 . 2 . 3 F o rm u la t io n ,  S to ra g e ,  a n d  S ta b i l i t y . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  3 1  
1 0 . 2 . 4 A dm in i s t ra t io n. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  3 1  
1 0 . 2 . 5 P h a rm a c o k in e t i c s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  3 1  
1 1 REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  3 2  
1 2 APPEND IX  1 :  ON- STUDY CHECK  L IST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  3 6  
1 3 APPEND IX  2 :  DATA  COLLECT ION  ELEMENTS  REQU IRED  BY  PROTOCOL .  3 7  
1 3 . 1 PAT IENT  ENROLLMENT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  3 7  
1 3 . 2 STUDY  DRUG  ADM IN ISTRAT ION  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  3 7  
1 3 . 3 LABORATORY  AND  DIAGNOST IC  TEST  DATA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  3 7  
1 3 . 4 ADVERSE  EVENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  3 7  
1 3 . 5 CONCOM ITANT  MEASURES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  3 7  
1 3 . 6 OFF  STUDY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  3 8  
 
A bb r e v i a t e d  T i t l e :  HPC  f o r  AHCT  in  PCM   
V e r s io n  d a t e :  S e p t em b e r  14,  20 17  
  
                                                                                                                                          P ag e  7 o f  38   
1  INTRODUCT ION  
1 . 1  STUDY  OBJECT IVES 
1 . 1 . 1  P r im a ry  O b j e c t iv es  
•  E v a lu a t e  th e  o v e r a l l  v a l id i ty  o f  a n  HPC  mo b i l i z a t io n  s t r a t e gy  (w i th  G -CSF  a lo n e  o r  in  
c omb in a t io n  w i th  p l e r ix a f o r )  u s ing  a  f o rmu l a  c a l cu l a t in g  th e  l ik e l ih o o d  o f  c o l l e c t in g  ≥ 5  
x  1 06 CD 3 4+ c e l l s /k g  in  a  s in g l e  mo b i l i z a t io n  cy c l e .    
•  Co l l e c t  a n d  c ry o p r e s e r v e “ HPC A p h e r e s i s”  p r o d u c t s  f o r  su b s e q u e n t  u s e  in  AHCT in  
su b j e c t s  w i th  P l a sm a  C e l l  My e lom a  (PCM ) .   
1 . 1 . 2  S e c o n d a ry  O b j e c t iv es  
•  D e t e rm in e  th e  p r o p o r t io n  o f  su b j e c t s  r e q u i r ing  a d d i t io n  o f  p l e r ix a f o r  to  th e  G -CSF  
mo b i l i z a t io n  r e g im e n . 
•  D e t e rm in e  th e  p r o p o r t io n  o f  su b j e c t s  a c h i e v ing  th e  t a r g e t  o r  o p t imum  g o a l  o f  ≥ 5  x  
1 06 CD 3 4+  c e l l s /k g  in  a  s in g l e  mo b i l i z a t io n  cy c l e  w i th  o r  w i th o u t  P l e r ix a f o r . 
•  D e t e rm in e  th e  p r o p o r t io n  o f  su b j e c t s  a c h i e v ing  th e  m in imum  g o a l  o f  ≥ 2  b u t  < 5  x  1 06 
CD 3 4+  c e l l s /k g  in  a  s in g l e  mo b i l i z a t io n  cy c l e  w i th  o r  w i th o u t  P l e r ix a f o r . 
•  D e t e rm ine  th e  d eg r e e  o f  tumo r  c e l l  c o n t am in a t io n  in  th e  f in a l  p r o d u c t .  
•  D e t e rm in e  th e  imp a c t  o f  p l e r ix a f o r  in  th e  d eg r e e  o f  tumo r  c e l l  c o n t am in a t ion  in  th e  
f in a l  p r o d u c t .  
1 . 2  BACKGROUND  AND  RAT IONALE 
1 . 2 . 1  O v e r v i ew  o f  T r e a tm e n t  o f  MM 
A p p r o x im a t e ly  2 0 , 0 0 0  n ew  c a s e s  o f  P l a sm a  C e ll  My e lom a  (PCM )  a r e  d i ag n o s e d  e a c h  y e a r  in  th e  
U n i t e d  S t a t e s .   I n  th e  g e n e r a l  p o p u l a t io n ,  th e  in c id e n c e  o f  PCM  i s  5  p e r  1 0 0 , 0 0 0  w i th  a n  a v e r ag e  a g e  o f  o n s e t  a r o u n d  7 0  y e a r s .  R a t e s  a r e  h ig h e r  in  A f r i c a n  Am e r i c a n s  a n d  in  m e n .  I t  i s  th e  s e c o n d  mo s t  c ommo n  h em a to lo g i c  m a l ig n a n cy  in  th e  U n i t e d  S t a t e s .  T h e r e  a r e  a n  e s t im a t e d  4 5 , 0 0 0  p e o p l e  l iv in g  w i th  PCM  in  th i s  c o u n t ry  a n d  i t  i s  e s t im a t e d  th a t  th e r e  w e r e  19 , 9 0 0  n ew  d i ag n o s e s  a n d  1 0 , 7 9 0  d e a th s  d u e  to  MM  in  2 0 0 7
[ 1 ].  T h e  m e d i a n  su r v iv a l  o f  p a t i e n t s  w i th  MM  w a s  l e s s  th a n  
o n e  y e a r  b e f o r e  in t r o d u c t io n  o f  a lky l a t ing  ag e n t s  (m e lp h a l a n )  in  th e  1 9 6 0 s  w h i c h  r e su l t e d  in  imp r o v e d  su r v iv a l  b u t  s t i l l  in  a  v e ry  l im i t e d  n umb e r  o f  c omp l e t e  r e sp o n s e s  a n d  in  n o  c u r a t iv e  e f f e c t .  
F o r  m a ny  y e a r s  d e x am e th a so n e  (D e x )  a lo n e  o r  in  c omb in a t io n  w i th  o r a l  m e lp h a l a n  (MP )  o r  w i th  
v in c r i s t in e  a n d  d o xo r u b i c in  (VAD )
[ 2] h a s  b e e n  th e  m a in s t ay  o f  in d u c t io n  th e r a py  f o r  n ew ly  
d i a g n o s ed  PCM .   R e c e n t ly ,  s e v e r a l  ag e n t s  w i th  n o v e l  m e c h a n i sm s  o f  a c t io n  ha v e  sh ow n  su p e r io r  a c t iv i ty  in  PC M .  T h a l id om id e  in  c omb in a t io n  w i t h  D e x  w a s  f o u n d  to  b e  sup e r io r  to  D e x a lo n e  a s  w e l l  a s  sup e r io r  to  VAD  in  r a n d om i z e d  t r i a l s
[ 3,  4 ].   A d d i t io n a l ly ,  b o r t e zom ib ,  a  p r o t e o som e  
in h ib i to r ,  h a s  b e e n  sh own  to  b e  su p e r io r  to  VAD  a s  in d u c t io n  th e r a py  in  r an d om i z e d  t r i a l[ 5 ].   
Tw o  p h a s e  I I I  s tu d i e s  show  a n  in c r e a s e d  o v e r a l l  su r v iv a l  w ith  o r a l  l e n a l id om id e  p lu s  D e x 
A bb r e v i a t e d  T i t l e :  HPC  f o r  AHCT  in  PCM   
V e r s io n  d a t e :  S e p t em b e r  14,  20 17  
  
                                                                                                                                          P ag e  8 o f  38  c omp a r e d  to  D e x p lu s  p l a c e b o  in  p r e v io u s ly  t r e a t e d  PC M  p a t i e n t s[ 6,  7 ].   Ph a s e  I I  s tu d i e s  in  n ew ly  
d i a g n o s ed  p a t i e n t s  c o r r ob o r a t e  th e s e  f in d in g s .   T h e r e f o r e ,  s ig n i f i c a n t  p r og r e s s  h a s  b e e n  m a d e  in  
th e  l a s t  d e c a d e  in  th e  m an a g e m e n t  o f  PCM  w i th  th e  a d v e n t  o f  th e r a p y  w i th th a l id om id e ,  b o r t e zom ib  a n d  mo r e  r e c e n t ly  l e n a l id om id e
[ 8 ] a n d  th e i r  c omb in a t io n  in  s t r a t e g i e s  in c lu d in g  h ig h -
d o s e  c h emo th e r a py  f o l low e d  by  a u to log o u s  h em a to p o i e t i c  s t em  c e l l  t r a n sp l a n t a t io n ( AHCT) .   I n  p a t i e n t s  n o t  e xp o s e d  to  th i s  n ew  g e n e r a t io n  o f  d r ug s ,  th e  m e d i a n  su r v iv a l  f o l low in g  r e l a p s e  af t e r  AHCT i s  a b o u t  1 8  mo n th s  w h i l e  in  p a t i e n t s  e xp o s e d  to  th e s e  d r ug s  f o l low in g  r e l a p s e  a f t e r  AHCT,  th e  m e d i a n  su r v iv a l  h a s  a lmo s t  d o u b l e d  to  3 6  mo n th s .   O v e r a l l ,  in  a  r e c e n t  s tu dy  f r om  M ay o  C l in i c ,  th e  m e d i a n  o v e r a l l  su r v iv a l  f o r  su b j e c t s  d i a g n o s e d  in  th e  l a s t  d e c a d e  w a s  4 4 . 8  mo n th s  ( 9 5%  C I ;  3 9 . 6 , 5 0 )  c omp a r e d  w i th  2 9 . 9  mo n th s  ( 9 5%  C I ;  2 8 . 3 ,  3 1 . 6 )  p <  . 0 0 1 , f o r  th o s e  d i a g n o s ed  e a r l i e r
[ 9].   T h e s e  su c c e s s e s  h a v e  a l low ed  mo v in g  th e s e  ag e n t s  to  f r o n t  l in e  th e r a py  in  
n ew ly  d i ag n o s e d  su b j e c t s  w i th  s ig n i f i c a n t  imp r o v em e n t  in  r e sp o n s e  r a t e s  a nd  EFS[ 1 0- 1 2 ].   T h e  
mu l t ip l e  imp r o v e d  th e r a p e u t i c  o p t io n s  n ow  a v a i l ab l e  a s  in d u c t io n  th e r a py  fo r  MM  w e r e  r e c e n t ly  r e v i ew e d
[ 13]a n d  a r e  a v a i l a b l e  a s  s t a n d a r d  o f  c a r e  fo r  n ew ly  d i ag n o s e d  MM .   G u id e l in e s  a r e  
d e s c r ib e d  a n d  r eg u l a r ly  up - d a t e d  by  th e  N a tio n a l  Comp r e h e n s iv e  C a n c e r  N e tw o r k    ( h t tp : / /www . n c c n . o rg /p r o f e s s io n a l s /p hy s i c i a n _g l s / f _ g u id e l in e s . a sp ) .
 
P r io r  to  th e  p r e s e n t  e r a  o f  n o v e l  th e r a p e u t i c  ag e n t s  f o r  PCM ,  AHCT h a s  b e en  sh ow n  to  s ig n i f i c a n t ly  in c r e a s e  th e  c omp l e t e  r em i s s io n s  (CR )  r a t e  to  a lmo s t  5 0%  in  s e l e c t e d  p a t i e n t s  ( v e r su s  1 – 1 3%  CR  w i th  c o n v e n t io n a l  d o s e  th e r a py ) ,  b u t  th e  d i s e a s e  r e c u r s  a lmo s t  w i th o u t  e x c e p t io n
[ 14- 1 6].   AHCT i n c r e a s e s  th e  CR  r a t e  a n d  t im e - to - p r o g r e s s io n  a n d  h a s  sh ow n  a  su r v iv a l  
imp r o v em e n t[ 1 7,  1 8 ] th o u g h  n o t  c o n s i s t e n t ly[ 19,  2 0].   I n  a  m e t a - a n a ly s i s  o f  2 4 11  su b j e c t s  o n  9  
r a n d om i z e d  t r i a l s ,  K o r e th  e t  a l .  sh ow e d  p r og r e s s io n  f r e e  su r v iv a l  ( PFS)  b en e f i t  b u t  n o t  o v e r a l l  su r v iv a l  ( OS)  b e n e f i t  f o r  AHCT w i th  s in g l e  a u to log o u s  t r a n sp l a n t a t io n  p e r fo rm e d  e a r ly  in  mu l t ip l e  my e lom a  o v e r  ch emo th e r a py  a lo n e
[ 18 ].  
O f  n o t e ,  p r io r  to  th e  p r e s e n t  e r a  o f  n o v e l  ag e n t s ,  th e r e  w a s  n o  a d v a n t ag e  in  d e l ay ing  AHCT u n t i l  d i s e a s e  p r og r e s s io n .  T h e  t r e a tm e n t  d u r a t io n  w a s  o v e r a l l  sh o r t e r  in  p a t i e n t s  t r a n sp l a n t e d  u p f r o n t  f o l low in g  in d u c t io n  c h emo th e r a py
[ 21].   I n  th e  p r e s e n t  e r a  o f  mo r e  e f f e c t iv e  in d u c t io n  th e r a py  
th o u g h ,  th i s  a s s e r t io n  n e ed s  to  b e  r e v i s i t e d  a n d  a t  l e a s t  tw o  r a n d om i z e d  t r i a l s  a r e  p r e s e n t ly  o n g o ing  to  a d d r e s s  th e  qu e s t io n  o f  u p f r o n t  v e r su s  d e l ay e d  AHCT f o l low in g  in d u c t io n  w i th  n o v e l  a g e n t s .  
O f  s ig n i f i c a n c e ,  to  th e  p r e s e n t  d ay ,  a c h i e v em e n t  o f  a  CR  c o n t in u e s  to  b e  th e  s in g l e  mo s t  
p r e d i c t iv e  f a c to r  f o r  EFS  a n d  OS  f o r  PCM
[ 2 2 ].   B e t t e r  r e sp o n s e s  l e a d  to  b e t t e r  r e sp o n s e  d u r a t io n s .  
O u t c om e s  o f  4 , 9 9 0  AHCT p a t i e n t s  a c c o r d in g  to  th e i r  b e s t  tumo r  r e sp o n s e  w e r e  r e p o r t e d  in  tw o  m e t a- a n a ly s e s  o f  2 1  s tu d i e s  ( 1 0  p r o sp e c t iv e  a n d  1 1  r e t r o sp e c t iv e ) .  B o th  m e t a - a n a ly s e s  in d i c a t e d  h ig h ly  s ig n i f i c a n t  a s so c i a t io n  b e tw e e n  m a x im a l  r e sp o n s e  (CR /VGPR )  d u r in g  o r  a f t e r  AHCT a n d  lo n g - t e rm  o u t c om e s  (OS  a n d  EFS )  a s  w e l l  a s  a  h ig h ly  s ig n i f i c a n t  a s so c i a t io n s  b e tw e e n  m a x im a l  r e sp o n s e  f o l low ing  in d u c t io n  th e r a py  a n d  EFS /OS
[ 2 3 ].    T h e r e f o r e ,  imp r o v em e n t  o f  th e  in i t i a l  CR  
r a t e  c o n t in u e s  to  b e  a t  th e  f o r e f r o n t  o f  c l in i c a l  r e s e a r c h  in  PCM .  
1 . 2 . 2  AMD 3 1 0 0  (P l e r ix a f o r ,  Mo zo b i l™ ,  G e n zym e )  
P l e r ix a f o r i s  a  sm a l l  mo l e c u l e  r e v e r s ib l e  in h ib i to r  o f  th e  b in d in g  o f  SDF - 1 αto  i t s  c o g n a t e  
r e c e p to r  CXCR4  a n d  mo b i l i z e s  h em a to p o i e t i c  s t em  c e l l s  f r om  th e  m a r r ow  to  th e  b lo o d[ 24 ,  25 ].   
P l e r ix a f o r  c l in i c a l  e xp e r i e n c e  a n d  to x i c i ty h a v e  b e e n  r e c e n t ly  r e v i ew e d[ 26 ,  27 ].  
A bb r e v i a t e d  T i t l e :  HPC  f o r  AHCT  in  PCM   
V e r s io n  d a t e :  S e p t em b e r  14,  20 17  
  
                                                                                                                                          P ag e  9 o f  38  M a x im a l  mo b i l i za t io n  o f  CD 3 4+  c e l l s  o c c u r s  8 - 1 0  h  a f t e r  d o s ing[ 26 ].  T h e r e  i s  a  h ig h ly  sy n e rg i s t i c  
in t e r a c t io n  o f  G -CSF  a n d  AMD 3 1 0 0  o n  mo b i l i z a t i o n[ 2 8 ].T h e  c omb in a t io n  p l e r ix a f o r /  G - CSF  i s  
mo r e  e f f e c t iv e  th a n  G-CSF  a lo n e  f o r  CD 3 4+ c e l l  mo b i l i z a t io n .  I n  a  s tu dy  o f  s t em  c e l l  
mo b i l i z a t io n  f o r  AHCT f o r  PCM ,  th e  p e r c e n t ag e  o f  p a t i e n t s  w h o  c o l l e c t e d  ≥ 6  x  1 06 CD 3 4+  
c e l l s /k g  in  ≤ 2  a p h e r e s e s  w a s  7 1 . 6%  ( 1 0 6  o f  1 4 8  p a t i e n t s )  in  th e  G -CSF  +  p l e r ix a f o r  g r o u p  a n d   
3 4 . 4%  ( 5 3  o f  1 5 4 )  in  th e  G -CSF  +  p l a c e b o  g r o u p  (p  <  . 0 0 1 ) .  5 4%  o f  G - CSF  +  p l e r ix a f o r- t r e a t e d  
p a t i e n t s  r e a c h e d  t a rg e t  a f t e r  o n e  a p he r e s i s ,  w h e r e a s  5 6%  o f  th e  G - CSF  +  p l a c e b o- t r e a t e d  p a t i e n t s  r e q u i r e d  4  a p h e r e s e s  to  r e a c h  t a rg e t
[ 29 ].   S im i l a r  r e su l t s  w e r e  f o u n d  in  a  p h a s e  I I I  r a n d om i z e d  
p l a c e b o  c o n t r o l l e d  s tu dy  in  n o n -H o d g k in ’ s  lymp hom a[ 3 0 ].  
P l e r ix a f o r  (Mo zo b i l™ )  r e c e iv e d  FDA  a p p r o v a l  in  D e c emb e r  2 0 0 8  f o r  u s e  in  s t em - c e l l  mo b i l i z a t io n  in  NHL  a nd  PCM .  T h i s  w a s  b a s e d  o n  th e  r e su l t s  o f  tw o  p l a c e bo - c o n t r o l l e d  c l in i c a l  t r i a l s .  I n  b o th  s tu d i e s ,  th e  su b j e c t s  w e r e  r a n d om i z ed  to  r e c e iv e  e i th e r  p l e r ix a f o r  0 . 2 4  mg /kg  o r  p l a c e b o  o n  e a c h  e v e n ing  p r io r  to  a p h e r e s i s .  T h ey  r e c e iv e d  d a i ly  mo r n ing  d o s e s  o f  G - CSF  1 0  m c g /kg  f o r  4  d ay s  p r io r  to  th e  f i r s t  d o s e  o f  p l e r ix a f o r  o r  p l a c e b o  a n d  o n  e a ch  mo r n in g  p r io r  to  a p h e r e s i s .  S tu dy  1
[ 3 0] e n r o l l e d  2 9 8  NHL  su b j e c t s .  F i f ty  n in e  p e r c e n t  o f  th e  su b j e c t s  mo b i l i z e d  
w i th  p l e r ix a f o r  a n d  G -CSF  c o l l e c t e d  ≥  5  x  1 06 CD 3 4+ c e l l s /k g  f r om  th e  p e r ip h e r a l  b lo o d  in  f o u r  
o r  f ew e r  a p h e r e s i s  s e s s ion s ,  c omp a r e d  w i th  2 0%  o f  su b j e c t s  mo b i l i z e d  w i th  p l a c e b o  a n d  G - CSF  ( p  <  0 . 0 0 1 ) .  T h e  m e d i a n  n umb e r  o f  a p h e r e s i s  d ay s  to  c o l l e c t  ≥  5  x  1 0
6 CD 3 4+ c e l l s /k g  w a s  3  
d ay s  f o r  th e  p l e r ix a f o r  g ro u p  a n d  n o t  e v a lu a b l e  f o r  th e  p l a c e b o  g r o u p .  S tu dy  2[ 29 ] e n r o l l e d  3 0 2  
MM  su b j e c t s .  S e v e n ty  two  p e r c e n t  o f  p a t i e n t s  mo b i l i z e d  w i th  p l e r i x a f o r  a n d  G - CSF  c o l l e c t e d  ≥  6  x  1 0
6 CD 3 4+ c e l l s /k g  f rom  th e  p e r ip h e r a l  b lo o d  in  tw o  o r  f ew e r  a p h e r e s i s  s e s s io n s ,  c omp a r e d  
w i th  3 4%  o f  p a t i e n t s  mo b i l i z e d  w i th  p l a c e b o  a n d  G -CSF  ( p  <  0 . 0 0 1 ) .  T h e  m e d i a n  n umb e r  o f  a p h e r e s i s  d ay s  to  c o l l e c t  ≥  6  x  1 0
6 CD 3 4+ c e l l s /k g  w a s  1  d ay  f o r  th e  p l e r ix a f o r  g r o u p  a n d  4  d ay s  
f o r  th e  p l a c e b o  g r o u p .  
Mo r e  r e c e n t  e xp e r i e n c e  h a s  n ow  a l so  b e e n  a c q u i r ed  in  u s in g  p l e r ix a f o r  a lo n e  a s  a  mo b i l i z a t io n  
a g e n t  p r io r  to  AHCT f o r  PCM[ 3 1 ]a n d  p r io r  to  a l lo  BMT[ 32 ].  
1 . 2 . 2 . 1  Pl e r ix a f o r  p h a rm a c o k in e t i c s 
P e a k  p l a sm a  c o n c e n t r a t ion s  o c c u r  a b o u t  3 0  to  6 0  m in u t e s  a f t e r  a  su b c u t a n eo u s  d o s e .  I t  i s  a b o u t  
5 8%  b o u n d  to  p l a sm a  p ro t e in s  a n d  l a rg e ly  c o n f in e d  to  th e  e x t r a v a s c u l a r  f lu id  sp a c e .  A b o u t  7 0%  o f  a  d o s e  i s  e l im in a t e d  in  th e  u r in e  w i th in  2 4  h o u r s  a f t e r  a  d o s e ,  a n d  th e  t e rm in a l  h a l f - l i f e  i s  a b o u t  3  to  5  h o u r s .   
I n  mo d e r a t e  a n d  s e v e r e  r e n a l  imp a i rm e n t  ( c r e a t in in e  c l e a r a n c e  5 0  m l /m in  o r  l e s s )  th e  d o s e  o f  
p l e r ix a f o r  sh o u ld  b e  r e d u c e d  to  1 6 0  m i c r og r am s /k g ,  g iv e n  by  su b c u t a n e o u s  in j e c t io n  a b o u t  1 0  h o u r s  b e f o r e  a p h e r e s i s ,  fo r  u p  to  4  c o n s e c u t iv e  d ay s .  T h e  d a i ly  d o s e  sh o u ld  n o t  e x c e e d  2 7  mg .  c omp l e t e  in f o rm a t io n  i s  a v a i l a b l e  a t  th e  f o l low in g  w e b  s i t e :  
h t tp : / /www . th om so n h c . c om /h c s / l ib r a r i a n /ND _T /HCS /ND _PR /M a in /CS /C 8B 2 5 5 /DUPL ICAT IO
NSH IELDSYNC /2 5 7 1 1 0 /ND _PG /PR IH /ND_B /HCS /SBK /1 /ND _P /M a in /PFA c t io n I d /h c s . c ommo n .R e t r i e v eD o c um e n tCommo n /D o c I d /2 0 5 5 1 -p /Co n t e n tS e t I d /3 0 /S e a r chT e rm /mo zo b i l /S e a r c hO p t io n /B e g inW i th  
1 . 2 . 3  E v a lu a t e  th e  n e e d  f o r  sy s t em a t i c  u s e  o f  P l e r ix a f o r  o n  d ay  4 
B a s e d  o n  r e c e n t  w o r k  f r om  th e  D e p a r tm e n t  o f  T r an s f u s io n  M e d i c in e  o f  th e  C l in i c a l  C e n t e r ,  th e  
y i e ld  o f  a n  a p h e r e s i s  p r o c e d u r e  c o u ld  b e  a c c u r a t e ly  p r e d i c t e d  o n  th e  b a s i s  o f  a  p r e - p r o c e d u r e  
A bb r e v i a t e d  T i t l e :  HPC  f o r  AHCT  in  PCM   
V e r s io n  d a t e :  S e p t em b e r  14,  20 17  
  
                                                                                                                                          P ag e  10 o f  38  p e r ip h e r a l  b lo o d  CD 3 4+  c e l l s  c o n t e n t  d e t e rm in a t io n[ 3 3 ].   H ow e v e r ,  th i s  w o r k  w a s  d o n e  p r io r  to  
th e  u s e  o f  p l e r ix a f o r  in  mo b i l i z a t io n  a n d  in  a  p o p u l a t io n  o f  h e a l thy  d o n o r s  fo r  a l lo g e n e i c  
t r a n sp l a n t a t io n .    
T h i s  s tu dy  w i l l  s e e k  to  v a l id a t e  th e  f o rmu l a  d e v e lo p e d  by  DTM  th a t  c a l c u l a t e s  th e  l ik e l ih o o d  o f  
c o l l e c t in g  ≥ 5  m i l l io n  CD 3 4+ c e l l s /k g  in  a  s ing l e  a p h e r e s i s  a f t e r  5  d ay s  o f  G -CSF  a lo n e  (w i th o u t  
p l e r ix a f o r ) .  T h e  e q u a t io n  i s  b a s e d  o n  th e  c i r c u l a t in g  b lo o d  CD 3 4+c e l l  c o n c en t r a t io n  in  h e a l thy  
su b j e c t s  o n  th e  mo r n in g  o f  d ay  
5  ( a f t e r  4  e v e n ing  d o s e s  o f  G -CSF );  s e e  F ig u r e  a n d  T ab l e .  
T h e r e f o r e ,  w i th  th e  k n ow l e d g e  
o f  th e  p r e - p r o c e d u r e  p e r ip h e r a l  b lo o d  CD 3 4
+ c e l l  c o u n t  a f t e r  4  
d o s e s  o f  G - CSF ,  th e  p a t i e n t ’ s  w e ig h t  a n d  th e  b lo o d  v o lum e  th a t  c a n  b e  p r o c e s s e d  d u r in g  a  s in g l e  a p h e r e s i s  p r o c e d u r e ,  i t  sh o u ld  b e  p o s s ib l e  to  p r e d i c t  w h i c h  su b j e c t s  w o u ld  mo s t  l ik e ly  a c h i e v e  a  c o l l e c t ion  o f  5  x  1 0
6 CD 3 4+ c e l l s /k g  w i th  a  
s in g l e  a p h e r e s i s .  T h e s e  su b j e c t s  w o u ld  n o t  n e e d  to  r e c e iv e  
p l e r ix a f o r  o n  d ay  4  o f  mo b i l i z a t io n  b u t  w o u ld  r e c e iv e  d ay  5  o f  G - CSF  a s  p l a n n e d . 
Tab l e  1  
P r ed i c t i on  o f  N e ed  fo r  P l e r i x a fo r  b a s ed  on  P r e- Aph e r e s i s  CD34  Coun t 
  T a rg e t M in imum  CD 3 4  
x 1 06/L   M in imum  
r equ i r ed  M in imum  a c c ep t ab l e  D 4   
P t  Kg   CD 3 4 p ro ce s s ed  y i e ld     p r e- aph e r e s i s   CD 3 4  coun t  (p r ed i c t ed )   
W g t x  1 06 in  2 5  L  p ro c edu r e CD 3 4 /uL w /o  p l e r ix a fo r 
≤6 0  3 0 0  1 2  2 1  2 4  
6 1 - 6 5 3 2 5  1 3  2 3  2 6  
6 6 - 7 0 3 5 0  1 4  2 6  2 8  
7 1 - 7 5 3 7 5  1 5  2 8  3 1  
7 6 - 8 0 4 0 0  1 6  3 1  3 3  
8 1 - 8 5 4 2 5  1 7  3 3  3 5  
8 6 - 9 0 4 5 0  1 8  3 6  3 8  
9 1 - 9 5 4 7 5  1 9  3 8  4 0  
≥9 6  5 0 0  2 0  4 0  4 2  
 
1 . 2 . 4  E v a lu a t io n  o f  m in im a l  r e s id u a l  d i s e a s e 
•  R e s id u a l  d i s e a s e  e v a lu a t io n  w i l l  b e  p e r f o rm e d  u s in g  h ig h  r e so lu t io n  d e t e c t io n  m e th o d s :   
•  Mu l t i c o lo r  F low  cy tom e t ry[ 34- 3 8 ] y  =  0 .4079x  +  3 .501
R ²  =  0 .7654
01020304050607080901001 10
0 20 40 60 80 100 120 140 160 180 200CD34  Ce l l  Y ie ld  (x106)
Pe r  L i te r  P rocessed
P reaphe res is  CD34  Coun t  (ce l ls /uL )CD34  Ce l l  Y ie ld /Ne t  L i te r  P rocessed  vs  P reaphe res is  
CD34  Coun t  in  240  NMDP  Dono rs  
A bb r e v i a t e d  T i t l e :  HPC  f o r  AHCT  in  PCM   
V e r s io n  d a t e :  S e p t em b e r  14,  20 17  
  
                                                                                                                                          P ag e  11 o f  38  •  Mo l ec u l a r  P a th o logy  
•  I d io ty p e - sp e c i f i c  PC R[ 3 9- 42 ].  
H ig h  s e n s i t iv i ty  d e t e c t ion  m e th o d s  m ay  b e  u s e d  fo r  th e  d e t e rm in a t io n  o f  th e  d eg r e e  o f  tumo r  c e l l  
c o n t am in a t io n  in  th e  HPC ,  A p h e r e s i s  p r o d u c t  a n d /o r  a s  a  su r r og a t e  m a r k e r  f o r  t r e a tm e n t  e f f i c a cy  c omp a r ing  p r e - t r e a tm e n t  v a lu e s  w i th  th o s e  o f  b e s t  r e sp o n s e .   F u r th e rmo r e ,  c l in i c a l  r e l a p s e  m ay  b e  a n t i c ip a t e d .   I n  a  s tu dy  u s ing  I gH  PCR  w i th  p a t i e n t - sp e c i f i c  p r o b e s ,  in c r e a s e  o f  c lo n o ty p i c  c e l l s  in  PB  w a s  d e t e c t a b l e  a  m e d i a n  o f  3  mo n th s  b e f o r e  c l in i c a l  r e l a p s e
[ 43 ].  
1 . 2 . 5  L a c k  o f  n e e d  f o r  pu rg ing  o f  HPC ,  A p h e r e s i s  p r o du c t  
Mu l t ip l e  s tu d i e s  h a v e  b e e n  p e r f o rm e d  in  a n  a t t emp t  to  imp r o v e  th e  EFS  p o s t - t r a n sp l a n t  by  
p u r g ing  th e  “HPC ,  A p h e r e s i s ”  p r o d u c t  f r om  m y e lom a  c e l l s .   R e su l t s  h a v e  b e e n  c o n f l i c t ing  a t  b e s t ,  b u t  mo s t ly  d i s a p p o in t in g  
[ 4 4].  
Tw o p h a s e  3  r a n d om i z e d  t r i a l s  c omp a r e d  p a t i e n t s  w i th  PCM  w h o  r e c e iv e d  a u to g r a f t s  p u rg e d  o f  tumo r  c e l l s  ( CD 3 4
+- s e l e c t e d  PBSC)  w i th  th o s e  w i th  u n s e l e c t e d  PBSC s[ 45 ,  46 ].  B o th  s tu d i e s  u s e d  a  
h ig h ly  s e n s i t iv e ,  tumo r - sp e c i f i c  PCR  t e c h n iq u e  to  id e n t i fy  th e  I g  h e a vy  c h a in  s e q u e n c e  o f  th e  my e lom a c lo n e  a n d  d e t e rm in e  th e  l e v e l  o f  tumo r  c e l l  c o n t am in a t io n .  B o th  s tu d i e s  a c h i e v e d  a  l a r g e  r e d u c t io n  in  tumo r  b u r d e n  ( a p p r o x im a t e ly  1  to  6  lo g  tumo r  lo a d  r e d u c t io n ) ,  b u t  n o  s ig n i f i c a n t  d i f f e r e n c e s  w e r e  o b s e r v e d  b e tw e e n  th e  2  g r o u p s  in  t e rm s  o f  r e spo n s e ,  EFS /PFS ,  o r  OS.  
T h e s e  d i s a p p o in t in g  r e su l t s  c l e a r ly  d emo n s t r a t e  th a t  th e  r e s id u al  tumo r  b u rd e n  in  th e  p a t i e n t  a n d  
th e  in a b i l i ty  to  e r a d i c a t e  i t  a t  th e  t im e  o f  th e  H ig h - D o s e  c h emo th e r a py  a r e  th e  p r im a ry  c a u s e  f o r  t r e a tm e n t  f a i lu r e  p o s t - AHCT a n d  sh o u ld  r em a in  th e  p r im a ry  f o c u s  f o r  imp r o v in g  t r a n sp l a n t  o u t c om e .  T h e r e  i s  mu c h  h o p e ,  h ow e v er ,  th a t  th e  comb in a t io n  o f  n o v e l  a g en t s  a n d  AHCT w i l l  a c h i e v e  mu c h  g r e a t e r  d i s e a s e  b u r d e n  r e d u c t io n  th a n  p r e v io u s ly  a c h i e v e d  in  th e  r a n d om i z e d  s tu d i e s  c i t e d  a b o v e .  T h e r e f o r e ,  tumo r  c e l l  c o n t am in a t io n  o f  HPC  p r o d u c t s  m ay  th e n  b e c om e  a n  imp e d im e n t  to  p r o lo n g e d  d i s e a s e  f r e e  su r v iv a l .   I t  w i l l  b e  imp o r t a n t  th e n  to  h a v e  k n ow l e dg e  o f  th e  p o t e n t i a l  c o n t r ib u t io n  o f  e a c h  mo b i l i z a t io n  s t r a t e gy  to  HPC  tumo r  c e l l  co n t am in a t io n .   T h i s  p r o to c o l  o f f e r s  a  g r e a t  o pp o r tu n i ty  to  c omp a r e  th e  c o n t r ib u t io n  o f  G -CSF  an d  p l e r ix a f o r  to  HPC  p r o d u c t  tumo r  c e l l  c o n t am in a t io n .  
1 . 2 . 6  U t i l i z a t io n  o f  HPC  p r o d u c t s in  NC I  p r o to c o l s  
T h e  c e l lu l a r  p r o d u c t s  c o l l e c t e d  o n  th i s  p r o to c o l  a r e  e x t r em e ly  l ik e ly  to  b e  su b s e q u e n t ly  u s e d  in  a  
CCR  p r o to c o l .   HPC  c o l l e c t io n  f o r  su b s e q u e n t  AHCT i s  a  r e c omm e n d a t io n  o f  th e  I n t e r n a t io n a l  My e lom a  Wo r k ing  G r o up  f o r  a l l  p a t i e n t s  t r e a t e d  fo r  PCM .  T h i s  p o s i t io n  i s  e c h o e d  in  s e v e r a l  r e c e n t  r e v i ew s
[ 47- 4 9 ].   
ET IB  h a s  p r e s e n t ly  o n e  pr o to c o l  o p e n  w h i c h  in c lud e s  AHCT f o r  PCM  ( 1 1 -C - 0 0 1 6 ) .   
T he  My e lom a  Pr og r am  i s  p r e s e n t ly  a c c r u ing  2  to  3  p a t i e n t s  p e r  w e e k ,  th e  m a jo r i ty  o f  w h om  a r e  
e i th e r  a l r e a dy  e l ig ib l e  f o r  p r o to c o l1 1 -C - 0 0 1 6  a t  th e  t im e  o f  th e i r  e n r o l lm e n t  o n  th e  L ymp h o id  M a l ig n a n c i e s  B r a n c h  (LYMB ) s tu d i e s  o r  a r e  l ik e ly  to  b e c om e  e l ig ib l e .   T h e  ET IB  p r o to c o l  in  p r e p a r a t io n  i s  a l so  l ik e ly  to  c a p tu r e  a  l a rg e  n umb e r  LYMB  r e c r u i t e d  su b j e c t s  a s  AHCT c o n t in u e s  to  p l ay  a  l a rg e  r o l e  in  PCM  th e r a py  in  sp i t e  o f  th e  r e c e n t  th e r a p e u t i c  a d v a n c e s  w i th  th e  u s e  o f  n o v e l  ag e n t s .   A t  th i s  p o in t  i t  i s  e xp e c t e d  th a t  mo r e  th a n  8 0%  o f  su b j e c t s  wh o  w o u ld  u n d e rg o  HPC  c o l l e c t io n  u n d e r  th i s  p r o to c o l  w o u ld  u n d e rg o  AHCT a s  p a r t  o f  a  CCR  s tu dy .  
A bb r e v i a t e d  T i t l e :  HPC  f o r  AHCT  in  PCM   
V e r s io n  d a t e :  S e p t em b e r  14,  20 17  
  
                                                                                                                                          P ag e  12 o f  38  2  EL IG IB IL ITY  ASSESSMENT  AND  ENROLLMENT 
2 . 1  EL IG IB IL ITY  CR ITER IA 
2 . 1 . 1  I n c lu s io n  C r i t e r i a  
2 . 1 . 1 . 1  Mu l t ip l e  My e lom a  c r i t e r i a 
•  Su b j e c t s  w i th  an  in d i c a t io n  f o r  AHCT f o r  th e  t r e a tm e n t  o f  PCM  a s  d e t e rm in e d  by  th e  
P I  o r  LA I.  
o Su b j e c t s  f o l low in g  in d u c t io n  t r e a tm e n t  f o r  PCM  
o Su b j e c ts  w i th  r e c u r r e n t  o r  p e r s i s t e n t  e v a lu a b l e  d i s e a s e w h o  h a v e  n o t  u n d e rg o n e  
AHCT f o r  th e  t r e a tm e n t  o f  th e  PCM.  
2 . 1 . 1 . 2  O th e r  e l ig ib i l i ty  c r i t e r i a 
•  A g e  > 1 8  y e a r s  a n d  l e s s  th a n  o r  e q u a l  to  7 5  y e a r s .   I n  su b j e c t s  b e tw e e n  6 5  an d  7 5  y e a r s  o f  
a g e ,  p hy s io lo g i c  ag e  a n d  c o -mo r b id i ty  w i l l  b e  th o ro u g h ly  e v a lu a t e d  b e f o r e  e n r o l l in g .   
•  K a r n o f sky  p e r f o rm a n c e  st a tu s  o f  7 0%  o r  g r e a t e r  (ECOG  0  o r  1 )   
•  E j e c t io n  f r a c t io n  (EF )  by  MUGA  o r  2- D  e c h o c a r d io g r am  w i th in  in s t i tu t io n  n o rm a l  l im i t s .   I n  
c a s e  o f  low  EF ,  th e  su b j e c t  m ay  r em a in  e l ig ib l e  a f t e r  a  s t r e s s  e c h o c a r d iog r am  i s  p e r f o rm e d  i f  
th e  EF  i s  mo r e  th a n  3 5%  a n d  i f  t h e  in c r e a s e  in  EF  w i th  s t r e s s  i s  e s t im a t e d  a t  1 0%  o r  mo r e . 
•  H g b >  8g /d l  ( t r a n s f u s io n  a c c e p t a b l e )  
•  N o  h i s to ry  o f  a b n o rm a l  b l e e d in g  t e n d e n cy .  
•  P a t i e n t s  mu s t  b e  a b l e  to  g iv e  in f o rm e d  c o n s e n t  
2 . 1 . 2  E x c lu s io n  C r i t e r i a 
•  P r io r  a l lo g e n e i c  s t em  c e l l  t r a n sp l a n t a t io n 
•  Hy p e r t e n sio n  n o t  a d e q u a t e ly  c o n t r o l l e d  by  3  o r  l e s s  m e d i c a t io n s .  •  C l in i c a l ly  s ig n i f i c a n t  c a rd i a c  p a th o logy :  my o c a r d i a l  in f a r c t io n  w i th in  6  mo n th s  p r io r  to  
e n r o l lm e n t ,  C l a s s  I I I  o r  IV  h e a r t  f a i lu r e  a c c o r d in g  to  NYHY ,  u n c o n t r o l l e d  a n g in a ,  s e v e r e  
u n c o n t r o l l e d  v e n t r i c u la r  a r r hy thm i a s ,  o r  e l e c t r o c a r d io g r a p h i c  e v id e n c e  o f  a c u t e  i s c h em i a  o r  a c u t e  c o n d u c t io n  sy s t em  a b n o rm a l i t i e s .  Sp e c i f i c a l ly ,  a ny  h i s to ry  o f  c a r d io- v a s c u l a r  p a th o lo gy  o r  symp tom s ,  n o t  c l e a r ly  f i t t in g  th i s  e x c lu s io n  c r i t e r io n  w i l l  p r omp t  a n  e v a lu a t io n  by  a  C l in i c a l  C e n t e r  C a r d io lo g i s t  a n d  e l ig ib i l i ty  w i l l  b e  c o n s id e r e d  o n  a  c a s e - by - c a s e  b a s i s .   Sh o u ld  th e  c a r d io lo g i s t  d e em  th e  p a t i e n t ’ s  f in d ing s  o n  w o r k - u p  to  b e  n o t  c l in i c a l ly  s ig n i f i c a n t  p a th o lo gy ,  th e  p a t i e n t  w i l l  h a v e  m e t  th i s  e x c lu s io n  c r i t e r io n .   
•  P a t i e n t s  w i th  a  h i s to ry  o f  c o r o n a ry  a r t e ry  by p a s s  g r a f t ing  o r  a ng io p l a s ty  w i l l  r e c e iv e  a  
c a r d io logy  e v a lu a t io n  a nd  b e  c o n s id e r e d  o n  a  c a s e - by - c a s e  b a s i s .  
•  A c t iv e  h e p a t i t i s  B  o r  C  in f e c t io n 
•  H IV  s e r o p o s i t iv e,  w i th  po s i t iv e  c o n f i rm a to ry  n u c l e i c  a c id  t e s t  
•  P a t i e n t s  k n ow n  o r  f o u n d  to  b e  p r eg n a n t .   
•  P a t i e n t s  o f  c h i ld b e a r ing  ag e  w h o  a r e  u nw i l l in g  to  p r a c t i c e  c o n t r a c e p t io n .  •  P a t i e n t s  m ay  b e  e x c lu d e d  a t  th e  d i s c r e t io n  o f  th e  P I/LA I  i f  i t  i s  d e em e d  th a t  a l low in g  
p a r t i c ip a t io n  w o u ld  r e p r e s e n t  a n  u n a c c e p t a b l e  m ed i c a l  o r  p sy c h i a t r i c  r i sk .  
A bb r e v i a t e d  T i t l e :  HPC  f o r  AHCT  in  PCM   
V e r s io n  d a t e :  S e p t em b e r  14,  20 17  
  
                                                                                                                                          P ag e  13 o f  38  2 . 1 . 3  R e c r u i tm e n t  s t r a t egy 
I t  i s  a n t i c ip a t ed  th a t  in t e rn a l  r e c r u i tm e n t  f r om  CCR  su b j e c t s  w i l l  b e  l ik e ly  su f f i c i e n t  f o r  th e  
e xp e c t e d  a c c r u a l .  
2 . 2  SCREEN ING EVALUAT ION 
2 . 2 . 1  H i s to ry  a n d  Phy s i c a l  e x am in a t io n 
A l l  p a t i e n t s  mu s t  h a v e  a  c omp l e t e  h i s to ry ,  r e v i ew  o f  sy s t em s a n d  p hy s i c a l  ex am in a t io n  w i th in  4  
w e e k s  o f  s tu dy  e n t ry  d a t e .   A p p r o p r i a t e  c o n su l t a t io n s  m ay  a l so  b e  o b t a in e d a s  in d i c a t e d  f o r  b e s t  c l in i c a l  c a r e .  
2 . 2 . 2  L a b o r a to ry  e v a lu a t io n 
T h e  f o l low in g  l a b o r a to ry  s tu d i e s  mu s t  b e  p e r f o rm e d  w i th in  th e  sp e c i f i e d  p e r io d  p r io r  to  s tu dy  
e n t ry  d a t e :   
•  S tu d i e s  p e r f o rm e d  a t  d i ag n o s i s  to  e s t a b l i sh  th e  d i a g n o s i s  o f  PCM  ( o r  su b s e q u e n t  s tu d i e s  
d emo n s t r a t in g  th e  p r e s e n c e  o f  d i s e a s e )  mu s t  b e  a v a i l a b l e  f o r  r e v i ew  a n d  d i ag n o s t i c  
c o n f i rm a t io n  a t  th e  NC I .   
•  CBC  w i th  d i f f e r e n t i a l  a nd  p l a t e l e t  c o u n t  (1  w e e k ) , 
•  A c u t e ,  H e p a t i c a n d  M in e r a l  p a n e l s  ( 1  w e e k) ,  •  PT /PTT ,  f ib r in o g e n  ( 1  w e e k) ,  •  ABO  ty p ing  ( 4  w e e k s ) ,  •  S e r o lo gy  f o r  h e p a t i t i s  B  a n d  C v i r u s ,  H IV- 1 /2 ,  HTLV  I / I I ,  T .  C r u z i  ( 4  w e e k s ) ,  N u c l e i c  a c id  
t e s t in g  (NAT )  f o r  t r a n sm i s s ib l e  d i s e a s e  ag e n t s ,  p e r  DTM  p o l i cy  ( 4  w e e k s ) ,  
•  β -HCG  o r  u r in e  p r eg n a n cy  t e s t  in  n o n -m e n o p a u s a l  w om e n  o n ly  ( 1  w e e k ) ,  •  ECG  ( 4  w e e k s ) 
2 . 3  R
EG ISTRAT ION  PROCEDURES 
A l l  p a t i e n t s  mu s t  b e  r e g i s t e r e d  o n  s tu dy  o n c e  s tu dy  c o n s e n t  h a s  b e e n  o b t a in ed .  T h i s  i s  ty p i c a l ly  
d o n e  a f t e r  e l ig ib i l i ty  h a s  b e e n  c o n f i rm e d .  A u th o r i z e d  s t a f f  mu s t  r eg i s t e r  a n  e l ig ib l e  c a n d id a t e  w i th  C e n t r a l  R e g i s t r a t io n  w i th in  2 4  h o u r s  a f t e r  th e  c a n d id a t e  s ig n ing  in f o rm e d  c o n s e n t .   A  r eg i s t r a t io n  c h e c k l i s t  f r om  th e  w e b  s i t e  ( h t tp : / /h om e . c c r . c a n c e r .g o v / in t r a / e l ig ib i l i ty /w e l c om e . h tm)  mu s t  b e  c omp l e t e d  a n d  s e n t  v i a  e n c ry p t e d  em a i l  to :   NC I  C e n t r a l  R e g i s t r a t io n  O f f i c e  n c i c e n t r a l r eg i s t r a t io n- l@m a i l . n ih . g o v .   T h e  C e n t r a l  R e g i s t r a t io n  O f f i c e  w i l l  s e n d  a  c o n f i rm a t io n  o f  e l ig ib i l i ty  a n d  w i l l  c a l l  Ph a rm a cy  to  a d v i s e  th em  o f  th e  a c c e p t a n c e  o f  th e  p a t i e n t  o n  th e  p r o to c o l  p r io r  to  th e  r e l e a s e  o f  a ny  in v e s t ig a t io n a l  ag e n t s .   V e r i f i c a t io n  o f  R eg i s t r a t io n  w i l l  b e  f o rw a r d e d  e l e c t r o n i c a l ly  v i a  e - m a i l.   F o r  q u e s t io n s  r eg a r d ing  r e g i s t r a t io n ,  a u th o r i z e d  in d iv id u a l s  sh o u ld  c a l l  th e  C e n t r a l  R e g i s t r a t io n  O f f i c e  b e tw e e n  th e  h o u r s  o f  8 :3 0AM  a n d  5 :0 0PM ,  Mo n d ay  –  F r id ay :  p h o n e  ( 3 0 1 )  4 0 2 - 1 7 3 2 .   V o i c em a i l  i s  a v a i l a b l e  d u r in g  n o n- b u s in e s s  h o u r s .  
3  STUDY  IMPLEMENTAT ION 
3 . 1  S
TUDY  OVERV IEW 
•  Su b j e c t s  w i l l  u n de r g o  mo b i l i z a t io n  a n d  c o l l e c t io n  o f  p e r ip h e r a l  b lo o d  s t em  c e l l s  f o r  
su b s e q u e n t  u s e  in  v a r io u s  c l in i c a l  p r o to c o l s .  
A bb r e v i a t e d  T i t l e :  HPC  f o r  AHCT  in  PCM   
V e r s io n  d a t e :  S e p t em b e r  14,  20 17  
  
                                                                                                                                          P ag e  14 o f  38  •  T h e   n e e d   f o r   a n   a d d i t io n a l   mo b i l i z in g   a g e n t   (p l e r ix a f o r )   to   b e   g iv e n   o n   d ay  4   o f  
mo b i l i z a t io n   w i l l   b e   e v a lu a t e d   in   r e a l   t im e   in   e a c h   p a t i e n t ,  b a s e d   o n   th e   p e r ip h e r a l  
b lo o d  CD 3 4  c o u n t  o n  th e  mo r n in g  o f  d ay  4  o f  G - CSF  a dm in i s t r a t io n.  
o P a t i e n t s  w i th  a  p e r ip h e r a l  CD  3 4+ c e l l s  c o u n t  o f  g r e a t e r   th a n  o r  e q u a l  to  4 2  c e l l s / μ l 
p e r f o rm e d  o n   th e   mo r n in g   o f   d ay   4 ,   a   m in imum   o f   3   h o u r s   a f t e r     th e   4th  G - CSF  
a dm in i s t r a t io n  w i l l  n o t  r e c e iv e  p l e r ix a f o r  b u t  w i l l  r e c e iv e  a  f i f th  d o s e  o f  f i lg r a s t im  in  th e  mo r n in g  o f  d ay  5 .  Th e  a p h e r e s i s  w i l l  s t a r t  th a t  mo r n in g ,  d ay  5  o f  mo b i l i z a t io n ,  a  m in imum  o f  3  h o u r s  a f t e r  th e  5
th G - CSF  a dm in i s t r a t io n.  
o P a t i e n t s  w i th  a  p e r ip h e r a l  CD  3 4+ c e l l s  c o u n t  o f  l e s s  th a n  4 2  c e l l s / μ l o n  th e  mo r n in g  
o f   d ay  4  o f   G- CSF   a dm in i s t r a t io n  m ay  r e c e iv e  e i th e r   f i lg r a s t im   a lo n e  o n   d ay   5   o f  mo b i l i z a t io n  o r  b o th  p l e r ix a f o r  in  e v e n in g  o f  d ay  4  a n d  f i lg r a s t im  in  th e  mo r n in g  o f  d ay  5  o f  mo b i l i z a t io n ,  d e p e n d in g  o n  th e i r  w e ig h t  a n d  th e i r  c i r c u l a t in g  CD3 4  c o u n t ,  a s  d e s c r ib e d  in  Tab l e  1 .  T h e  a p h e r e s i s  w i l l  s t a r t  th a t  mo r n in g ,  d ay  5  o f  mo b i l i z a t io n ,  a  m in imum  o f  3  h o u r s  a f t e r  th e  a dm in i s t r a t io n  o f  th e  5
th G - CSF  d o s e  ( a n d  p l e r ix a f o r ,  i f  
in d i c a t e d ) .  
•  T h e   c o l l e c t io n   t a rg e t   d o s e   i s   5   x   1 06  CD 3 4+  c e l l s /k g ,  to   b e   su f f i c i e n t   f o r   a   d o u b l e  
AHCT i f   c l in i c a l ly   in d i c a t e d  ( o r   f o r   a   r e s c u e   p r o c e d u r e   a s   r e q u i r e d   o n   som e  t r a n sp l a n t  p r o to c o l s )  (m in imum  d o s e  i s  4  x  1 0
6  CD 3 4+  c e l l s /k g  f o r  a  d o u b l e  t r a n sp l a n t  
a n d  2  x  1 06  CD 3 4+  c e l l s / k g  f o r  a  s ing l e  a u to log o u s  t r a n sp l a n t ) .  
3 . 2  TREATMENT  SCHEMA  
 
 
 
*  G - CSF  1 0- 1 6μg /kg /d o s e  ( a c c o r d ing  to  DTM  a lg o r i thm  in  s e c t io n  3 . 3 . 1 )  su b c u t a n e o u s ly  
* *  P l e r ix a f o r 2 4 0  m c g /kg ,  n o t  to  e x c e e d  2 4 , 0 0 0  m c g  to t a l   M o b i l i z a t ion 
D ay  1 :   -  G - CSF 1 0 - 1 6  μg /kg /d o s e  * ( a t  9  am  + /-  1  h )  D ay  2 :   -  G - CSF 1 0 - 1 6  μg /kg /d o s e  * ( a t 9  am  + /-  1  h )  D ay  3 :   -  G - CSF 1 0 - 1 6  μg /kg /d o s e  * ( a t  9  am  + /-  1  h )  D ay  4 : -  G- CSF 1 0 - 1 6  μg /kg /d o s e  * ( a t  6  am  + /-  1  h )  D ay  4 :   -  c i r c u l a t ing  b lo o d  CD  34  c e l l  c o u n t ,  d r aw n  a  m in imum  o f  3  h o u r s  
a f t e r  th e  G -CSF  d o s e  
  -  i f  D ay  4  CD  3 4  <  4 2  c e l l s / μ l,  r e f e r  t o  Tab l e  1  fo r  d e c i s ion :   
 - P l e r ix a f o r* * a s  in d i c a t e d  in  Tab l e  1  t o  b e  g iv en  a t  1 0pm  on  da y  
4  
D ay  5:   -  G - CSF 1 0 - 1 6  μg /kg /d o s e  *  3  h o u r s  p r io r  to  a p h e r e s i s ( a t  6  am )  
   -  s ta r t  a p h e r e s i s  #1  th e  s am e  d a y      
A bb r e v i a t e d  T i t l e :  HPC  f o r  AHCT  in  PCM   
V e r s io n  d a t e :  S e p t em b e r  14,  20 17  
  
                                                                                                                                          P ag e  15 o f  38   
    
 
     
 
    
3 . 3  DRUG  ADM IN ISTRAT ION 
•  Fi lg r a s t i m  w i l l  b e  a dm in i s t e r e d  a s  a  s ing l e  d a i ly  do s e  in  a  d o s e  r a ng e  o f  1 0-
1 6 u g /kg /d ay  su b c u t a n e ou s ly  f o r  5 - 7 d ay s  ( s e e  T a b l e  b e low  f o r  s l id in g - s c a l e  f i lg r a s t im  
d o s e  s c h e d u l e ) .   
•  T h e  f i lg r a s t im  d o s e s  f o r  d ay s  1 - 3 a r e  to  b e  g iv e n  a t  a p p r o x im a t e ly  9 :0 0  a .m . (+ / -  1  h ) .  
O n  d ay  4 ,  th e  f i lg r a s t im d o s e  i s  to  b e  g iv e n  a t  6 :0 0  a .m .  (+ / -  1 h ) .  
•  T h e  f i lg r a s t im  d o s e  to  b e  a dm in i s t e r e d  o n  d ay  5  ( an d  i f  n e c e s s a ry  d ay s  6  a nd  7 )  m ay  
b e  c omb in e d  w i th  a  c o n cu r r e n t  d ay  4  d o s e  o f  p l e r ix a f o r  2 4 0  m c g /kg  su b c u t a n e o u s ly  b a s e d  o n  th e  p e r ip h e r a l  b lo o d  CD 3 4
+ c e l l  c o u n t  ( s e e  T a b l e  1  f o r  p r e d i c t io n  o f  n e e d  
f o r  p l e r ix a f o r  b a s e d  o n  p a t i e n t  w e ig h t  a n d  c i r c u l a t in g  CD 3 4+ c e l l  c o u n t ) .    
•  O n  d ay s  5 ,  6  o r  7,  f i lg r a s t im  ( o r  b o th  d r u g s )  mu s t  b e  g iv e n  a p p r o x im a t e ly  3  h o u r s  
p r io r  to  s t a r t in g  a p h e r e s i s .   
•  I t  i s  n o t  a n t i c ip a t e d  th a t  a  f o u r th  c o n s e cu t iv e  a p h e r e s i s  p r o c e d u r e  w i l l  b e  r eq u i r e d ;  
h ow e v e r ,  th e r e  m ay  b e  c i r c um s t a n c e s ,  su c h  a s  t e ch n i c a l  p r o b l em s  d u r ing  ap h e r e s i s  o r  d am ag e  to  a  p r o d u c t  d u r in g  p r o c e s s ing  th a t  r e q u i r e  a n  a d d i t io n a l  p r o c e d u r e .   I n  th i s  c a s e ,  th e  s am e  mo b i l i z a t i o n  r eg im e n  g iv e n  p r io r  to  th e  p r e v io u s  a p h e r e s i s  p ro c e d u r e s  w i l l  b e  g iv e n  ag a in .   T h e  m a x imum  n umb e r  o f  c o n s e c u t iv e  a p h e r e s i s  p r o c e du r e s  p e r f o rm e d  in  a ny  p a t i e n t  w i l l  b e  4 .   
3 . 3 . 1  F i lg r a s t im  a dm in i s t r a t io n 
F i lg r a s t im  w i l l  b e  a dm in i s t e r e d  a c c o r d ing  to  a  v i a l- b a s e d  a lg o r i thm  to  r e d u c e  w a s t ag e  a n d  
in c r e a s e  th e  to t a l  f i lg r a s t im  d o s e  g iv e n  to  l ig h t e r  w e ig h t  d o n o r s  in  o r d e r  to  imp r o v e  CD 3 4  y i e ld s
[ 33 ].  T h e  w e igh t  o n  d ay  1  w i l l  b e  u s e d  f o r  a l l  c a l c u l a t io n s N o t  r ea ch ed;    
<4  x 1 06 CD 3 4 /k g  
co l l e c t ed  
N o t  r ea ch ed ;    
>  4  b u t  < 5  
x1 06 CD 3 4 /k g  
 M in imum   
d o s e  r ea ch e d  M ay  p r o c e e d 
to  2n d 
mo b i l i z a t io n  
cy c l e  •  C r y o p r e s e r v e 
•  P ro c e e d  to  AHCT A ph e r e s i s T a rg e t  d o s e :  5  x  1 06CD 3 4+c e l l s  /  k g  
F o l low in g  a p h e r e s i s  # 1 ,  p r o c e e d  to  a p h e r e s i s  # 2  /  # 4 :  
G iv e 8 - 1 0  h o u r s  p r io r  to  a p h e r e s i s  # 2 /  # 4  
o -P l e r ix a f o r  2 4 0  μg /kg  
G iv e  3  h o u r s  p r io r  to  a p h e r e s i s  # 2 /  # 4 :  
      -G - CSF 1 0 - 1 6  μg /kg   
      Ta rg e t  d o s e  r e a c h e d ?  
r e a ch e d  A f t e r  a ph e r e s i s  1 /2 
A f t e r  a ph e r e s i s  3 
A bb r e v i a t e d  T i t l e :  HPC  f o r  AHCT  in  PCM   
V e r s io n  d a t e :  S e p t em b e r  14,  20 17  
  
                                                                                                                                          P ag e  16 o f  38   Su b j e c t  W e ig h t T o t a l  F i lg r a s t im  D o s e D o s e  /k g  ( r a ng e )   
  3 8  -  < 4 9 kg  6 0 0  m c g    ( 1 2 . 5  to  1 5 . 8  m c g /kg )    
  4 9  -  <  5 7  kg       7 8 0  m c g    ( 1 3 . 9  to  1 5 . 9  m c g /kg )   
  5 7  -  < 6 1 kg   9 0 0  m c g    ( 1 5 . 0  to  1 5 . 8  m c g /kg )  
  6 1  -  < 6 8  kg        9 6 0  m c g    ( 1 4 . 3  to  1 5 . 7  m c g /kg )  
  6 8  -  < 1 0 9  kg     1 0 8 0  m c g   ( 1 0 . 0  to  1 5 . 9  m c g /kg )    
  >  1 0 9  k g       1 2 0 0  m c g   ( 1 1 . 0  o r  l e s s )    
 
3 . 3 . 2  P l e r ix a f o r  A dm in i s t r a t io n 
I f  p l e r ix a f o r  i s  n e c e s s a ry ,  i t  w i l l  b e  g iv e n  o n  d ay  4 ,  8 - 1 0  h o u r s  b e f o r e  th e  d ay  5  a p h e r e s i s  
Su bj e c t  W e ig h t  T o t a l  P l e r ix a f o r  D o s e <  9 0  k g     c a l c u l a t e  d o s e  a t  2 4 0  m cg /kg  >  9 0  k g     2 4 , 0 0 0  m c g  ( f l a t  d o s e ,  e qu a l  to  o n e  f u l l  1 . 2 -mL  v i a l ) 
 
3 . 3 . 3  A p h e r e s i s 
HPC ,  A p h er e s i s  c o l l e c t ion  w i l l  b e  p e r f o rm e d  in  th e  D ow l in g  A p h e r e s i s  C l in i c  o f  th e  D e p a r tm e n t  
o f  T r a n s f u s io n  M e d i c in e  (DTM ) .   A  DTM  p hy s i c i a n  i s  w i th in  th e  imm e d i a t e  v i c in i ty  o f  th e  p r o c e d u r e  o r  a v a i l a b l e  w i th in  o n e  m in u t e  by  p ag e r .  T h e  m in imum  CD 3 4
+ c e l l  d o s e  th a t  mu s t  b e  
c o l l e c t e d  in  o r d e r  to  p r o c e e d  w i th  a  s ing l e  a u to log o u s  t r a n sp l a n t a t io n  i s  2  x  1 06 CD 3 4+ c e l l s /k g .   
A s  s t a n d a r d  o f  c a r e  n o t  in f r e q u e n t ly  c a l l s  f o r  t a n d em  t r a n sp l a n t s  in  mu l t ip l e  my e lom a  a n d  a s  som e  NC I  p r o to c o l s  r e q u i r e  th a t  a  b a c k u p  p r o d u c t  b e  c o l l e c t e d  in  c a s e s  o f  s in g l e  t r a n sp l a n t s  ,  a  h ig h e r  d o s e  o f   >  5  x1 0
6 CD 3 4+ c e l l s /k g  w i l l  b e  t a r g e t e d ,  to  p e rm i t  mo r e  th a n  o n e  cy c l e  o f  h ig h  
d o s e  c h emo th e r a py  w i th  a u to lo g o u s  s t em  c e l l  r e s cu e .   B a s e d  o n  th e  mo b i l i z a t io n  r e sp o n s e  o f  in d iv id u a l  su b j e c t s ,  th i s  m ay  r e q u i r e  a d d i t io n a l  co l l e c t io n s  e v e n  i f  th e  m in imum  r e q u i r e d  f o r  a  s in g l e  t r a n sp l a n t  ( 2 x1 0
6 CD 3 4  c e l l s /k g )  h a s  b e e n  c o l l e c t e d  in  a  s ing l e  a p h e r e s i s  p r o c e d u r e .   
T h e  v o lum e  p r o c e s s e d  p e r  a p h e r e s i s  p r o c e du r e  w i l l  b e  d e t e rm in e d  by  DTM  m e d i c a l  s t a f f  o n  th e  d ay  o f  a p h e r e s i s ,  b a s e d  on  p e a k  CD 3 4
+ c e l l  mo b i l i z a t io n  r e sp o n s e  to  f i lg r a s t im  a n d  o p t imum  a n d  
m in imum CD 3 4  c e l l  d o s e  n e e d e d .  I n  g e n e r a l ,  v o lum e  p r o c e s s ed  w i l l  r a ng e  f r om  1 2  to  3 0  l i t e r s  p e r  p r o c e d u r e  f o r  1  to 3  co n s e c u t iv e  d a i ly  p r o c e d u r e s ,  n o t  to  e x c e e d  a  to t a l  o f  6 0  l i t e r s  o v e r  3 d ay s .   I f  th e  m in im a l  c e l l  d o s e  n e c e s s a ry  to  p r o c e e d  w i th  a  s in g l e  a u to lo g ou s  t r a n sp l a n t  (≥2  x1 0
6 CD 3 4+  c e l l s /k g )  i s  n o t  a c h i e v e d  w i th  3  d a i ly  l a r g e  v o lum e  l e u k a p h e r e s i s  p r o c e d u r e s ,  th e n  i t  
i s  e x c e e d in g ly  u n l ik e  th a t  a  f o u r th  c o n s e c u t iv e  a ph e r e s i s  p r o c e d u r e  w i l l  r e a c h  th i s  g o a l .  T h e  p a t i e n t  in  su c h  c a s e s  i s  l ik e ly  to  h a v e  m in im a l  m a r r ow  r e s e r v e  a n d  n o t  mob i l i z e  p r o g e n i to r  c e l l s  in  r e sp o n s e  to  p h a rm a c o lo g i c  ag e n t s .   I n  c o n t r a s t ,  i f  a  t e c h n i c a l  m i sh a p  o c cu r s  d u r in g  a p h e r e s i s ,  o r  p r o d u c t  c o n t am in a t io n  o c c u r s  d u r ing  p r o c e s s ing ,  r e su l t in g  in  in a d v e r t e n t  p r o d u c t  lo s s ,  th e n  a  f o u r th  d a i ly  p r o c e d u r e  m ay  b e  c o n s id e r e d . 
A l l  d e c i s io ns  a b o u t  th e  n e e d  f o r  a  th i r d  d ay  o f  c o l l e c t io n  w i l l  b e  m a d e  in  c on c e r t  b e tw e e n  P I /LA I  
a n d  DTM  p hy s i c i a n s .  
 Co l l e c t io n s  w i l l  b e  p e r f o rm e d  w i th  u s e  o f  a  d u a l - a c c e s s  c o n t in u o u s - f low  a ph e r e s i s  d e v i c e  
(Sp e c t r a  A p h e r e s i s  Sy s t em ,  C a r id i a n ) .  M a ny  su b j e c t s  w i l l  r e q u i r e  a  c e n t r a l  d o u b l e  lum e n  a p h e r e s i s  c a th e t e r .  Su b j e c t s  w i l l  r e c e iv e  c o n t in u o u s  in t r a v e n o u s  c a l c ium  p r o p hy l a x i s  to  p r e v e n t  c i t r a t e  to x i c i ty  d u r in g  a ph e r e s i s ,  in  a c c o r d a n c e  w i th  s t a n d a r d  DTM  p o l i c i e s .  
A bb r e v i a t e d  T i t l e :  HPC  f o r  AHCT  in  PCM   
V e r s io n  d a t e :  S e p t em b e r  14,  20 17  
  
                                                                                                                                          P ag e  17 o f  38  T h e  p r o d u c t s  w i l l  b e  c ry o p r e s e r v e d  in  th e  C e l l  P r o c e s s in g  S e c t io n ,  DTM ,  CC  a n d  w i l l  b e  s to r e d  
in  th e  v a p o r  p h a s e  o f  l iq u id  n i t r o g e n .   
3 . 3 . 4  I n a d e q u a t e  c o l l e c t io n  
I f ,  a f t e r  3  o r  4  c o n s e c u t iv e  d a i ly  p r o c e d u r e s ,  th e  to t a l  n umb e r  o f  CD 3 4+  c e l l s  c o l l e c t e d  i s :  
•  G r e a t e r  o r  e q u a l  to  4 x1 06/k g ;  th e  su b j e c t  w i l l  n o t  b e  o f f e r e d  a  2nd c o l l e c t io n  cy c l e  a n d  
w i l l  c om e  o f f  s tu dy.  
•  L e s s  th a n  4 x1 06/k g ;  o n  a  c a s e  by  c a s e  b a s i s ,  th e  su b j e c t  m ay  b e  o f f e r e d  a  2nd 
c o l l e c t io n  cy c l e  o n  s tu dy .  
A l l  d e c i s io n  a b o u t  th e  n e e d  f o r  a n  a d d i t io n a l  cy c l e  o f  c o l l e c t io n  w i l l  b e  m ad e  in  c o n c e r t  b e tw e e n  
P I/LA I  a n d  DTM  p hy s i c i a n s .  
3 . 3 . 5  S a lv a g e  c o l l e c t io n  r eg im e n 
Su b j e c ts  w i th  a n  in a d e q u a t e  c o l l e c t io n  a s  d e f in e d  a b o v e  m ay  b e  o f f e r e d  a  2ndmo b i l i z a t io n  a n d  
c o l l e c t io n  cy c l e .   T h e  f o l low in g  r eg im e n  i s  sug g e s t e d ;  
D ay  1 :  -  G - CSF  1 0- 1 6  μg /kg /d o s e  * ( a p p r o x im a t e ly  a t  9 am ,  + / -  1 h )  D ay  2 :  -  G - CSF  1 0- 1 6  μg /kg /d o s e  * ( a p p r o x im a t e ly  a t  9  am,  + / -  1 h )  D ay  3 :  -  G - CSF  1 0- 1 6  μg /kg /d o s e  * ( a p p r o x im a t e ly  a t  9  am ,  + / -  1 h )  D ay  4 :  -  G - CSF  1 0- 1 6  μg /kg /d o s e  * ( a p p r o x im a t e ly  a t  6  am ,  + / -  1 h )    -  P l e r ix a f o r **  ( a t  8 - 1 0  pm )  
D ay  5 :  -  3  h o u r s  p r io r  to  a p h e r e s i s  ( a p p r o x im a t e ly  a t  6  am )  
    -  G - CSF  1 0- 1 6  μg /kg /d o s e *    -  P l e r ix a f o r * *  ( a t  8 - 1 0  pm )  D ay  6 :  -  3  h o u r s  p r io r  to  a p h e r e s i s  ( a p p r o x im a t e ly  a t  6  am )      -  G - CSF  1 0- 1 6  μg /kg /d o s e *     -  P l e r ix a f o r * *  ( a t  8 - 1 0  pm )   D ay  7:   -  3  h o u r s  p r io r  to  a p h e r e s i s  ( a p p r o x im a t e ly  a t  6  am )      -  G - CSF  1 0- 1 6  μg /kg /d o s e *        
T h e  s a lv ag e  r eg im e n  m ay  s t a r t  n o  so o n e r  th a n  4  w e e k s  a f t e r  th e  l a s t  a p h e r e s i s  p r o c e d u r e . I f ,  a f t e r  a  s e c o n d  c o l l e c t io n ,  th e  c umu l a t iv e  CD 3 4
+c e l l  n umb e r  c o l l e c t e d  d u r in g  th e  tw o  
c o l l e c t io n s  i s  l e s s  th a n  2 x 1 06 c e l l s  /  k g ,  th e  p r o d u c t  m ay  b e  d i s c a r d e d  s in c e  n o  t r a n sp l a n t  w i l l  b e  
p e r f o rm e d .   
3 . 4  DOSE  MOD IF ICAT IONS 
S e e  d o s ag e  a lg o r i thm  a b o v e  in  s e c t io n s  3 . 3 . 1 a n d  3 . 3 . 2  
T h e r e  a r e  n o  p l a n n e d  d o s e  mo d i f i c a t io n s .  
A bb r e v i a t e d  T i t l e :  HPC  f o r  AHCT  in  PCM   
V e r s io n  d a t e :  S e p t em b e r  14,  20 17  
  
                                                                                                                                          P ag e  18 o f  38   
3 . 5  STUDY  CALENDAR 
 
 ON 
STUDY D a y  1 D a y  2 D a y  3 D a y  4 D a y  5 D a y  6 D a y  7 D a y  p o s t 
la s t  aph e r e s i s  
H i s t o r y  &  Ph y s i c a l   ( 2  w e ek ) X        X 
CBC ,  d i f f ,  p l t s  ( 1  w e ek ) X         X  
Ch em i s t r i e s  ( 1  w e ek ) X        X 
PT /PTT ,  f ib r in o g en  ( 1  w e ek ) X          
S e r o lo gy :  HBV ,  HCV ,  H IV ,  
HTLV ,  T .C ru z i ( 4  w e ek s )  X         
ABO  t yp in g  ( 4  w e ek s )  X          
DTM   NAT  t e s t in g  ( 4  w e ek s ) X          
β- HCG  /  u r in e  p r e gn an c y  t e s t  n on  m enopau s a l  wom en  on ly  ( 1  w e ek )  X          
ECG  ( 4  w e ek s ) X          
M ob i l i z a t ion  th e r apy           
G- CSF (g i v en  in  th e  m o rn ing)   X X X X X X  ( o r  n o t ) X  ( o r  n o t )  
P l e r i x a fo r (g i v en  in  th e  ev en in g )      X  ( o r  n o t ) X  ( o r  
no t )  X  ( o r  n o t ) X  ( o r  n o t )  
Aph e r e s i s      X  X  ( o r  n o t )  X  ( o r  n o t )  
P e r iph e ra l  CD 34*  c oun t ( in  am )      X  X 
p r e -
a ph e r e s i s  X  ( o r  n o t ) X  ( o r  n o t )  
P e r iph e ra l  B lo od  MRD   (FACS  &  m o l e cu la r )  X   
  X  X  ( p r e ) X  ( o r  n o t )  X  ( o r  n o t )  
Aph e r e s i s  p rodu c t  MRD 
(FACS  &  m o l e cu la r )       X  X  ( o r  n o t )    
 
3 . 6  OFF  STUDY  CR ITER IA 
3 . 6 . 1  C r i t e r i a  f o r  r emo v a l  f r om  p r o to c o l  th e r a py  
•  Su b j e c t ’ s  d e c i s io n 
•  A d v e r s e  e v e n t  r e l a t e d  to  th e  f i lg r a s t im  o r  p l e r ix a f o r  a dm in i s t r a t io n  w h i c h ,  in  th e  
o p in io n  o f  th e  P I /LA I ,  w a r r a n t s  d i s c o n t in u a t io n  o f  th e  t r e a tm e n t .  
3 . 6 . 2  O f f- S tu dy  C r i t e r i a 
•  A d e q u a t e  c o l l e c t io n  o f  >  4 x  1 06 CD 3 4+  c e l l s /k g : s u b j e c t  w i l l  b e  e v a lu a t e d  th e  d ay  
f o l low in g  th e  l a s t  a p h e r e s i s  p r o c e d u r e .   I f  n o  s ig n i f i c a n t  c omp l i c a t io n  f r om  th e  
p r o c e d u r e  h a s  a r i s e n ,  th e  su b j e c t  w i l l  b e  t a k e n  o f f  s tu dy .  
•  Comp l e t e d  a  s e c o n d  mo b i l i z a t io n / c o l l e c t io n  cy c l e ( “ s a lv ag e  cy c l e ” ) ,  r eg a r d l e s s  o f  th e  
to t a l  n umb e r  o f  c e l l s  c o l l e c t e d  
•  A ny  g r a d e  > 2  a d v e r s e  e v e n t  p o s s ib ly ,  p r o b a b ly  o r  d e f in i t e ly  r e l a t e d  to  th e  p r o c e d u r e  
w i l l  b e  f o l low e d  u n t i l  r e so lu t io n  o r  c l in i c a l  s t a b i l i z a t io n  b e f o r e  th e  su b j e c t  i s  t a k e n  o f f  s tu dy .  
A bb r e v i a t e d  T i t l e :  HPC  f o r  AHCT  in  PCM   
V e r s io n  d a t e :  S e p t em b e r  14,  20 17  
  
                                                                                                                                          P ag e  19 o f  38  •  D e a th 
•  P I  d e c i s io n  to  e n d  th i s  s tu dy  
 
3 . 6 . 3  O f f  P r o to c o l  T h e r a py  a nd O f f  S tu dy  P r o c e d u r e 
A u th o r i z e d  s t a f f  mu s t  n o t i fy  C e n t r a l  R eg i s t r a t io n  O f f i c e  (CRO )  w h e n  a  sub j e c t  i s  o f f  p r o to c o l  
th e r a py  a n d  wh e n  a  su b j e c t  i s  t a k e n  o f f - s tu dy .  A  P a r t i c ip a n t  S t a tu s  U p d a t e  F o rm f r om  th e  w e b  s i t e  ( h t tp : / /h om e . c c r . c a n c e r .g o v / in t r a / e l ig ib i l i ty /w e l c om e . h tm)  m a in  p ag e  mu s t  b e  c omp l e t e d  a n d  s e n t  v i a  e n c ry p t e d  em a i l  to :   NC I  C e n t r a l  R eg i s t r a t io n  O f f i c e  n c i c e n t r a l r eg i s t r a t io n-l@m a i l . n ih . g o v .  
4  CONCOM ITANT  MED ICAT IONS /MEASURES 
A na lg e s i c  m e d i c a t io n s  m ay  b e  n e e d e d  d u r ing  f i lg r a s t im  th e r a py .  
5  B IOSPEC IMEN  COLLECT ION 
5 . 1  C
ORRELAT IVE  STUD IES  FOR  RESEARCH/PHARMACOK INET IC  STUD IES 
5 . 1 . 1  C l in i c a l  e n d  p o in t s  
•  D e t e rm in a t io n  o f  th e  p r op o r t io n  o f  su b j e c t s  r e q u i r in g  a d d i t io n  o f  pl e r ix a f o r  to  th e  
mo b i l i z a t io n  r e g im e n 
•  D e t e rm in a t io n  o f  th e  p r op o r t io n  o f  su b j e c t s  a c h i ev in g  th e  t a rg e t  g o a l  o f  5  x  1 06 c e l l s  /  
K g  w i th  o n e  o r  tw o  a p h e r e s i s  p r o c e d u r e s  w i th  o r  w i th o u t  P l e r i x a f o r .  
5 . 1 . 2  B io lo g i c  e n d  p o in t s  
•  D e t e rm in a t io n  o f  th e  d eg r e e  o f  tumo r  c e l l c o n t am in a t io n  in  th e  f in a l  p r o d u c t .  
•  D e t e rm in a t io n  o f  th e  imp a c t  o f  p l e r ix a f o r  in  th e  d eg r e e  o f  tumo r  c e l l  c o n t am in a t io n  o f  
th e  f in a l  p r o d u c t .  
5 . 1 . 2 . 1  P e r ip h e r a l  b lo o d  
-  2 0  c c  in  G r e e n  T o p  tu b e  to  th e  NC I  C l in i c a l  F low  Cy tom e t ry  c o r e  (F low  cy tom e t ry )  
-  2 0  c c  in  L a v e n d e r T o p  tub e  to  D r .  F ig g ’ s  l a b  f o r  p r o c e s s ing  a n d  s to r ag e  -  T im e  p o in t s : 
-  A t  b a s e l in e ,   -  d ay  4  ( c o l l e c t e d  a f t e r  th e  4
th d o s e  o f  G - CSF ),  
-  d ay  5 ,  p r e - a p h e r e s i s  -  a n d  d ay s  6 ,  7 ,  i f  c o l l e c t ed  o n  th e s e  d ay s .  
5 . 1 . 2 . 2  A p h e r e s i s  P r o d u c t  
F o r  e a c h  d ay  o f  a p h e r e s i s   -  1 - 2  c c  in  r e d  to p  tu b e  to  th e  NC I  C l in i c a l  F low  Cy tom e t ry  c o r e  (F low  cy tom e t ry )  
-  1 - 2  c c  in  r e d  to p  tu b e  to  D r .  F ig g’ s  l a b  f o r  p r o c e s s in g  a n d  s to r ag e+  
N o t e  fo r  F ig g ’ s  lab  b lo od  c o l l e c t ion:  P l e a s e  e- m a i l  Ju l i e  B a r n e s  a t  Ju l i e . b a r n e s@ n ih .g o v  a n d  
P a u l a  C a r t e r  p c a r t e r a@m a i l . n ih . g o v  a t  l e a s t  2 4  h o u r s  b e f o r e  t r a n sp o r t ing  s amp l e s  ( th e  F r id ay  b e f o r e  i s  p r e f e r r e d ) . 
A bb r e v i a t e d  T i t l e :  HPC  f o r  AHCT  in  PCM   
V e r s io n  d a t e :  S e p t em b e r  14,  20 17  
  
                                                                                                                                          P ag e  20 o f  38  F o r  s amp l e  p i c k u p ,  p ag e  1 0 2 - 1 1 9 6 4q a a a s.  
F o r  imm e d i a t e  h e lp ,  c a l l  2 4 0- 7 6 0 - 6 1 8 0  (m a in  b loo d  p r o c e s s ing  c o r e  n umb e r )  o r ,  i f  n o  a n sw e r ,  
2 4 0 - 7 6 0 - 6 1 9 0  (m a in  c l in i c a l  p h a rm a c o lo gy  l a b  n umb e r ) .  
F o r  q u e s t io n s  r eg a r d ing  s amp l e  p r o c e s s ing ,  c o n t a c t  Ju l i e  B a r n e s  by  e -m a i l  o r  a t  2 4 0- 7 6 0 - 6 0 4 4 .  
 
5 . 2  SAMPLE  STORAGE, TRACK ING  AND  DISPOS IT ION 
5 . 2 . 1  C l in i c a l  HPC ,  A ph e r e s i s  P r o d u c t s  T h e  c ry o p r e s e r v e d  HPC s  w i l l  b e  s to r e d  in  th e  C e l l  P r o c e s s in g  l a b o r a to ry  u n t i l  th ey  a r e  in f u s e d  
f o r  a u to log o u s  t r a n sp l a n t a t io n .  I n  th e  e v e n t  a  su b j e c t  w i sh e s  to  u n d e rg o  AHCT a t  a n  o u t s id e  in s t i tu t io n ,  th e  HPC  p r o d u c t  m ay  b e  sh ip p e d  to  th a t  in s t i tu t io n  in  a c c o r d a n c e  w i th  r eg u l a t io n s  a n d  DTM  S t a n d a r d  O p e r a t in g  P r o c e d u r e s .  I f  a l l  o r  p a r t  o f  th e  HPC  p r o d u c t s  i s  n o  lo n g e r  n e e d e d  f o r  a u to log o u s  t r a n sp l a n t a t io n ,  th e  c e l l s  w i th  e i th e r  b e  i s su e d  to  th e  in v e s t ig a to r  f o r  IRB  a p p r o v e d  r e s e a r c h  o r  d i sp o s e d  o f .   
5 . 2 . 2  S to r a g e /T r a c k ing 
S amp l e s  w i l l  b e  o r d e r e d  in  CR IS  a n d  t r a c k e d  th r o ug h  a  C l in i c a l  T r i a l  D a t a  M a n ag em e n t  sy s t em .   
Sh o u ld  a  CR IS  s c r e e n  n o t  b e  a v a i l a b l e ,  th e  CR IS  d ow n t im e  p r o c e d u r e s  w i l l  b e  f o l low e d .   
R e s e a r c h  samp l e s  w i l l  n o t  b e  s e n t  o u t s id e  N IH  w i th o u t  IRB  n o t i f i c a t io n  a nd  a n  e x e c u t e d  MTA .  
5 . 2 . 2 . 1  L a b e l in g  o f  S amp l e s A l l  sp e c im e n s  a r e  to  b e  l a b e l e d  p e r  th e  lo c a l  s i t e ’ s  s t a n d a r d  p r o c e d u r e s .  T h e  f o l low in g  
in f o rm a t io n ,  i f  n o t  p r o v id e d  o n  th e  sp e c im e n  l a b e l ,  mu s t  b e  l in k e d  to  th e  sp e c im e n  l a b e l  a n d  p r o v id e d  o n  th e  in v e n to ry  sh e e t :   
-  p a t i e n t  s tu dy  ID  #   
-  s amp l e  ty p e  -  d a t e / t im e  o f  d r aw  (DD /MMM /YY  2 4 :0 0 )  -  t im e p o in t  ( e x .  D ay  4 ,  5 ,  6 ,  7 ,  e t c . )  -  a ny  c o l l e c t io n  i s su e s  ( sho r t  d r aw ,  d e l ay e d  p r o c e s s in g ,  e t c . )  -  p r o to c o l  t i t l e /n umb e r  -  in s t i tu t e  n am e  -  c o n t a c t  in f o rm a t io n  
D o  n o t  in c lud e  th e  p a t i e n t  n am e ,  m e d i c a l  r e c o r d  numb e r ,  o r  in i t i a l s .  5 . 2 . 2 . 2  S amp l e  D a t a  Co l l e c t io n A l l  s amp l e s  s e n t  to  th e  C l in i c a l  Ph a rm a c o logy  P r og r am  (CPP )  w i l l  b e  b a r c od e d ,  w i th  d a ta  
e n t e r e d  a n d  s to r e d  in  th e  P a t i e n t  S amp l e  D a t a  M an a g em e n t  Sy s t em  (PSDMS )  u t i l i z e d  by  th e  CPP .  T h i s  i s  a  s e c u r e  p r og r am ,  w i th  a c c e s s  to  th e  PSDM  Sy s t em  l im i t e d  to  d e f in e d  CPP  p e r so n n e l ,  w h o  a r e  i s su ed  in d iv id u a l  u s e r  a c c o u n t s .  I n s t a l l a t io n  o f  PSDMS  i s  l im i t e d  to  c omp u t e r s  sp e c i f i e d  by  D r .  F ig g .  T h e s e  c omp u t e r s  a l l  h a v e  a  p a s sw o r d  r e s t r i c t e d  lo g in  s c r e e n .  
A bb r e v i a t e d  T i t l e :  HPC  f o r  AHCT  in  PCM   
V e r s io n  d a t e :  S e p t em b e r  14,  20 17  
  
                                                                                                                                          P ag e  21 o f  38  A l l  CPP  p e r so n n e l  w i th  a c c e s s  to  p a t i e n t  in f o rm a t io n  a n n u a l ly  c omp l e t e  th e  N IH  o n l in e  
P r o t e c t io n  o f  H um a n  Su b j e c t s  c o u r s e .   
PSDMS  c r e a t e s  a  u n iq u e  b a r c o d e  ID  f o r  e v e ry  s amp l e  a n d  s amp l e  b o x ,  w h i c h  c a n n o t  b e  t r a c e d  
b a c k  to  p a t i e n t s  w i th o u t  PSDMS  a c c e s s .  T h e  d a t a  r e c o r d e d  f o r  e a c h  s amp l e  in c lu d e s  th e  p a t i e n t  ID ,  n am e ,  t r i a l  n am e /p r o to c o l  n umb e r ,  t im e  d r aw n ,  cy c l e  t im e  p o in t ,  d o s e ,  m a t e r i a l  ty p e ,  a s  w e l l  a s  b o x  a n d  f r e e z e r  lo c a t io n .  P a t i e n t  d emo g r a p h i c s  a s so c i a t e d  w i th  th e  c l in i c a l  c e n t e r  p a t i e n t  n umb e r  a r e  p r o v id e d  in  th e  sy s t em .  F o r  e a c h  s amp l e ,  th e r e  a r e  n o t e s  a s so c i a t e d  w i th  th e  p r o c e s s ing  m e th o d  ( d e l ay  in  s amp l e  p r o c e s s ing ,  s to r a g e  c o n d i t io n s  o n  th e  w a r d ,  e t c . ) .  
5 . 2 . 2 . 3  S amp l e  S to r a g e 
B a r c o d e d  s amp l e s  a r e  s to r e d  in  b a r c o d e d  b o x e s  in  a  lo c k e d  f r e e z e r  a t  e i th e r  - 2 0  o r  - 8 0 ° C  
a c c o r d ing  to  s t a b i l i ty  r e qu i r em e n t s .   T h e s e  f r e e z e r s  a r e  lo c a t e d  o n s i t e  in  th e  CPP   a n d  o f f s i t e  a t  NC I  F r e d e r i c k  C e n t r a l  R e p o s i to ry  S e r v i c e s  in  F r ed e r i c k ,  MD .  V i s i to r s  to  th e  l a b o r a to ry  a r e  r e q u i r e d  to  b e  a c c omp a n i e d  by  l a b o r a to ry  s t a f f  a t  a l l  t im e s .   
A c c e s s  to  s to r e d  c l in i c a l  s amp l e s  i s  r e s t r i c t e d .  S amp l e s  w i l l  b e  s to r e d  u n t i l  r e q u e s t e d  by  a  
r e s e a r c h e r  n am e d  o n  th e  p r o to c o l .  A l l  r e q u e s t s  a r e  mo n i to r e d  a n d  t r a c k e d  in  th e  PSDM  Sy s t em . A l l  r e s e a r c h e r s  a r e  r e q u i r e d  to  s ig n  a  f o rm  s t a t in g  tha t  th e  s amp l e s  a r e  o n ly  to  b e  u s e d  f o r  r e s e a r c h  p u r p o s e s  a s so c i a t e d  w i th  th i s  t r i a l  ( a s  p e r  th e  IRB  a p p r o v e d  p r o to co l )  a n d  th a t  a ny  u n u s e d  s amp l e s  mu s t  b e  r e tu r n e d  to  th e  CPP .  I t  i s  th e  r e sp o n s ib i l i ty  o f  th e  NC I  P r in c ip a l  I n v e s t ig a to r  to  e n su r e  th a t  th e  s amp l e s  r e q u e s t e d  a r e  b e ing  u s e d  in  a  m a n n e r  c o n s i s t e n t  w i th  IRB  a p p r o v a l .  
F o l low in g  c omp l e t io n  o f  th i s  s tu dy ,  s amp l e s  w i l l  r em a in  in  s to r ag e  a s  d e t a i l e d  a b o v e .  A c c e s s  to  
th e s e  s amp l e s  w i l l  o n ly  b e  g r a n t e d  f o l low in g  IRB  a p p r o v a l  o f  a n  a d d i t io n a l  p r o to c o l ,  g r a n t ing  th e  r ig h t s  to  u s e  th e  m a t e r i a l .   
I f ,  a t  a ny  t im e ,  a  p a t i e n t  w i th d r aw s  f r om  th e  s tu dy  a n d  d o e s  n o t  w i sh  f o r  th e i r  e x i s t in g  s amp l e s  to  
b e  u t i l i z e d ,  th e  in d iv id u a l  mu s t  p r o v id e  a  w r i t t e n  r e q u e s t .  F o l low ing  r e c e ip t  o f  th i s  r e q u e s t ,  th e  s amp l e s  w i l l  b e  d e s t r oy ed  ( o r  r e tu r n e d  to  th e  p a t i en t ,  i f  so  r e q u e s t e d ) ,  a n d  r e p o r t e d  a s  su ch  to  th e  IRB .  A ny  s amp l e s  lo s t  ( in  t r a n s i t  o r  by  a  r e s e a r c h e r )  o r  d e s t r oy e d  d u e  to  u n k n ow n  s amp l e  in t e g r i ty  ( i . e .  b r o k e n  f r e e z e r  a l low s  f o r  e x t e n s iv e  s amp l e  th aw ing ,  e t c . )  w i l l  b e  re p o r t e d  a s  su c h  to  th e  IRB .  
S amp l e  b a r c o d e s  a r e  l in k e d  to  p a t i e n t  d emog r a p h i c s  a n d  l im i t e d  c l in i c a l  in f o rm a t io n .  T h i s  
in f o rm a t io n  w i l l  o n ly  b e  p r o v id e d  to  in v e s t ig a to r s  l i s t e d  o n  th i s  p r o to c o l ,  v i a  r eg i s t e r e d  u s e  o f  th e  PSDMS .  I t  i s  c r i t i c a l  th a t  th e  s amp le  r em a in s  l in k ed  to  p a t i e n t  in f o rm a t io n  su c h  a s  r a c e ,  ag e ,  d a t e s  o f  d i ag n o s i s  a n d  d e a th ,  a n d  h i s to lo g i c a l  in f o rm a t io n  a b o u t  th e  tumo r ,  in  o r d e r  to  c o r r e l a t e  g e n o ty p e  w i th  th e s e  v a r i a b l e s .  
5 . 2 . 3  P r o to c o l  Comp l e t io n /S amp l e  D e s t r u c t io n 
O n c e  p r im a ry  r e s e a r c h  ob j e c t iv e s  f o r  th e  p r o to c o l  a r e  a c h i e v e d ,  r e s e a r c h e r s  c a n  r e q u e s t  a c c e s s  to  
r em a in in g  s amp l e s ,  p r o v id in g  th ey  h a v e  b o th  a p p ro v a l  o f  th e  P r in c ip a l  I n v e s t ig a to r  o f  th e  o r ig in a l  p r o to c o l  u n d e r  wh i c h  th e  s amp l e s  o r  d a t a  w e r e  c o l l e c t e d  a n d  e i th e r  a n  IRB  ap p r o v e d  p r o to c o l  a n d  p a t i e n t  c o n s e n t  o r  th e  OSHRP A u th o r i z a t io n  F o rm  s t ip u l a t in g  th a t  th e  a c t iv i ty  i s  e x emp t  f r om  IRB  r e v i ew .   
A bb r e v i a t e d  T i t l e :  HPC  f o r  AHCT  in  PCM   
V e r s io n  d a t e :  S e p t em b e r  14,  20 17  
  
                                                                                                                                          P ag e  22 o f  38  S amp l e s ,  a n d  a s so c i a t e d  d a t a ,  c a n  o n ly  b e  p e rm a n e n t ly  a r c h iv e d  i f  th e  su b j e c t  h a s  p r o v id e d  
in f o rm e d  c o n s e n t .  I f  r e s e a r c h e r s  h a v e  s amp l e s  r em a i n in g  o n c e  th ey  h a v e  comp l e t e d  a l l  s tu d i e s  a s so c i a t e d  w i th  th e  p r o to c o l ,  th ey  mu s t  b e  r e tu r n ed  to  th e  P r e c l in i c a l  S e r v i c e  l a b o r a to ry .  
T h e  P r e c l in i c a l  S e r v i c e  s t a f f  w i l l  r e p o r t  to  th e  P r in c ip a l  I n v e s t ig a to r s  a ny  d e s t r oy ed  s amp l e s ,  i f  
s amp l e s  b e c om e  u n s a lv ag e a b l e  b e c a u s e  o f  e n v i r onm e n t a l  f a c to r s  ( e .g .  b r ok e n  f r e e z e r  o r  l a c k  o f  d ry  i c e  in  a  sh ip p ing  c o n t a in e r ) ,  lo s t  in  t r a n s i t  b e tw e e n  f a c i l i t i e s  o r  m i sp l a c e d  by  a  r e s e a r c h e r .  T h e  P r in c ip a l  I n v e s t ig a to r s  w i l l  a n n u a l ly  r e p o r t  th i s  in f o rm a t io n  to  th e  IRB .  
6  DATA  COLLECT ION  AND  EVALUAT ION  
6 . 1  D
ATA  COLLECT ION 
T h e  P I  w i l l  b e  r e sp o n s ib l e  f o r  o v e r s e e ing  e n t ry  o f  d a t a  in to  a n  in - h o u s e  p a s sw o r d  p r o t e c t e d  
e l e c t r o n i c  sy s t em  a n d  e n su r in g  d a t a  a c c u r a cy ,  c o n s i s t e n cy  a n d  t im e l in e s s .  T h e  p r in c ip a l  in v e s t ig a to r ,  a s so c i a t e  inv e s t ig a to r s / r e s e a r c h  n u r s e s  a n d /o r  a  c o n t r a c t e d  d a t a  m a n ag e r  w i l l  a s s i s t  w i th  th e  d a t a  m a n ag em en t  e f f o r t s .  A l l  d a t a  o b t a in e d  d u r in g  th e  c o n d u c t  o f  th e  p r o to c o l  w i l l  b e  k e p t  in  s e c u r e  n e tw o r k  d r iv e s  o r  in  a p p r o v e d  a l t e r n a t iv e  s i t e s  th a t  c omp ly  w i th  N IH  s e c u r i ty  s t a n d a r d s .  P r im a ry  a n d  f in a l  a n a ly z e d  d a t a  w i l l  h av e  id e n t i f i e r s  so  th a t  r e s e a r c h  d a t a  c a n  b e  
a t t r ib u t e d  to  a n  in d iv id u a l  h um a n  su b j e c t  p a r t i c ip an t .  
E n d  o f  s tu dy  p r o c e d u r e s :  D a t a  w i l l  b e  s to r e d  a c c o r d in g  to  HHS  a n d ,  FDA  r e g u l a t io n s  a n d  N IH  
I n t r amu r a l  R e c o r d s  R e t e n t io n  S c h e d u l e  a s  a p p l i c ab l e .   
L o s s  o r  d e s t r u c t io n  o f  d a t a :  Sh o u ld  w e  b e c om e  aw a r e  th a t  a  m a jo r  b r e a c h  in  o u r  p l a n  to  p r o t e c t  
su b j e c t  c o n f id e n t i a l i ty  a nd  t r i a l  d a t a  h a s  o c c u r r e d ,  th e  IRB  w i l l  b e  n o t i f i e d .  
•  A l l  p a t i e n t s ’  d a t a  mu s t  b e  r e c o r d e d  in  th e  p r og r e s s  n o t e s  a n d  f low  sh e e t s  o f  th e  p a t i e n t  c h a r t  m a in t a in e d  by  th e  M e d i c a l  R e c o r d s  D e p a r tm e n t  o f  p a r t i c ip a t ing  in s t i tu t io n s  o r  a v a i l a b l e  e l e c t r o n i c a l ly  o n  th e  CR IS  sy s t em  o f  th e  N IH  C l in i c a l  C e n t e r .   D u p l i c a t e  o f  k ey  d a t a  m a y b e  k e p t  in  a  r e s e a r c h  f o ld e r  m a in t a in e d  by  th e  E xp e r im e n t a l  T r a n sp l a n t a t io n  &  Immu n o lo gy  B r a n c h  o r  th e  r e s e a r c h  o f f i c e  o f  p a r t i c ip a t ing  in s t i tu t io n s . 
•  P a t i e n t ’ s  d emo g r a p h i c s w i l l  b e  c o l l e c t e d . 
•  No  sp e c i f i c  to x i c i ty  d a t a  o r  a d v e r s e  e v e n t  r e l a t e d  to  th e  my e lom a  th e r a py  w i l l  b e  
c o l l e c t e d  f o r  s tu dy  p u r p o s e s.   
•  D a t a  o n  A d v e r s e  E v e n t s  r e q u i r ing  IRB  r e p o r t ing  ( s e e  s e c t io n 7 . 3 )  f o l low in g  f i lg r a s t im  a n d  
p l e r ix a f o r  a dm in i s t r a t io n  w i l l  b e  c o l l e c t e d . 
•  A l l  c l in i c a l d a t a  p e r t a in in g  to  a  su b j e c t ’ s  d e a th  w h i l e  o n  p r o t o c o l  w i l l  b e  c o l l e c t e d . •  D a t a  w i l l  b e  p r o sp e c t iv e ly  c o l l e c t e d  a n d  e n t e r e d  in  r e a l  t im e  in to  th e  C a n c e r  C e n t r a l  
C l in i c a l  D a t a  Sy s t em  d a t a b a s e  (NC I  C3D ;  in f o rm a t io n  a t  h t tp : / / c c r t r i a l s . n c i . n ih . g o v ) .  I t  i s  
e xp e c t e d  th a t  c l in i c a l  d a t a  b e  e n t e r e d  in to  C3D  n o  l a t e r  th a n  a f t e r  1 0  b u s in e s s  d ay s  o f  th e  o c c u r r e n c e .   T h e  NC I  P I  a n d  r e s e a r c h  n u r s e  w i l l  h a v e  a c c e s s  to  th i s  d a t a  v i a  w e b  a c c e s s .  
•  A l l  p a t i e n t  r e c or d s  w i l l  b e  k e p t  c o n f id e n t i a l  a c c o rd in g  to  in d iv id u a l  in s t i tu t io n  p o l i c i e s  
a n d  p r o c e d u r e s  c on c e r n in g  p a t i e n t  in f o rm a t io n .   
•  A l l  g r a d e  3  a n d  g r a d e  4  no n  h em a to lo g i c  a d v e r s e  ev e n t s  w i l l  b e  r e c o r d e d  ( s e e  s e c t io n  7 . 3 . 2  f o r  e x c e p t io n s ) .
 
A bb r e v i a t e d  T i t l e :  HPC  f o r  AHCT  in  PCM   
V e r s io n  d a t e :  S e p t em b e r  14,  20 17  
  
                                                                                                                                          P ag e  23 o f  38  6 . 2  TOX IC ITY  CR ITER IA 
T h e  f o l low in g  a d v e r s e  e v e n t  ma n ag em e n t  g u id e l in e s  a r e  in t e n d e d  to  e n su r e  th e  s a f e ty  o f  e a c h  
p a t i e n t  w h i l e  o n  th e  s tu d y .   T h e  d e s c r ip t io n s  a n d  g r a d in g  s c a l e s  f o u n d  in  th e  r e v i s e d  NC I  Commo n  T e rm in o lo g y  C r i t e r i a  f o r  A d v e r s e  E v e n t s  (CTCAE )  v e r s io n  4 . 0  w i l l  b e  u t i l i z e d  f o r  AE  r e p o r t ing .   A l l  a p p r o p r i a t e  t r e a tm e n t  a r e a s  sh o u ld  h a v e  a c c e s s  to  a  c o py  o f  th e  CTCAE  v e r s io n  4 . 0 .   A  c o py  o f  th e  CTCAE  v e r s io n  4 . 0  c a n  b e  d ow n lo a d e d  f r om  th e  CTEP  w e b  s i t e  ( h t tp : / / c t e p . c a n c e r .g o v /p ro to c o lD e v e lo pm e n t / e l e c t r o n i c _ a p p l i c a t io n s / c t c . h tm# c t c _ 4 0 ) .   
7  SAFETY  REPORT ING  REQU IREMENTS /DATA  AND  SAFETY  MON ITOR ING  
PLAN 
7 . 1  D
ATA  REPORT ING  & RECORDS  TO  BE  KEPT  
 A l l  c l in i c a l  d a t a  w i l l  b e  r e c o r d e d  in  th e  p a t i e n t ’ s  ch a r t  a s  p e r  in s t i tu t io n s ’  p r a c t i c e s  (m a in t a in e d  
by  th e  N IH  C l in i c a l  C e n t e r  D e p a r tm e n t  o f  M e d i c a l  R e c o r d s  a n d  o n  th e  e l e c t r o n i c  c h a r t  CR IS  sy s t em ) .   T h e  p a t i e n t  r e co r d s  w i l l  b e  m a in t a in e d  by  th e  C l in i c a l  A s so c i a t e  an d  o th e r  p r o to c o l  p e r so n n e l .   E a c h  p a t i e n t ’ s  N IH  C lin i c a l  C e n t e r  m ed i c a l  r e c o r d  mu s t  r e f l e c t  a l l  o f  th e  f o l low in g  in f o rm a t io n :  
•  T h e  p a t i e n t  m e t  a l l  e l ig ib i l i ty  c r i t e r i a . 
•  S ig n e d  I n f o rm e d  Co n s e n t  d o c um e n t  w a s  o b t a in e d  b e f o r e  t r e a tm e n t .  
•  Sp e c i f i c  d a t e s  a n d  t im e s  o f  a l l  t r e a tm e n t s  sp e c i f i ed  in  th e  p r o to c o l ,  d o s es  adm in i s t e r e d ,  
a n d  d o c um e n t a t io n  f o r  th e  r e a so n  f o r  a ny  d o s e  mod i f i c a t io n .   
•  D o c um e n t a t io n  o f  a l l  to x i c i t i e s  w i th  g r a d ing  a c c o rd in g  to  NC I  CTCAE  v e r s io n  4 . 0  a s  
sp e c i f i e d  in  th e  p r o to c o l .  
•  D o c um e n t a t io n  o f  a l l  f o l low - u p s  a s  sp e c i f i e d  in  th e  p r o to c o l .  
7 . 2  D
EF IN ITIONS 
7 . 2 . 1  A d v e r s e  E v e n t 
A n  a d v e r s e  e v e n t  i s  d e f in e d  a s  a ny  r e a c t io n ,  s id e  e f f e c t ,  o r  u n tow a r d  e v e n t  th a t  o c c u r s  d u r ing  th e  
c o u r s e  o f  th e  c l in i c a l  t r i a l  a s so c i a t e d  w i th  th e  u s e  o f  a  d r ug  in  h um a n s ,  w h e th e r  o r  n o t  th e  e v e n t  i s  c o n s id e r e d  r e l a t e d  to  th e  t r e a tm e n t  o r  c l in i c a l ly  s ig n i f i c a n t .  F o r  th i s  s tu d y ,  AE s  w i l l  in c lu d e  e v e n t s  r e p o r t e d  by  th e  p a t i e n t ,  a s  w e l l  a s  c l in i c a l ly  s ig n i f i c a n t  a b n o rm a l  f ind in g s  o n  p hy s i c a l  e x am in a t io n  o r  l a b o r a to ry  e v a lu a t io n .  A  n ew  i l ln e s s ,  symp tom ,  s ig n  o r  c l in i c a l ly  s ig n i f i c a n t  l a b o r a t o ry  a b n o rm a l i ty  o r  w o r s e n ing  o f  a  p r e - e x i s t in g  c o n d i t io n  o r  a b n o rm a l i ty  i s  c o n s id e r e d  a n  AE .   A l l  AE s  mu s t  b e  r e co r d e d  o n  th e  AE  c a s e  r e po r t  f o rm  u n l e s s  o th e rw i s e  n o t e d  a b o v e  in  S e c t io n  6 . 1 .  
A l l  AE s ,  in c lu d in g  c l in i c a l ly  s ig n i f i c a n t  a b n o rm a l  f in d in g s  o n  l a b o r a to ry  ev a lu a t io n s ,  r eg a r d l e s s  
o f  s e v e r i ty ,  w i l l  b e  f o l low e d  u n t i l  r e tu r n  to  b a s e l in e  o r  s t a b i l i z a t io n  o f  e v en t .  S e r io u s  a d v e r s e  e v e n t s  th a t  o c c u r  mo r e  th a n  3 0  d ay s  a f t e r  th e  l a s t  adm in i s t r a t io n  o f  in v e s t ig a t i o n a l  a g e n t / in t e r v e n t io n  a n d  h av e  a n  a t t r ib u t io n  o f  a t  l e a s t  p o s s ib ly  r e l a t e d  to  th e  a g e n t / in t e r v e n t io n  sh o u ld  b e  r e c o r d e d  a n d  r e p o r t e d  a s  p e r  s e c t io n  7 . 3  
  A n  a b n o rm a l  l a b o r a to ry  v a lu e  w i l l  b e  c o n s id e r e d  a n  AE  i f  th e  l a b o r a to ry  ab n o rm a l i ty  i s  
c h a r a c t e r i z e d  by  a ny  o f  th e  f o l low in g :  
A bb r e v i a t e d  T i t l e :  HPC  f o r  AHCT  in  PCM   
V e r s io n  d a t e :  S e p t em b e r  14,  20 17  
  
                                                                                                                                          P ag e  24 o f  38  •  R e su l t s  in  d i s c o n t in u a t io n  f r om  th e  s tu dy  
•  I s  a s so c i a t e d  w i th  c l in i c a l  s ig n s  o r  symp tom s   
•  R e q u i r e s  t r e a tm e n t  o r  a ny  o th e r  th e r a p e u t i c  in t e r v e n t io n 
•  I s  a s so c i a t e d  w i th  d e a th  o r  a n o th e r  s e r io u s  a d v e r s e  e v e n t ,  in c lu d ing  h o sp i t a l i z a t io n .   
•  I s  ju dg e d  by  th e  I n v e s t ig a to r  to  b e  o f  s ig n i f i c a n t  c l in i c a l  imp a c t  
•  I f  a ny  a b n o rm a l  l a b o r a to ry  r e su l t  i s  c o n s id e r e d  c l in i c a l ly  s ig n i f i c a n t ,  th e  in v e s t ig a to r  w i l l  
p r o v id e  d e t a i l s  a b o u t  th e  a c t io n  t a k e n  w i th  r e sp e c t  to  th e  t e s t  d r u g  a n d  a b o u t  th e  p a t i e n t ’ s  o u t c om e .  
7 . 2 . 2  Su sp e c t e d  a d v e r s e  r e a c t io n 
Su sp e c t e d  a d v e r s e  r e a c t io n  m e a n s  a ny  a d v e r s e  e v e n t  f o r  w h i c h  th e r e  i s  a  r e a so n a b l e  p o s s ib i l i ty  
th a t  th e  d r u g  c a u s e d  th e  ad v e r s e  e v e n t .  A  su sp e c t ed  a d v e r s e  r e a c t io n  imp l i e s  a  l e s s e r  d eg r e e  o f  c e r t a in ty  a b o u t  c a u s a l i ty  th a n  a d v e r s e  r e a c t io n ,  w h i c h  m e a n s  a ny  a d v e r s e  e v e n t  c a u s e d  by  a  d r ug .  
7 . 2 . 3  U n e xp e c t e d  a d v e r s e  r e a c t io n 
A n  a d v e r s e  e v e n t  o r  su sp e c t e d  a d v e r s e  r e a c t io n  i s  c o n s id e r e d  “ u n e xp e c t e d ”  i f  i t  i s  n o t  l i s t e d  in  
th e  in v e s t ig a to r  b r o c h u r e  o r  i s  n o t  l i s t e d  a t  th e  sp e c i f i c i ty  o r  s e v e r i ty  th a t  h a s  b e e n  o b s e r v e d ;  o r ,  i f  a n  in v e s t ig a to r  b r o c h u r e  i s  n o t  r e q u i r e d  o r  a v a i l ab l e ,  i s  n o t  c o n s i s t e n t  w i th  th e  r i sk  in f o rm a t io n  d e s c r ib e d  in  th e  g e n e r a l  in v e s t ig a t io n a l  p l a n  o r  e l s ew h e r e  in  th e  c u rr e n t  a p p l i c a t io n .  "U n e xp e c t e d ” ,  a l so  r e f e r s  to  a d v e r s e  ev e n t s  o r  su sp e c t e d  a d v e r s e  r e a c t io n s  th a t  a r e  m e n t io n e d  in  th e  in v e s t ig a to r  b r o c h u r e  a s  o c c u r r in g  w i th  a  c l a s s  o f  d r ug s  o r  a s  a n t i c ip a t ed  f r om  th e  p h a rm a c o log i c a l  p r o p e r t i e s  o f  th e  d r ug ,  b u t  a r e  n o t  sp e c i f i c a l ly  m e n t io n e d  a s  o c c u r r in g  w i th  th e  p a r t i c u l a r  d r ug  u n d e r  in v e s t ig a t io n .  
7 . 2 . 4  S e r io u s  
A n  U n a n t i c ip a t e d  P r o b l em  o r  P r o to c o l  D e v i a t io n  i s  s e r io u s  i f  i t  m e e t s  th e  d e f in i t io n  o f  a  S e r io u s  
A d v e r s e  E v e n t  o r  i f  i t  c omp r om i s e s  th e  s a f e ty ,  w e l f a r e  o r  r ig h t s  o f  su b j e c t s  o r  o th e r s .  
7 . 2 . 5  S e r io u s  A d v e r s e  E v e n t  
A n  a d v e r s e  e v e n t  o r  su sp e c t e d  a d v e r s e  r e a c t io n  i s  c o n s id e r e d  s e r io u s  i f  in  th e  v i ew  o f  th e  
in v e s t ig a to r  o r  th e  sp o n so r ,  i t  r e su l t s  in  a ny  o f  th e  f o l low in g :  
•  D e a th , 
•  A  l i f e- th r e a t e n ing  a d v e r s e  d r ug  e xp e r i e n c e  
•  I n p a t i e n t  h o sp i t a l i z a t io n  o r  p r o lo n g a t io n  o f  e x i s t in g  h o sp i t a l i z a t io n  
•  A  p e r s i s t e n t  o r  s ig n i f i c a n t  d i s a b i l i ty / in c a p a c i ty 
•  A  c o ng e n i t a l  a n om a ly /b i r th  d e f e c t . 
•  Imp o r t a n t  m e d i c a l  e v e n t s  th a t  m ay  n o t  r e su l t  in  d e a th ,  b e  l i f e - th r e a t e n ing ,  o r  r e q u i r e  h o sp i t a l i z a t io n  m ay  b e  co n s id e r e d  a  s e r io u s  a d v e r s e  d r ug  e xp e r i e n c e  w h e n ,  b a s e d  u p o n  a p p r o p r i a t e  m e d i c a l  ju dgm e n t ,  th ey  m ay  j e o p a r d i z e  th e  p a t i e n t  o r  su b j e c t  an d  m ay  r e q u i r e  m e d i c a l  o r  su rg i c a l  in t e rv e n t io n  to  p r e v e n t  o n e  o f  th e  o u t c om e s  l i s t e d  in  th i s  d e f in i t io n .  
A bb r e v i a t e d  T i t l e :  HPC  f o r  AHCT  in  PCM   
V e r s io n  d a t e :  S e p t em b e r  14,  20 17  
  
                                                                                                                                          P ag e  25 o f  38  7 . 2 . 6  D i s a b i l i ty 
A  su b s t a n t i a l  d i s r u p t io n  o f  a  p e r so n ’ s  a b i l i ty  to  c on d u c t  n o rm a l  l i f e  f u n c t ion s .  
7 . 2 . 7  L i f e- th r e a t e n ing  a d v e r s e  d r u g  e xp e r i e n c e  
A ny  a d v e r s e  e v e n t  o r  su sp e c t e d  a d v e r s e  r e a c t io n  th a t  p l a c e s  th e  p a t i e n t  o r  su b j e c t ,  in  th e  v i ew  o f  
th e  in v e s t ig a to r  o r  sp o n so r ,  a t  imm e d i a t e  r i sk  o f  d e a th  f r om  th e  r e a c t io n  a s  i t  o c c u r r e d ,  i . e . ,  i t  d o e s  n o t  in c lu d e  a  r e a c t ion  th a t  h a d  i t  o c c u r r e d  in  a  mo r e  s e v e r e  f o rm ,  m ig h t  h a v e  c a u s e d  d e a th .  
7 . 2 . 8  P r o to c o l  D e v i a t io n  (N IH  D e f in i t io n )  
A ny  c h a ng e ,  d iv e rg e n c e ,  o r  d e p a r tu r e  f r om  th e  IRB  a p p r o v e d  r e s e a r c h  p r o to c o l .   
7 . 2 . 9  N o n- c omp l i a n c e  (N IH  D e f in i t io n )  
T h e  f a i lu r e  to  c omp ly  w i th  a p p l i c a b l e  N IH  H um a n  R e s e a r c h  P r o t e c t io n s  P r o g r am  (HRPP )  
p o l i c i e s ,  IRB  r e q u i r em e n t s ,  o r  r eg u l a to ry  r e q u i r em e n t s  f o r  th e  p r o t e c t io n  o f  h um a n  r e s e a r c h  su b j e c t s .  
7 . 2 . 1 0  U n a n t i c ip a t e d  P r o b l em  
A ny  in c id e n t ,  e xp e r i e n c e ,  o r  o u t c om e  th a t :  
•   I s  u n e xp e c t e d  in  t e rm s  o f  n a tu r e ,  s e v e r i ty ,  o r  f r e qu e n cy  in  r e l a t io n  to   
( a )  th e  r e s e a r c h  r i sk s  th a t  a r e  d e s c r ib e d  in  th e  IRB - a p p r o v e d  r e s e a r c h  p r o to c o l  a n d  
in f o rm e d  c o n s e n t  d o c um e n t ;  I n v e s t ig a to r ’ s  B r o c hu r e  o r  o th e r  s tu dy  d o c um e n t s ,  a n d  
( b )  th e  c h a r a c t e r i s t i c s  o f  th e  su b j e c t  p o p u l a t io n  b e in g  s tu d i e d ;  AND 
•  I s  r e l a t e d  o r  p o s s ib ly  r e l a t e d  to  p a r t i c ip a t io n  in  th e  r e s e a r c h ;  AND 
•  Su g g e s t s  th a t  r e s e a r c h  p l a c e s  su b j e c t s  o r  o th e r s  a t  a  gr e a t e r  r i s k  o f  h a rm  ( in c lu d in g  
p hy s ic a l ,  p sy ch o lo g i c a l ,  e c o n om i c ,  o r  so c i a l  h a rm )  th a n  w a s  p r e v io u s ly  k now n  o r  
r e c og n i z e d .  
7 . 3  NC I- IRB
 AND  CL IN ICAL  DIRECTOR  REPORT ING 
A s  su b j e c t s  w i l l  b e  e n r o l l e d  o n  p r o to c o l  a t  th e  t im e  th ey  a r e  r e c e iv ing  c o n cu r r e n t ,  o f f - p r o to c o l ,  s t a n d a r d  o f  c a r e  th e r a py  w i th  e xp e c t e d  to x i c i ty ,  th e  to x i c i ty  o f  a ny  c o n c u r r e n t  th e r a py  w i l l  n o t  b e  r e p o r t e d  f o r  th i s  s tu dy .   A d v e r s e  E v e n t  r e p o r t in g  w i l l  b e  l im i t e d  to  e v e n t s  o c c u r r ing  d u r ing  o r  imm e d i a t e ly  f o l low ing  th e  a p h e r e s i s  p r o c e d u r e .  
7 . 3 . 1  NC I- IRB  a n d  NC I  CD  Exp e d i t e d  R e p o r t in g  o f  Un a n t i c ip a t e d  P r o b l em s  a nd  D e a th s  
T h e  P r o to c o l  P I  w i l l  r e p o r t  in  th e  N IH  P r o b l em  F o rm  to  th e  NC I -IRB  a n d  NC I  C l in i c a l  D i r e c to r :  
•  A l l  d e a th s ,  e x c e p t  d e a th s  d u e  to  p r og r e s s iv e  d i s e a s e   
•  A l l  P r o to c o l  D e v i a t io n s 
•  A l l  U n a n t i c ip a t e d  P r o b l em s 
•  A l l  n o n -c omp l i a n c e  
 
A bb r e v i a t e d  T i t l e :  HPC  f o r  AHCT  in  PCM   
V e r s io n  d a t e :  S e p t em b e r  14,  20 17  
  
                                                                                                                                          P ag e  26 o f  38  R e p o rt s  mu s t  b e  r e c e iv e d  w i th in  7  d ay s  o f  P I  aw a r e n e s s  v i a  iR IS .  
7 . 3 . 2  NC I- IRB  R e q u i r em e n t s  fo r  P I  R e p o r t in g  a t  Co n t in u in g  R e v i ew  
T h e  p r o to c o l  P I  w i l l  r e p o r t  to  th e  NC I -IRB :   
1 .  A  summ a ry  o f  a l l  p r o to co l  d e v i a t io n s  in  a  t a b u l a r  f o rm a t  to  in c lu d e  th e  d a t e  th e  d e v i a t io n  
o c c u r r e d ,  a  b r i e f  d e s c r ip t io n  o f  th e  d e v i a t io n  a n d  any  c o r r e c t iv e  a c t io n .  
2 .  A  summ a ry  o f  a ny  in s t a n c e s  o f  n o n- c omp l i a n c e  3 .  A  t a b u l a r  summ a ry  o f  th e  f o l low in g  a d v e r s e  e v e n t s :  
•  A l l  G r a d e  2  un e xp e c t ed e v e n t s  th a t  a r e  p o s s ib ly ,  p r o b a b ly  o r  d e f in i t e ly  r e l a t e d  to  th e  
r e s e a r c h ;   
•  A l l  G r a d e  3  an d  4  e v e n t s  th a t  a r e  p o s s ib ly ,  p r o b a b ly  o r  d e f in i t e ly  r e l a t e d  to  th e  
r e s e a r c h ;   
•  A l l  G r a d e  5  ev e n t s  r eg a rd l e s s  o f  a t t r ib u t io n ;   
•  A l l  S e r io u s  E v e n t s  r eg a rd l e s s  o f  a t t r ib u t io n .   
NOTE:  G r a d e  1  e v e n t s  a r e  n o t  r e q u i r e d  to  b e  r e p o r t e d .   
7 . 3 . 3  E x ce p t io n s  to  r e p o r t in g :  
T h e  f o l low in g  e v e n t s  th a t  a r e  p o s s ib ly ,  p r o b a b ly  o r  d e f in i t e ly  r e l a t e d  to  th e  r e s e a r c h  wi l l  
n o t  b e  r e p o r t e d :  o O f  a ny  g r a d e :  L e u k o cy to s i s  o r  n e u t r o p h i l i a,  e l e v a t e d  LDH ,  p a r e s th e s i a s ,  b on e  p a in ,  
f e v e r ,  f a t ig u e ,  mu s c l e  c r am p s ,  b a c k / l e g  p a in ,  sp l e nom e g a ly  
o O f  g r a d e  < 3 :  T h r omb o cy to p e n i a,  a n em i a ,  hy p o c a l c em i a ,  hy p om ag n e s em i a ,  e l e v a t e d  
t r a n s am in a s e s  o r  a lk a l in e  p h o sp h a t a s e ,  d i a r r h e a ,  n a u s e a ,  v om i t in g ,  f l a tu l e n c e ,  f a t ig u e ,  a r th r a lg i a ,  h e a d a c h e  a n d  d i z z in e s s ,  m i ld  in j e c t io n  s i t e  r e a c t io n s .  
7 . 4  D
ATA  AND  SAFETY  MON ITOR ING  PLAN 
7 . 4 . 1  P r in c ip a l  I n v e s t ig a to r /R e s e a r c h  T e am   
I n  o r d e r  to  a s su r e  o p t im a l  c o n c o r d a n c e  b e tw e e n  th e  p r o to c o l  r e q u i r em e n t s  an d  th e  b e s t  p o s s ib l e  
c l in i c a l  c a r e  o f  th e  p a t i e n t s ,  th e  P I /LA I  o r  d e s ig n a t e  w i l l  c o - s ig n  a  p a t i e n t  r eg i s t r a t io n  c h e c k  l i s t  ( S e c t io n  1 2 ) .  
T h e  c l in i c a l  r e s e a r c h  t e am  w i l l  m e e t  o n  a  w e e k ly b a s i s  w h e n  p a t i e n t s  a r e  b e in g  a c t iv e ly  t r e a t e d  
o n  th e  t r i a l  to  d i s c u s s  e a ch  p a t i e n t .  D e c i s io n s  a b o u t  d o s e  l e v e l  e n r o l lm e n t  an d  d o s e  e s c a l a t io n  i f  a p p l i c a b l e  w i l l  b e  m a d e  b a s e d  o n  th e  to x i c i ty  d a t a  f r om  p r io r  p a t i e n t s .   
A l l  d a t a  w i l l  b e  c o l l e c t e d  in  a  t im e ly  m a n n e r  a n d  r e v i ew e d  by  th e  p r in c ip a l  in v e s t ig a to r  o r  
d e s ig n a t e .  A d v e r s e  e v e n t s  w i l l  b e  r e p o r t e d  a s  r e q u i r e d  a b o v e .  Any  s a f e ty  co n c e r n s ,  n ew  i n f o rm a t io n  th a t  m ig h t  a f f e c t  e i th e r  th e  e th i c a l  a n d  o r  s c i e n t i f i c  c o n d u c t  o f  th e  t r i a l ,  o r  p r o to c o l  d e v i a t io n s  w i l l  b e  imm e d i a t e ly  r e p o r t e d  to  th e  IRB  u s in g  iR IS .   
T h e  Pr in c ip a l  I n v e s t ig a to r  w i l l  r e v i ew  a d v e r s e  e v en t  a n d  r e sp o n s e  d a t a  o n  e a c h  p a t i e n t  to  e n su r e  
s a f e ty  a n d  d a t a  a c c u r a cy .  T h e  Pr in c ip a l  I n v e s t ig a to r  w i l l  p e r so n a l ly  c o n d u c t  o r  su p e r v i s e  th e  
A bb r e v i a t e d  T i t l e :  HPC  f o r  AHCT  in  PCM   
V e r s io n  d a t e :  S e p t em b e r  14,  20 17  
  
                                                                                                                                          P ag e  27 o f  38  in v e s t ig a t io n  a n d  p r o v id e  a p p r o p r i a t e  d e l eg a t io n  o f  r e sp o n s ib i l i t i e s  to  o th e r  m emb e r s  o f  th e  
r e s e a r c h  s t a f f .  
8  STAT IST ICAL  CONS IDERAT IONS 
T h e  p r im a ry  c l in i c a l  p u rp o s e  o f  th i s  p r o to c o l  i s  to  p e rm i t  c o l l e c t io n  o f  a p h e r e s i s  p r o d u c t s  a s  
n e e d e d  in  c o n n e c t io n  w i th  AHCT in  su b j e c t s  w i th  P l a sm a  C e l l  My e lom a  (PCM ) .  T h e  o v e r a l l  su c c e s s  r a t e  o f  th e  a lg o r i thm  sh ow n  in  Tab l e  1 a n d  in  s e c t io n  3 . 1  w i l l  b e  e v a lu a t e d  a n d  w i l l  b e  c o n s id e r e d  th e  p r im a ry  s c i e n t i f i c  e n d p o in t  f o r  th e  s tu dy .   I n  a d d i t io n ,  a s  a  d e s c r ip t iv e  s tu dy ,  t h e  p e r c e n t  o f  p a t i e n t s  a c h i ev in g  e i th e r  o f  tw o  l e v e l s  o f  CD 3 4+  c e l l  c o l le c t io n  ( o p t imum  c o l l e c t io n  
o f   ≥ 5  x  1 0
6 CD 3 4+  c e l l s /k g ,  o r  m in imum  c o l l e c t io n  o f  ≥ 2  b u t  <  5  x  1 06 CD 3 4+  c e l l s /k g )  in  o n e  
a p h e r e s i s  p r o c e d u r e ,  in  tw o  p r o c e d u r e s ,  a n d  in  g r e a t e r  th a n  tw o  p r o c e d u r e s  w i l l  b e  d e t e rm in e d  
a c c o r d ing  to  w h e th e r  p a t i e n t s  h a v e  r e c e iv e d  f i lg r a s t im  a lo n e  v e r su s  f i lg r a s t im  p lu s  p l e r ix a f o r .   B a s e d  o n  th e  a lg o r i thm  sh ow n  in  t a b l e  1  a n d  in  s e c t io n  3 . 1 ,  p a t i e n t s  e i th e r  w i l l  o r  w i l l  n o t  r e c e iv e  p l e r ixa f o r  to  p o t e n t i a l ly  b o o s t  th e  CD 3 4  p r o c e s s ed  y i e ld .   
 S i x ty p a t i e n t s  o r  mo r e  w i l l  b e  e n r o l l e d  o n  th i s  s tu d y  d u r ing  a  th r e e  y e a r  p e r io d ,  a n d  b a s e d  o n  
h i s to r i c a l  d a t a ,  i t  i s  a n t i c ip a t e d  th a t  a p p r o x im a t e ly  7 5%  w i l l  n o t n e e d  p l e r ix a f o r  ( 4 5 )  a n d  2 5%  w i l l n e e d  p l e r ix a f o r  ( 1 5 ) .  T h e  o v e r a l l  su c c e s s  o f  th e  a lgo r i thm  ( p e r c e n t  o f  p a t i e n t s  a c h i e v ing  o p t imum  c o l l e c t io n  o f   5  x  1 0
6 CD 3 4+  c e l l s /k g  in  o n e  mo b i l i z a t io n  cy c l e ,  w h o  w e r e  p r e d i c t e d  
to  d o  so  u s in g  th e  a lg o r i thm )  w i l l  b e  d e t e rm in e d  a s  f o l low s .  I f  6 0  to t a l  p a t i e n t s  a r e  e n r o l l e d  a n d  i f  5 0  o r  mo r e  o f  6 0  h a v e  a  su c c e s s f u l  c o l l e c t io n ,  th e n  th e  p r o b a b i l i ty  o f  th i s  o c c u r r ing  w i l l  b e  9 6 . 6%  i f  th e  t r u e  r a t e  o f  su c c e s s  w e r e  9 0%  w h i l e  i t  w o u ld  b e  1 . 4%  i f  th e  t r u e  r a t e  o f  su c c e s s  w e r e  7 0% .  T h u s ,  i f  a  h ig h  f r a c t io n  ( 5 0+ /6 0 )  h a s  a  su c c e s s f u l  c o l l e c t io n ,  th e r e  i s  a  mu c h  g re a t e r  l ik e l ih o o d  th a t  th e  t r u e  r a t e  o f  o v e r a l l  su c c e s s  w i th  th e  a lg o r i thm  i s  9 0%  a s  o p p o s e d  to  7 0% .   
I n  a d d i t io n ,  t h e  su c c e s s  r a t e  o f  th e  a lg o r i thm  w i l l  b e  e v a lu a t e d  s e p a r a t e ly  fo r  th o s e  w h o  d o  a n d  
d o  n o t  r e c e iv e  p l e r ix a f o r .  I f  4 1 /4 5  n o t  r e c e iv in g  p l e r ix a f o r  h a v e  a  su c c e s s f u l  c o l l e c t io n  in  o n e  cy c l e ,  th e  a s so c i a t e d  9 5%  C I  w i l l  e x t e n d  f r om  a p p r o x im a t e ly  7 9  to  9 8% .  Amo n g  th o s e  r e c e iv in g  p l e r ix a f o r ,  i f  1 3 /1 5  h a v e  a  su c c e s s f u l  c o l l e c t io n  in  o n e  a p h e r e s i s ,  th e  9 5%  C I  r a ng e s  f r om  6 0%  to  9 8% .  T h e  o v e r a l l  su c c e s s  ra t e  o f  th e  a lg o r i thm ,  a s  d e s c r ib e d  a b o v e ,  a n d  i d e a l ly ,  th e  f r a c t io n s  th a t  h a v e  a  su c c e s s f u l  c o l l e c t io n  w o u ld  b e  h ig h  a n d  su c c e s s  r a t e s  w o u ld  b e  s im i l a r  to  o n e  a n o th e r  in  b o th  g r o u p s ,  b u t  th e  su c c e s s  r a t e s  w i l l  o n ly  b e  c omp a r e d  d e s c r ip t iv e ly  s in c e  th e r e  i s  l im i t e d  p ow e r  f o r  a ny  c omp a r i son .  I n  a d d i t io n  to  th e  f r a c t io n s  w h o  h a v e  su c c e s s f u l  c o l l e c t io n s ,  th e  to t a l  n umb e r  o f  a p h e r e s i s  p r o c e d u r e s  p e r  p a t i e n t  a n d  th e  to t a l  n umb e r  o f  l i t e r s  p ro c e s s e d  p e r  p a t i e n t  d u r in g  th e  c o l l e c t io n  c o u r s e  to  a c h i e v e  e i th e r  th e  o p t imum  o r  th e  m in imum  CD 3 4+  c e l l  d o s e  w i l l  b e  r e p o r t e d  a n d  in f o rm a l ly  c omp a r e d  b e tw e e n  p a t i e n t s  r e c e iv in g  f i lg r a s t im  a lo n e  v e r su s  
f i lg r a s t im  p lu s  p l e r ix a f o r .   
 A s  a n  e xp lo r a to ry ,  s e c o nd a ry  a n a ly s i s ,  i f  su f f i c i e n t  d a t a  a r e  a v a i l a b l e ,  a  mu l t iv a r i a b l e   lo g i s t i c  
r eg r e s s io n  a n a ly s i s  m ay  b e p e r f o rm e d ,  u s ing  p a t i en t  a n d  d i s e a s e  c h a r a c t e r i s t i c s  ( a v a i l a b l e  d a t a  p o t e n t i a l ly ,  b u t  n o t  m a n d a to r i ly ,  f r om  amo ng :  g e nd e r ,  r a c e ,  ag e ,  w e ig h t ,  b a s e l in e  h emo g lo b in ,  to t a l  WBC ,  n e u t r o p h i l ,  m o n o cy t e ,  lymp h o cy t e ,  a nd  p l a t e l e t  c o u n t ,  n umb e r  o f  p r io r  cy c l e s  o f  cy to to x i c  c h emo th e r a py ,  to t a l  p r io r  d o s e  o f  l e n a l idom id e  a n d  s im i l a r  ag e n t s  p e r  kg )  to  c o n s t r u c t  a  mo d e l  f o r  r i sk  o f  a c c e p t a b l e  v s .  n o n - a c c e p t a b l e  CD 3 4  mo b i l i z a t io n  w i th  f i lg r a s t im  a lo n e.  
A bb r e v i a t e d  T i t l e :  HPC  f o r  AHCT  in  PCM   
V e r s io n  d a t e :  S e p t em b e r  14,  20 17  
  
                                                                                                                                          P ag e  28 o f  38  B e c a u s e  o f  a n  e xp e c t a t ion  o f  l im i t e d  p a t i en t s ,  c o n s t r u c t io n  o f  a  s im i l a r  mo d e l  f o r  r i sk  o f  p o o r  
mo b i l i z a t io n  w i th  u s e  o f  c omb in e d  f i lg r a s t im  p lu s  p l e r ix a f o r  w i l l  n o t  l ik e ly  b e  a t t emp t e d.   
I t  i s  e xp e c t e d  th a t  u p  to  3  y e a r s  m ay  b e  r e q u i r e d  to  o b t a in  6 0  e v a lu a b l e  su b j e c t s  o n  th i s  p r o to c o l .   
T h e  a c c r ua l  c e i l in g  w i l l  b e  s e t  a t  7 0  p a t i e n t s  to  a l low  f o r  f l e x ib i l i ty .  
9  HUMAN  SUBJECTS  PROTECT IONS 
9 . 1  RAT IONALE  FOR  SUBJECT  SELECT ION 
T h e  s tu dy  i s  o p e n  to  a l l  su b j e c t s  w i th  a  c l in i c a l  ind i c a t io n  f o r  a u to log o u s  s t em  c e l l  
t r a n sp l a n t  f o r  th e  t r e a tm en t  o f  mu l t ip l e  my e lom a  
9 . 2  PART IC IPAT ION  OF  CH ILDREN 
Ch i ld r e n  w i l l  n o t  b e  e n r o l l e d  o n  th i s  s tu dy  a s  PCM  i s  n o t  a  d i s e a s e  s e e n  in  th e  p e d i a t r i c  
p o p u l a t io n .  
9 . 3  PART IC IPAT ION  OF  SUBJECTS  UNABLE  TO  GIVE  CONSENT 
A d u l t s  u n a b l e  to  g iv e  c on s e n t  a r e  e x c lu d e d  f r om  e n r o l l in g  in  th e  p r o to c o l .  H ow e v e r  r e- c o n s e n t  
m ay  b e  n e c e s s a ry  a n d  th e r e  i s  a  p o s s ib i l i ty ,  th o u g h  u n l ik e ly ,  th a t  su b j e c t s  c ou ld  b e c om e  d e c i s io n a l ly  imp a i r e d .  F o r  th i s  r e a so n  a n d  b e c a u s e  th e r e  i s  a  p r o sp e c t  o f  d i r e c t  b e n e f i t  f r om  r e s e a r c h  p a r t i c ip a t io n  ( s e c t io n  0 ,  a l l  su b j e c t s  ≥  a g e  1 8  w i l l  b e  o f f e r e d  th e  o pp o r tu n i ty  to  f i l l  in  th e i r  w i sh e s  f o r  r e s e a r c h  a n d  c a r e ,  a n d  a s s ig n  a  sub s t i tu t e  d e c i s io n  m a k e r  on  th e  “N IH  A d v a n c e  D i r e c t iv e  f o r  H e a l th  C a r e  a n d  M e d i c a l  R e s e a r c h  P a r t i c ip a t io n ”  f o rm  so  tha t  a n o th e r  p e r so n  c a n  m a k e  d e c i s io n s  a b o u t  th e i r  m e d i c a l  c a r e  in  th e  e v en t  th a t  th ey  b e c om e  in c ap a c i t a t e d  o r  c o g n i t iv e ly  imp a i r e d  d u r in g  th e  c o u r s e  o f  th e  s tu d y .  N o t e :  T h e  P I  o r  A I  w i l l  c o n t a c t  th e  N IH  A b i l i ty  to  Co n s e n t  A s s e s sm e n t  T e am  f o r  e v a lu a t io n .   F o r  th o s e  su b j e c t s  th a t  b e c om e  in c a p a c i t a t e d  a n d  d o  n o t  h a v e  p r e - d e t e rm in e d  su b s t i tu t e  d e c i s io n  m a k e r ,  th e  p r o c e d u r e s  d e s c r ib e d  in  MEC  Po l i cy  8 7 - 4  f o r  a p p o in t ing  a  su r r o g a t e  d e c i s io n  m a k e r  f o r  a d u l t  su b j e c t s  w h o  a r e  ( a )  d e c i s io n a l ly  imp a i r e d ,  a n d  ( b )  w h o  d o  n o t  h a v e  a  l eg a l  g u a r d i a n  o r  du r a b l e  p ow e r  o f  a t to r n ey ,  w i l l  b e  f o l low ed .  
9 . 4  E
VALUAT ION  OF  BENEF ITS  AND  RISKS/DISCOMFORTS 
Su b j e c t s  u n d e rg o in g  a p h e r e s i s  f o r  c o l l e c t io n  o f  a  mo b i l i z e d  HPC ,  A p h e r e s i s  p r o d u c t  m ay  
e xp e r i e n c e  h e a d a c h e ,  b on e  a n d  jo in t  p a in  d u e  to  f i lg r a s t im ,  n a u s e a  a n d  a b dom in a l  p a in  d u e  to  p l e r ix a f o r ,  b l e e d ing  a n d  p a in  d u e  to  th e  d i s c om f o r t  o f  c e n t r a l  l in e  in s e r t io n ,  hy p o c a l c em ic  symp tom s  d u e  to  th e  c i t r a t e  a n t i c o ag u l a n t  u s e d  d u r in g  a p h e r e s i s ,  a n d  v a so v a g a l  e v e n t s  in c lu d ing  b r a dy c a r d i a ,  hy p o t e n s io n ,  sy n c o p e  a n d  v e ry  r a r e ly ,  s e i zu r e s ,  a s so c i a t e d  w i th  r e f l e x  n e u r o v a s c u l a r  r e a c t io n s  to  a p h e r e s i s .  R a r e ly ,  c a r d io v a s c u l a r  e v e n t s  m ay  o c c u r  d u e  to  p r e v io u s ly  p r e s e n t  b u t  u n d i a g n o s e d  c o r o n a ry  o r  c e r e b r o v a s c u l a r  o c c lu s iv e  c o n d i t io n s .   
T h e  b e n e f i t  i s  to  b e  a b l e  to  u n d e rg o  a n  a u to lo g o u s  s t em  c e l l  t r a n sp l a n t  w h i ch  i s  k n ow n  to  
imp r o v e  o u t c om e  in  PCM.  
9 . 5  R
ISKS/BENEF ITS  ANALYS IS 
T h e  p o t e n t i a l  b e n e f i t s  o u tw e ig h  th e  r i sk  f o r  a  p r o c e d u r e  c o n s id e r e d  w o r ldw id e  a  s t a n d a r d  
p r a c t i c e  f o r  th e  t r e a tm e n t  o f  PCM.  
A bb r e v i a t e d  T i t l e :  HPC  f o r  AHCT  in  PCM   
V e r s io n  d a t e :  S e p t em b e r  14,  20 17  
  
                                                                                                                                          P ag e  29 o f  38  9 . 6  CONSENT  AND  ASSENT  PROCESS  AND  DOCUMENTAT ION 
P r io r  to  r e c e iv ing  a ny  th e r a py ,  p a t i e n t s  mu s t  h a v e  th e i r  e l ig ib i l i ty  c o n f i rm ed  a n d  mu s t  h a v e  
s ig n e d  a n  in f o rm e d  c o n s e n t .   T h e  P r in c ip a l  I n v e s t ig a to r  o r  L e a d  As so c i a t e  I n v e s t ig a to r  w i l l  r e v i ew  o r d e r s  f o r  mo b i l i z in g  ag e n t  a dm in i s t r a t io n .  
T h e  in v e s t ig a t io n a l  n a tu r e  a n d  r e s e a r c h  o b j e c t iv e s  o f  th i s  t r i a l ,  th e  p r o c e d u r e s  a n d  t r e a tm e n t s  
in v o lv e d  a n d  th e i r  a t t e n d a n t  r i sk s  a n d  d i s c om f o r t s  a n d  b e n e f i t s ,  a n d  p o t e n t i a l  a l t e r n a t iv e  th e r a p i e s  w i l l  b e  c a r e f u l ly  e xp l a in e d  to  th e  su b j e c t s  d u r in g  th e  I n f o rm e d  Con s e n t  p r o c e s s .   A  s ig n e d  I n f o rm e d  Co n s e n t  d o c um e n t  w i l l  b e  o b t a in e d  p r io r  to  e n t ry  o n to  th e  s tu dy  by  th e  P r in c ip a l  I n v e s t ig a to r  o r  a n  A s so c i a t e  I nv e s t ig a to r . 
A l l  p a t i e n t s  mu s t  h a v e  a  c o py  o f  th e i r  s ig n e d  I n f o rm e d  Co n s e n t  d o c um e n t  m a in t a in e d  in  th e  
c h a r t  d u r ing  th e r a py .  
 R e su l t s  o f  th e  s tu dy  o r  o f  in d iv id u a l  p a t i e n t s  m ay  b e  r e p o r t e d  a t  m e e t ing s  o r  in  s c i e n t i f i c  
p u b l i c a t io n s  w i th  r emo v a l  o f  sp e c i f i c  p a t i e n t  id e n t i f i e r s . 
9 . 6 . 1  T e l e p h o n e  r e - c o n s e n t  p r o c e d u r e  R e c o n s e n t  o n  th i s  s tu dy  m ay  b e  o b t a in e d  v i a  t e l ep h o n e  a c c o r d ing  to  th e  f o l low in g  p r o c e d u r e :  th e  
in f o rm e d  c o n s e n t  d o c um e n t  w i l l  b e  s e n t  to  th e  su b j e c t .   A n  e xp l a n a t io n  o f  th e  s tu dy  w i l l  b e  p r o v id e d  o v e r  th e  t e l e p ho n e  a f t e r  th e  su b j e c t  h a s  h a d  th e  o p p o r tu n i ty  to  r e a d  th e  c o n s e n t  f o rm .   T h e  su b j e c t  w i l l  sig n  a n d  d a t e  th e  in f o rm e d  c o n s en t .  A  w i tn e s s  to  th e  su b j e c t ’ s  s ig n a tu r e  w i l l  s ig n  a n d  d a t e  th e  c o n s e n t .  
T h e  o r ig in a l  in f o rm e d  c on s e n t  d o c um e n t  w i l l  b e  s e n t  b a c k  to  th e  c o n s e n t in g  in v e s t ig a to r  w h o  
w i l l  s ig n  a n d  d a t e  th e  c on s e n t  f o rm  w i th  th e  d a t e  th e  c o n s e n t  w a s  o b t a in e d  v i a  t e l e p h o n e .   A  f u l ly  e x e c u t e d  c o py  w i l l  b e  r e tu r n e d  v i a  m a i l  f o r  th e  sub j e c t ’ s  r e c o r d s .   T h e  in f o rm e d  c o n s e n t  p r o c e s s  w i l l  b e  d o c um e n t e d  o n  a  p r o g r e s s  n o t e  by  th e  c o n s e n t in g  in v e s t ig a to r  a n d  a  c o py  o f  th e  in f o rm e d  c o n s e n t  d o c um e n t  a n d  n o t e  w i l l  b e  k e p t  in  th e  su b j e c t ’ s  r e s e a r c h  r e c o r d .  
9 . 6 . 2  Sh o r t  f o rm  c o n s e n t  p r o c e s s  f o r  n o n -E ng l i sh  sp e a k in g  p a t i e n t s  
I f  th e r e  i s  a n  u n e xp e c t e d  e n r o l lm e n t  o f  a  r e s e a r c h  p a r t i c ip a n t  f o r  w h om  th e r e  i s  n o  t r a n s l a t e d  
e x t a n t  IRB  a p p r o v e d  c o n s e n t  d o c um e n t ,  th e  p r in c ip a l  in v e s t ig a to r  a n d /o r  tho s e  a u th o r i z e d  to  o b t a in  in f o rm e d  c o n s e n t  w i l l  u s e  th e  Sh o r t  F o rm  O r a l  Co n s e n t  P r o c e s s  a s  d e s c r ib e d  in  MAS  Po l i cy  M7 7 - 2 ,  OHSRP  SOP  1 2 ,  4 5  CFR  4 6 . 1 1 7  ( b )  ( 2 )  a n d  2 1  CFR  5 0 . 2 7  ( b )  ( 2 ) .   T h e  summ a ry  th a t  w i l l  b e  u s e d  i s  th e  E n g l i sh  v e r s io n  o f  th e  e x t a n t  IRB  a p p r o v e d  c o n s e n t  d o c um e n t .   S ig n e d  c o p i e s  o f  b o th  th e  E ng l i sh  v e r s io n  o f  th e  c o n s e n t  a n d  th e  t r a n s l a t e d  sh o r t  fo rm  w i l l  b e  g iv e n  to  th e  su b j e c t  o r  th e i r  l eg a l ly  a u th o r i z e d  r e p r e s e n t a t iv e  a n d  th e  s ig n e d  o r ig in a l  w i l l  b e  f i l e d  in  th e  m ed i c a l  r e c o r d . 
U n l e s s  th e  P I  i s  f lu e n t  in  th e  p r o sp e c t iv e  su b j e c t ’ s  l a n g u ag e ,  a n  in t e r p r e t e r  w i l l  b e  p r e s e n t  to  
f a c i l i t a t e  th e  c o n v e r s a t ion .   P r e f e r a b ly  som e o n e  wh o  i s  in d e p e n d e n t  o f  th e  su b j e c t  ( i . e . ,  n o t  a  f am i ly  m emb e r )  w i l l  a s s i s t  in  p r e s e n t in g  in f o rm a t io n  a n d  o b t a in in g  c o n s e n t .  Wh e n e v e r  p o s s ib l e ,  in t e r p r e t e r s  w i l l  b e  p r o v id e d  c o p i e s  o f  th e  r e l e v a n t  c o n s e n t  d o c um e n t s  w e l l  b e f o r e  th e  c o n s e n t  c o n v e r s a t io n  w i th  th e  sub j e c t  ( 2 4  to  4 8  h o u r s  i f  po s s ib l e ) .   
W e  r e q u e s t  p r o sp e c t iv e  IRB  a p p r o v a l  o f  th e  u s e  o f  th e  sh o r t  f o rm  p r o c e s s  an d  w i l l  n o t i fy  th e  IRB  
a t  th e  t im e  o f  c o n t in u in g  r e v i ew  o f  th e  f r e q u e n cy  o f  th e  u s e  o f  th e  Sh o r t  F o rm .  
A bb r e v i a t e d  T i t l e :  HPC  f o r  AHCT  in  PCM   
V e r s io n  d a t e :  S e p t em b e r  14,  20 17  
  
                                                                                                                                          P ag e  30 o f  38  9 . 7  SUBJECT  INFORMAT ION  AND  CONF IDENT IAL ITY 
A s  in f o rm a t io n  i s  g a th e r ed  f r om  th i s  t r i a l ,  c l in i c a l  r e su l t s  w i l l  b e  sh a r e d  w i th  p a t i e n t s .   
A ny  n ew  s ig n i f i c a n t  o b s e r v a t io n ( s )  f o u n d  d u r ing  th e  c o u r s e  o f  th e  r e s e a r c h ,  w h i c h  m ay  a f f e c t  a  
p a t i e n t ’ s  w i l l in g n e s s  to  p a r t i c ip a t e  f u r th e r  w o u ld  b e  e xp l a in e d .    
Co n f id e n t i a l i ty  o f  in f o rm a t io n  c o n c e r n ing  p a r t i c ip a n t s  w i l l  b e  m a in t a in e d  in c lu d in g  in  a l l  
p u b li c a t io n s  a n d  p r e s e n t a t io n s  r e su l t in g  f r om  th i s  s tu dy .   N am e s  o f  p a r t i c ip an t s  o r  m a t e r i a l  id e n t i fy ing  p a r t i c ip a n t s  w i l l  n o t  b e  r e l e a s e d  w i th o u t  p e rm i s s io n ,  e x c e p t  a s  su c h  r e l e a s e  i s  r e q u i r e d  by  l aw .   R e c o r d s  a t  th e  N a t io n a l  C a n c e r  I n s t i tu t e  a r e  m a in t a in e d  a c c o r d ing  to  c u r r e n t  l e g a l  r e q u i r em e n t s ,  a n d  a r e  m a d e  a v a i l a b l e  f o r  r e v i ew ,  a s  r e q u i r e d  by  th e  Fo o d  a n d  D r ug  A dm in i s t r a t io n  o r  o th e r  au th o r i z e d  u s e r s ,  o n ly  u n d e r  th e  g u id e l in e s  e s t a b l i sh e d  by  th e  F e d e r a l  P r iv a cy  A c t .    
S e e  s e c t io n  5 . 2  f o r  sp e c i f i c s  o f  s amp l e  m a n ag em en t  a n d  s to r ag e .   
1 0  PHARMACEUT ICAL  INFORMAT ION 
1 0 . 1  F
ILGRAST IM  (NEUPOGEN ® ,G -CSF ) 
N e u p og e n®  ( f i lg r a s t im ,  G -CSF ) i s  a  h um a n  g r a n u lo cy t e  c o lo ny - s t imu l a t in g  f a c to r  (G -
CSF )  p r o d u c e d  by  r e c omb in a n t  DNA  t e c h n o logy .  Ne u p og e n ® i s  in d i c a t e d  to  d e c r e a s e  th e  
in c id e n c e  o f  in f e c t io n ,  a s  m a n i f e s t e d  by  f e b r i l e  n eu t r o p e n i a ,  in  p a t i e n t s  w i th  n o n -my e lo id  
m a l ig n a n c i e s  r e c e iv ing  my e lo su p p r e s s iv e  a n t i- c an c e r  d r ug s  a s so c i a t e d  w i th  a  s ig n i f i c a n t  in c id e n c e  o f  s e v e r e  n e u t ro p e n i a  w i th  f e v e r .   
1 0 . 1 . 1  So u r c e  
N e u p og e n
 ® w i l l  b e  o b t a in e d  f r om  th e  c omm e r c i a l  su p p ly  in  th e  C l in i c a l  C e n t e r  
Ph a rm a cy . 1 0 . 1 . 2  A d v e r s e  e f f e c t s 
B o n e  p a in ,  w h i c h  c a n  som e t im e s  b e  s e v e r e .   O th e r  a d v e r s e  r e a c t io n s  in c lud e  f e v e r ,  
f a t ig u e ,  mu s c l e  c r amp s ,  b a c k / l eg  p a in ,  sp l e n om eg a ly ,  th in n ing  h a i r ,  a l l e rg i c  r e a c t io n s  a n d  f l a r e  
o f  k n ow n  a u to - immu n e  d i s e a s e .  
1 0 . 1 . 3  F o rmu l a t io n ,  S to r ag e ,  a nd  S t a b i l i ty  
R e c omb in a n t  g r a n u lo cy t e -c o lo ny  s t imu l a t in g  f a c to r  (G -CSF )  m a n u f a c tu r ed  by  Amg e n  
(T h o u s a n d  O a k s ,  CA )  i s  su p p l i e d  a s  a  c l e a r  s t e r i l e  so lu t io n  o f  3 0 0  m c g /mL  p a c k ag e d  in to  e i th e r  
1 -mL  ( 3 00  m cg )  o r  1 . 6 -mL  ( 4 8 0  m cg )  v i a l s .   N eu p o g e n
 ® sh o u ld  b e  s to r ed  in  th e  r e f r ig e r a to r  a t  
2 °  to  8 °C  ( 3 6 °  to  4 6 °F ) .  A v o id  sh a k in g .  P r io r  to  in j e c t io n ,  N e u p og e n ® m ay  b e  a l low e d  to  r e a c h  
r o om  t emp e r a tu r e  f o r  a  m a x imum  o f  2 4  h o u r s .  A ny  v i a l  o r  p r e f i l l e d  sy r ing e  l e f t  a t  r o om  t emp e r a tu r e  f o r  g r e a t e r  th a n  2 4  h o u r s  sh o u ld  b e  d i s c a r d e d .  D o  n o t  f r e e z e .  G - CSF  i s  s t a b l e  f o r  a t  l e a s t  1  y e a r  w h e n  r e f r ig e r a t e d .  
1 0 . 1 . 4  A dm in i s t r a t io n 
G -CSF  w i l l  b e  a dm in i s t e r e d  a s  a  su b c u t a n e o u s  in j e c t io n  to  mo b i l i z e p e r ip h e r a l  b lo o d  
s t em  c e l l s  f o r  c o l l e c t io n  by  a p h e r e s i s .  S e e  S e c t io n  3 . 3 . 1 f o r  s l id in g  s c a l e  G -CSF  d o s in g  a lg o r i thm  
f o r  mo b i l i z a t io n .  
A bb r e v i a t e d  T i t l e :  HPC  f o r  AHCT  in  PCM   
V e r s io n  d a t e :  S e p t em b e r  14,  20 17  
  
                                                                                                                                          P ag e  31 o f  38  P a t i e n t s  m ay  b e  in s t r u c t ed  o n  th e  s e l f - a dm in i s t r a t io n  o f  G -CSF . 
1 0 . 2  PLER IXAFOR  (MOZOB IL®)  
P l e r ix a f o r i s  a  CXCR4  c h emo k in e  r e c e p to r  a n t ag o n i s t  th a t  b lo c k s  th e  b in d in g  o f  s t r om a l  
c e l l - d e r iv e d  f a c to r  1α  (SDF - 1 α) .  I t  in h ib i t s  th e  r e t e n t io n  o f  h em a to p o i e t i c  s t em  c e l l s  in  b o n e  
m a r r ow ,  a n d  in c r e a s e s  th e i r  n umb e r  in  p e r ip h e r a l  b lo o d .  I t  i s  u s e d  w i th  g r an u lo cy t e  c o lo ny -
s t imu l a t in g  f a c to r  (G -CSF )  to  mo b i l i z e  s t em  c e l l s  f o r  c o l l e c t io n  a n d  su b s e qu e n t  a u to lo g o u s  t r a n sp l a n t a t io n .  
1 0 . 2 . 1  So u r c e  
 Mo zo b i l
® w i l l  b e  o b t a in e d  f r om  th e  c omm e r c i a l  su p p ly  in  th e  C l in i c a l  C e n t e r  Ph a rm a cy . 
1 0 . 2 . 2  A d v e r s e  e f f e c t s 
Commo n  a d v e r s e  e f f e c t s  in c lu d e  d i a r r h e a ,  n a u s e a ,  v om i t in g ,  f l a tu l e n c e ,  f a t ig u e ,  
a r th r a lg i a ,  h e a d a c h e  a n d  d i z z in e s s ,  m i ld  in j e c t io n  s i t e  r e a c t io n s .   
L e s s  c ommo n ly ,  in somn i a  o r  sy s t em i c  r e a c t io n s  o c c u r r ing  a b o u t  3 0  m in u t e s  a f t e r  
in j e c t io n  ( u r t i c a r i a ,  p e r io r b i t a l  sw e l l in g ,  dy sp n e a ,  a n d  hy p o x i a ) .   
Som e  c a s e s  o f  v a so v ag a l  r e a c t io n s ,  o r th o s t a t i c  hy po t e n s io n ,  a n d  sy n c o p e ,  w i th in  1  h o u r  
o f  in j e c t io n ,  h a v e  a l so  b e e n  r e p o r t e d .   1 0 . 2 . 3  F o rmu l a t io n ,  S to r ag e ,  a nd  S t a b i l i ty  
  Su b c u t a n e o u s  So lu t io n :  2 0  mg /m l   I n sp e c t  v i a l  f o r  p a r t i c u l a t e  m a t t e r  a n d  d i s c o lo r a t i o n  p r io r  to  a dm in i s t r a t io n ;  d o  n o t  u s e  i f  
p a r t i c u l a t e  m a t t e r  p r e s e n t  o r  so lu t io n  i s  d i s c o lo r e d .  (P r o d  I n f o  MOZOB IL (R )  su b c u t a n e o u s  in j e c t io n ,  2 0 0 8 ) .  
S to r e  a t  c o n t r o l l e d  r o om  t emp e r a tu r e ,  2 5  d eg r e e s  C  ( 7 7  d e g r e e s  F ) ,  w i th  e x c u r s io n s  
p e rm i t t e d  b e tw e e n  1 5  a nd  3 0  d e g r e e s  C  ( 5 9  a n d  86  d e g r e e s  F ) .  
1 0 . 2 . 4  A dm in i s t r a t io n 
P l e r ix a f o r  2 4 0µg /k g  w i l l  b e  a dm in i s t e r e d  f o r  o n e  to  th r e e  c o n s e c u t iv e  d ay s  a s  a  
su b c u t a n e o u s  in j e c t io n  to  mo b i l i z e  p e r ip h e r a l  b lo o d  s t em  c e l l s  f o r  c o l l e c t io n  by  a p h e r e s i s .   
P l e r ix a f o r  w i l l  b e  a dm in i s t e r e d o n  d ay  4  a n d  p o s s ib ly  d ay  5  a n d  6  o f  f i lg r a s t im  
a dm in i s t r a t io n ,  8  to  1 0  h o u r s  b e f o r e  a p h e r e s i s  b eg in s .   1 0 . 2 . 5  Ph a rm a c o k in e t i c s 
P e a k  p l a sm a  c o n c e n t r a t ion s  o f  p l e r ix a f o r  o c c u r  a bo u t  3 0  to  6 0  m in u t e s  a f t e r  a  
su b c u t a n e o u s  d o s e .  I t  i s  ab o u t  5 8%  b o u n d  to  p l a sm a  p r o t e in s  a n d  l a rg e ly  co n f in e d  to  th e  
e x t r a v a s c u l a r  f lu id  sp a c e .  A b o u t  7 0%  o f  a  d o s e  i s  e l im in a t e d  in  th e  u r in e  w i th in  2 4  h o u r s  a f t e r  a  d o s e ,  a n d  th e  t e rm in a l  h a l f - l i f e  i s  a b o u t  3  to  5  h o u r s .   
 P l e r ix a f o r i s  n o t  m e t a b o l i z e d  u s in g  h um a n  l iv e r  m i c r o som e s  o r  h um a n  p r im a ry  
h e p a to cy t e s .  A d d i t io n a l ly ,  p l e r ix a f o r  d o e s  n o t  e xh ib i t  in h ib i to ry  a c t iv i ty  tow a r d s  th e  m a jo r  d r ug  m e t a b o l i z in g  cy to c h r om e  P4 5 0  e n zym e s  n o r  d id  i t  in d u c e  CYP1A 2 ,  CYP2B6 ,  o r  CYP3A 4 .  
A bb r e v i a t e d  T i t l e :  HPC  f o r  AHCT  in  PCM   
V e r s io n  d a t e :  S e p t em b e r  14,  20 17  
  
                                                                                                                                          P ag e  32 o f  38   
 
1 1   REFERENCES  
1 .   J em a l ,  A . ,  e t  a l . ,  Ca n c e r  s tat i s t i c s ,  2 0 0 8 .  CA  C a n c e r  J  C l in ,  2 0 0 8 .  5 8 ( 2 ) :  p .  7 1 - 9 6 .  
2 .   A l e x a n i a n ,  R . ,  B .  B a r log i e ,  a n d  S .  T u c k e r ,  VAD- ba s e d  r e g im e n s  a s  p r im a r y  t r e a tm e n t  fo r  
m u l t ip l e  m y e lom a . Am e r i c a n  jo u r n a l  o f  h em a to log y ,  1 9 9 0 .  3 3 ( 2 ) :  p .  8 6 - 9 .  
3 .   T o s i ,  P . ,  e t  a l . ,  N e u ro lo g i c a l  to x ic i t y  o f  lo n g - t e rm  (> 1  y r )  th a l id om id e  th e rap y  in  p a t i e n t s  
w i th  m u l t ip l e  m y e lom a . E u r o p e a n  jo u r n a l  o f  h a em a to lo gy ,  2 0 0 5 .  7 4 ( 3 ) :  p .  2 1 2 - 6 .  
4 .   R a jk um a r ,  S .V . ,  e t  a l . ,  Ph a s e  I I I  c l in i c a l  t r ia l  o f  t h a l id om id e  p lu s  d e x am e th a so n e  
c om p a r e d  w i th  d e x am e th a so n e  a lo n e  in  n ew l y  d ia g n o s e d  m u l t ip l e  m y e lom a :  a  c l in i c a l  
t r ia l  c o o rd in a t e d  b y  th e  E a s t e rn  Co o p e ra t i v e  O n co lo g y  G ro u p .  Jo u r n a l  o f  c l in i c a l  o n c o lo gy ,  2 0 0 6 .  2 4( 3 ) :  p .  4 3 1 - 6 .  
5 .   H a r o u s s e a u ,  J .L . ,  e t  a l . ,  VELCADE /D e x am e th a so n e  (V e l /D )  V e r su s  VAD  a s  I n d u c t io n  
T r e a tm e n t  P r io r  to  A u to l o g o u s  S t em  C e l l  T ra n sp l a n t io n  (A SCT )  in  N ew l y  D ia g n o s e d  M u l t ip l e  M y e lom a  (MM ) :  U p d a t e d  R e su l t s  o f  th e  IFM  2 0 0 5 /0 1  T r ia l . ASH  A n n u a l  M e e t in g  A b s t r a c t s ,  2 0 0 7 .  1 1 0 ( 1 1 ) :  p .  4 5 0 - .  
6 .   W e b e r ,  D .M . ,  e t  a l . ,  L e n a l id om id e  p lu s  d e x am e th a so n e  fo r  r e la p s e d  m u l t ip l e  m y e lom a  in  
No r th  Am e r i c a . T h e  N ew  E n g l a n d  jo u r n a l  o f  m e d i c in e ,  2 0 0 7 .  3 5 7 ( 2 1 ) :  p .  21 3 3 - 4 2 .  
7 .   D imo p o u lo s ,  M . ,  e t  a l . ,  L e n a l id om id e  p lu s  d e x am e th a so n e  fo r  r e la p s e d  o r  r e f ra c to r y  
m u l t ip l e  m y e lom a . T h e  N ew  E ng l a n d  jo u r n a l  o f  m e d i c in e ,  2 0 0 7 .  3 5 7 ( 2 1 ) :  p .  2 1 2 3 - 3 2 .  
8 .   R i c h a r d so n ,  P . ,  M a n a g em e n t  o f  th e  r e la p s e d / r e f ra c to r y  m y e lom a  p a t i e n t :  s t ra t e g i e s  
in c o rp o ra t in g  l e n a l id om i d e .  S em in .H em a to l . ,  2 0 0 5 .  4 2 ( 4  Su p p l  4 ) :  p .  S9 - 1 5 .  
9 .   K um a r ,  S .K . ,  e t  a l . ,  Im p ro v e d  su r v i v a l  in  m u l t ip l e  m y e lom a  a n d  th e  im p a c t  o f  n o v e l  
th e ra p i e s .  B lo o d ,  2 0 0 8 .  11 1 ( 5 ) :  p .  2 5 1 6 - 2 5 2 0 .  
1 0 .   R a jk um a r ,  S .V . ,  e t  a l . ,  A  R a n d om i z e d  T r ia l  o f  L e n a l id om id e  P lu s  H ig h -D o s e  
D e x am e th a so n e  (RD )  V e r su s  L e n a l id om id e  P lu s  Low -D o s e  D e x am e th a so n e  (R d )  in  N ew l y  D ia g n o s e d  M u l t ip l e  M y e lom a  (E 4A 0 3 ) :  A  T r ia l  Co o rd in a t e d  b y  th e  E a s t e rn  Co o p e ra t i v e  O n c o lo g y  G ro u p . ASH  A n n u a l  M e e t in g  A b s t r a c t s ,  2 0 0 7 .  1 1 0 (1 1 ) :  p .  7 4 - .  
1 1 .   R i c h a r d so n ,  P . ,  e t  a l . ,  L e n a l id om id e ,  B o r t e zom ib ,  a n d  D e x am e th a so n e  (R e v /V e l /D e x )  a s  
F ro n t -L in e  Th e ra p y  fo r  P a t i e n t s  w i th  M u l t ip l e  M y e lom a  (MM ) :  P r e l im in a r y  R e su l t s  o f  a  P h a s e  1 /2  S tu d y . B lo o d  (ASH  A n n u a l  M e e t ing  Ab s t r a c t s ) ,  2 0 0 7 .  1 1 0 ( 1 1 ) :  p .  1 8 7 .  
1 2 .   Z o n d e r ,  J .A . ,  e t  a l . ,  S u p e r io r i t y  o f  L e n a l id om id e  (L e n )  P lu s  H ig h -D o s e  D e x am e th a so n e  
(HD )  Com p a r e d  to  HD  A lo n e  a s  T r e a tm e n t  o f  N ew l y -D ia g n o s e d  M u l t ip l e  M y e lom a  (NDMM ) :  R e su l t s  o f  th e  R a n d om i z e d ,  D o u b l e -B l in d e d ,  P la c e b o -Co n t ro l l ed  SWOG  T r ia l  S 0 2 3 2 .  B lo o d  (ASH  A n nu a l  M e e t in g  A b s t r a c t s ) ,  20 0 7 .  1 1 0 ( 1 1 ) :  p .  7 7 .  
1 3 .   P a lumb o ,  A .  a n d  S .V .  R a jk um a r ,  T r e a tm e n t  o f  n ew l y  d ia g n o s e d  m y e lom a . L e u k em i a ,  
2 0 0 8 .  
A bb r e v i a t e d  T i t l e :  HPC  f o r  AHCT  in  PCM   
V e r s io n  d a t e :  S e p t em b e r  14,  20 17  
  
                                                                                                                                          P ag e  33 o f  38  1 4 .  V e so l e , D .H . ,  e t  a l . ,  H ig h- d o s e  th e ra p y  fo r  r e f ra c to r y  m u l t ip l e  m y e lom a :  im p ro v e d  
p ro g n o s i s  w i th  b e t t e r  su p p o r t i v e  c a r e  a n d  d o u b l e  t ra n sp la n t s .  B lo o d ,  1 9 9 4 .  8 4 ( 3 ) :  p .  9 5 0 -
9 5 6 .  
1 5 .   A t t a l ,  M . ,  e t  a l . ,  S in g l e  v e r su s  d o u b l e  a u to lo g o u s  s t em - c e l l  t ra n sp la n ta t io n  fo r  m u l t ip l e  
m y e lom a . N ew  E ng l a n d  Jo u r n a l  o f  M e d i c in e ,  2 0 0 3 .  3 4 9 ( 2 6 ) :  p .  2 4 9 5 - 2 5 0 2 .  
1 6 .   Ch i ld ,  J .A . ,  e t  a l . ,  H ig h- d o s e  c h em o th e ra p y  w i th  h em a to p o i e t i c  s t em - c e l l  r e s c u e  fo r  
m u l t ip l e  m y e lom a . N ew  E n g l a n d  Jo u r n a l  o f  M e d i c in e ,  2 0 0 3 .  3 4 8 ( 1 9 ) :  p .  18 7 5 - 1 8 8 3 .  
1 7 .  L e vy ,  V . ,  e t  a l . ,  A  m e ta- an a l y s i s  o n  d a ta  f rom  5 7 5  p a t i e n t s  w i th  m u l t ip l e  m y e lom a  
ra n d om l y  a s s ig n e d  to  e i th e r  h ig h - d o s e  th e ra p y  o r  c o n v e n t io n a l  th e ra p y .  M e d i c in e  (B a l t imo r e ) ,  2 0 0 5 .  8 4 ( 4 ) :  p .  2 5 0 - 2 6 0 .  
1 8 .   K o r e th ,  J . ,  e t  a l . ,  H ig h- d o s e  th e ra p y  w i th  s in g l e  a u to lo g o u s  t ra n sp la n ta t io n  v e r su s  
c h em o th e ra p y  fo r  n ew l y  d ia g n o s e d  m u l t ip l e  m y e lom a :  A  s y s t em a t i c  r e v i ew  a n d  m e ta -a n a l y s i s  o f  ra n d om i z e d  c o n t ro l l e d  t r ia l s .  B io l .B lo o d  M a r r ow  T r a n sp l a n t . ,  2 0 0 7 .  1 3 ( 2 ) :  p .  1 8 3 - 1 9 6 .  
1 9 .   S e g e r e n ,  C .M . ,  e t  a l . ,  O v e ra l l  a n d  e v e n t -f r e e  su r v i v a l  a r e  n o t  im p ro v e d  b y  th e  u s e  o f  
m y e lo a b la t i v e  th e ra p y  fo l low in g  in t e n s i f i e d  c h em o th e ra p y  in  p r e v io u s l y  u n t r e a t e d  p a t i e n t s  w i th  m u l t ip l e  m y e lom a :  a  p ro sp e c t i v e  ra nd om i z e d  p h a s e  3  s tu d y .  B lo o d ,  2 0 0 3 .  1 0 1 ( 6 ) :  p .  2 1 4 4 - 2 1 5 1 .  
2 0 .  B a r log i e ,  B . ,  e t  a l . ,  S ta n d a rd  c h em o th e ra p y  c om p a r e d  w i th  h ig h - d o s e  c h emo ra d io th e ra p y  
fo r  m u l t ip l e  m y e lom a :  f in a l  r e su l t s  o f  p h a s e  I I I  U S  I n t e rg ro u p  T r ia l  S 9 3 2 1 .  J .C l in .O n c o l . ,  2 0 0 6 .  2 4 ( 6 ) :  p .  9 2 9 - 9 3 6 .  
2 1 .   F e rm a n d ,  J .P . ,  e t  a l . ,  H ig h- d o s e  th e ra p y  a n d  a u to lo g o u s  p e r ip h e ra l  b lo o d  s t e m  c e l l  
t ra n sp la n ta t io n  in  m u l t ip l e  m y e lom a :  up - f ro n t  o r  r e s c u e  t r e a tm e n t?  R e su l t s  o f  a  m u l t i c e n t e r  s e q u e n t ia l  ra n d om i z e d  c l in i c a l  t r ia l . B lo o d ,  1 9 9 8 .  9 2 ( 9 ) :  p .  3 1 3 1 - 6 .  
2 2 .   G ay ,  F . ,  e t  a l . ,  Com p l e t e  r e sp o n s e  c o r r e la t e s  w i th  lo n g -t e rm  p ro g r e s s io n - f r e e  a n d  o v e ra l l  
su r v i v a l s  in  e ld e r l y  m y e lom a  t r e a t e d  w i th  n o v e l  a g e n t s :  a n a l y s i s  o f  1 1 7 5  p a t i e n t s .  B lo o d ,  2 0 1 0 :  p .  b lo o d - 2 0 1 0 - 0 9 -3 0 7 6 4 5 .  
2 3 .   v a n  d e  V e ld e ,  H . J . ,  e t  a l . ,  Com p l e t e  r e sp o n s e  c o r r e la t e s  w i th  lo n g - t e rm  su r v i v a l  a n d  
p ro g r e s s io n - f r e e  su r v i v a l  in  h ig h - d o s e  th e ra p y  in  m u l t ip l e  m y e lom a .  H a em a to lo g i c a ,  2 0 0 7 .  9 2 ( 1 0 ) :  p .  1 3 9 9 - 4 06 .  
2 4 .   H a t s e ,  S . ,  e t  a l . ,  Ch em o k in e  r e c e p to r  in h ib i t io n  b y  AMD 3 1 0 0  i s  s t r i c t l y  c o n f in e d  to  
CXCR 4 . FEBS  L e t t ,  2 0 02 .  5 2 7 ( 1 - 3 ) :  p .  2 5 5 - 6 2 .  
2 5 .   Ro s e n k i ld e ,  M .M . ,  e t  a l . ,  M o l e c u la r  m e c h a n i sm  o f  AMD 3 1 0 0  a n ta g o n i sm  in  th e  CXCR 4  
r e c e p to r :  t ra n s f e r  o f  b in d in g  s i t e  to  th e  CXCR 3  r e c e p to r .  J  B io l  Ch em ,  2 0 0 4 .  2 7 9 ( 4 ) :  p .  3 0 3 3 - 4 1 .  
2 6 .   D e v in e ,  S .M . ,  e t  a l . ,  R a p id  m o b i l i za t io n  o f  CD 3 4+  c e l l s  fo l low in g  a dm in i s t r a t io n  o f  th e  
CXCR 4  a n ta g o n i s t  AMD 3 1 0 0  to  p a t i e n t s  w i th  m u l t ip l e  m y e lom a  a n d  n o n -Ho d g k in ' s  l ym p h om a .  J  C l in  O n c o l ,  2 0 0 4 .  2 2 ( 6 ) :  p .  1 0 9 5 - 1 0 2 .  
2 7 .   D iP e r s io ,  J .F . ,  e t  a l . ,  P l e r i x a fo r . N a t  R e v  D r ug  D i s c o v ,  2 0 0 9 .  8 ( 2 ) :  p .  1 0 5 - 10 7 .  
A bb r e v i a t e d  T i t l e :  HPC  f o r  AHCT  in  PCM   
V e r s io n  d a t e :  S e p t em b e r  14,  20 17  
  
                                                                                                                                          P ag e  34 o f  38  2 8 .   F lom e n b e rg ,  N . ,  e t  a l . ,  Th e  u s e  o f  AMD 3 1 0 0  p lu s  G -CSF  fo r  a u to lo g o u s  h em a top o i e t i c  
p ro g e n i to r  c e l l  m o b i l i za t i o n  i s  su p e r io r  to  G -CSF  a lo n e .  B lo o d ,  2 0 0 5 .  1 0 6 (5 ) :  p .  1 8 6 7 -
7 4 .  
2 9 .   D iP e r s io ,  J .F . ,  e t  a l . ,  P l e r i x a fo r  a n d  G -CSF  v e r su s  p la c e b o  a n d  G -CSF  to  m o b i l i z e  
h em a to p o i e t i c  s t em  c e l l s  fo r  a u to lo g o u s  s t em  c e l l  t ra n sp la n ta t io n  in  p a t i e n t s  w i th  m u l t ip l e  m y e lom a . B lo o d ,  2 0 0 9 .  1 1 3 ( 2 3 ) :  p .  5 7 2 0 -6 .  
3 0 .   D iP e r s io ,  J .F . ,  e t  a l . ,  P h a s e  I I I  p ro sp e c t i v e  ra n d om i z e d  d o u b l e - b l in d  p la c eb o - c o n t ro l l e d  
t r ia l  o f  p l e r i x a fo r  p lu s  g r a n u lo c y t e  c o lo n y - s t im u la t in g  fa c to r  c om p a r e d  w i th  p la c e b o  p lu s  g ra n u lo c y t e  c o lo n y - s t im u la t in g  fa c to r  fo r  a u to lo g o u s  s t em - c e l l  m o b i l i za t io n  a n d  t ra n sp la n ta t io n  fo r  p a t i e n t s  w i th  n o n -H o d g k in ' s  l ym p h om a .  J  C l in  O n c o l ,  2 0 0 9 .  2 7 ( 2 8 ) :  p .  4 7 6 7 - 7 3 .  
3 1 .   F lom e n b e rg ,  N . ,  e t  a l . ,  P l e r i x a fo r  (M o zo b i l )  a lo n e  to  m o b i l i z e  h em a to p o i e t i c  s t em  c e ll s  
f rom  m u l t ip l e  m y e lom a  pa t i e n t s  fo r  a u to lo g o u s  t ra n sp la n ta t io n .  B io l  B lo o d  M a r r ow  T r a n sp l a n t ,  2 0 1 0 .  1 6 ( 5 ) :  p .  6 9 5 - 7 0 0 .  
3 2 .   D e v in e ,  S .M . ,  e t  a l . ,  R a p id  m o b i l i za t io n  o f  fu n c t io n a l  d o n o r  h em a to p o i e t i c  c e l l s  w i th o u t  
G -CSF  u s in g  AMD 3 1 0 0 ,  a n  a n ta g o n i s t  o f  th e  CXCR 4 /SDF- 1  in t e ra c t io n .  B lo o d ,  2 0 0 8 .  1 1 2 ( 4 ) :  p .  9 9 0 - 8 .  
3 3 .   V a su ,  S . ,  e t  a l . ,  D o n o r  d em o g ra p h i c  a n d  la b o ra to r y  p r e d i c to r s  o f  a l lo g e n e i c  p e r ip h e ra l  
b lo o d  s t em  c e l l  m o b i l i za t io n  in  a n  e th n i c a l l y  d i v e r s e  p o p u la t io n .  B lo o d ,  2 0 0 8 .  1 1 2 ( 5 ) :  p .  2 0 9 2 - 1 0 0 .  
3 4 .  S a n  Mig u e l ,  J .F . ,  e t  a l . ,  Imm u n o p h e n o t y p i c  e v a lua t io n  o f  th e  p la sm a  c e l l  c om p a r tm e n t  in  
m u l t ip l e  m y e lom a :  a  to o l  fo r  c om p a r in g  th e  e f f i c a c y  o f  d i f f e r e n t  t r e a tm e n t  s t ra t e g i e s  a n d  p r e d i c t in g  o u t c om e .  B lo o d ,  2 0 0 2 .  9 9 ( 5 ) :  p .  1 8 5 3 - 6 .  
3 5 .   R aw s t r o n ,  A .C . ,  e t  a l . ,  F low c y tom e t r i c  d i s e a s e  mo n i to r in g  in  m u l t ip l e  m y e lom a :  th e  
r e la t io n sh ip  b e tw e e n  n o rm a l  a n d  n e o p la s t i c  p la sm a  c e l l s  p r e d i c t s  o u t c om e  a f t e r  t ra n sp la n ta t io n .  B lo o d ,  2 0 0 2 .  1 0 0 ( 9 ) :  p .  3 0 9 5 - 1 0 0 .  
3 6 .   L iu ,  H . ,  e t  a l . ,  F low  c y tom e t r i c  m in im a l  r e s id u a l  d i s e a s e  m o n i to r in g  in  p a t i e n t s  w i th  
m u l t ip l e  m y e lom a  u n d e rgo in g  a u to lo g o u s  s t em  c e l l  t ra n sp la n ta t io n :  a  r e t ro sp e c t i v e  s tu d y .  L e u k  L ymp h om a ,  2 0 0 8 .  4 9 ( 2 ) :  p .  3 0 6 - 1 4 .  
3 7 .   P a iv a ,  B . ,  e t  a l . ,  M u l t ip a ram e t e r  f low  c y tom e t r i c  r em i s s io n  i s  th e  m o s t  r e l e v a n t  
p ro g n o s t i c  fa c to r  fo r  m u l t ip l e  m y e lom a  p a t i e n t s  wh o  u n d e rg o  a u to lo g o u s  s t em  c e l l  t ra n sp la n ta t io n .  B lo o d ,  2 0 0 8 .  1 1 2 ( 1 0 ) :  p .  4 0 1 7 - 2 3 .  
3 8 .   P a iv a ,  B . ,  e t  a l . ,  M u l t ip a ram e t e r  f low  c y tom e t r y  q ua n t i f i c a t io n  o f  b o n e  m a r r ow  p la sm a  
c e l l s  a t  d ia g n o s i s  p ro v id e s  m o r e  p ro g n o s t i c  in fo rm a t io n  th a n  m o rp h o lo g i c a l  a s s e s sm e n t  in  m y e lom a  p a t i e n t s .  H a em a to lo g i c a ,  2 0 0 9 .  9 4( 1 1 ) :  p .  1 5 9 9 - 6 0 2 .  
3 9 .   C a v o ,  M . ,  e t  a l . ,  M o l e c u la r  m o n i to r in g  o f  m in im a l  r e s id u a l  d i s e a s e  in  p a t i e n t s  in  lo n g -
t e rm  c om p l e t e  r em i s s io n  a f t e r  a l lo g e n e i c  s t em  c e l l  t ra n sp la n ta t io n  fo r  m u l t i p l e  m y e lom a .  B lo o d ,  2 0 0 0 .  9 6 ( 1 ) :  p .  3 55 - 7 .  
4 0 .   L emo l i ,  R .M . ,  e t  a l . ,  E n g ra f tm e n t ,  c l in i c a l ,  a n d  m o l e c u la r  fo l low - u p  o f  p a t i e n t s  w i th  
m u l t ip l e  m y e lom a  wh o  w e r e  r e in fu s e d  w i th  h ig h l y  p u r i f i e d  CD 3 4+  c e l l s  to  su p p o r t  s in g l e  o r  ta n d em  h ig h - d o s e  c h em o th e ra p y .  B lo o d ,  2 0 0 0 .  9 5 ( 7 ) :  p .  2 2 3 4 - 9 .  
A bb r e v i a t e d  T i t l e :  HPC  f o r  AHCT  in  PCM   
V e r s io n  d a t e :  S e p t em b e r  14,  20 17  
  
                                                                                                                                          P ag e  35 o f  38  4 1 .  M a r t in e l l i ,  G . ,  e t  a l . ,  P o l ym e ra s e  c h a in  r e a c t io n - ba s e d  d e t e c t io n  o f  m in im a l  r e s id u a l  
d i s e a s e  in  m u l t ip l e  m y e lom a  p a t i e n t s  r e c e i v in g  a l lo g e n e i c  s t em  c e l l  t ra n sp la n ta t io n .  
H a em a to log i c a ,  2 0 0 0 .  8 5( 9 ) :  p .  9 3 0 - 4 .  
4 2 .  M a r t in el l i ,  G . ,  e t  a l . ,  M o l e c u la r  r em i s s io n  a f t e r  a l lo g e n e i c  o r  a u to lo g o u s  t ra n sp la n ta t io n  
o f  h em a to p o i e t i c  s t em  c e l l s  fo r  m u l t ip l e  m y e lom a .  J  C l in  O n c o l ,  2 0 0 0 .  1 8 ( 1 1 ) :  p .  2 2 7 3 - 8 1 .  
4 3 .   F e n k ,  R . ,  e t  a l . ,  L e v e l s  o f  m in im a l  r e s id u a l  d i s e a s e  d e t e c t e d  b y  q u a n t i ta t i v e  m o l e c u la r  
m o n i to r in g  h e ra ld  r e la p s e  in  p a t i e n t s  w i th  m u l t ip l e  m y e lom a . H a em a to lo g i c a ,  2 0 0 4 .  8 9 ( 5 ) :  p .  5 5 7 - 6 6 .  
4 4 .   D iP e r s io ,  J .F . ,  e t  a l . ,  R e l e v a n c e  a n d  C l in i c a l  Im p l i c a t io n s  o f  Tum o r  C e l l  M o b i l i za t io n  in  
th e  A u to lo g o u s  T ra n sp la n t  S e t t in g .  B io lo gy  o f  B lo o d  a n d  M a r r ow  T r a n sp l a n t a t io n ,  2 0 1 1 .  1 7 ( 7 ) :  p .  9 4 3 - 9 5 5 .  
4 5 .   S t ew a r t ,  A .K . ,  e t  a l . ,  P u rg in g  o f  a u to lo g o u s  p e r ip h e ra l - b lo o d  s t em  c e l l s  u s in g  CD 3 4  
s e l e c t io n  d o e s  n o t  im p ro v e  o v e ra l l  o r  p ro g r e s s io n - f r e e  su r v i v a l  a f t e r  h ig h -d o s e  c h em o th e ra p y  fo r  m u l t ip l e  m y e lom a :  R e su l t s  o f  a  m u l t i c e n t e r  ra n d om i z e d  co n t ro l l e d  t r ia l .  Jo u r n a l  o f  C l in i c a l  O n c o lo gy ,  2 0 0 1 .  1 9( 1 7 ) :  p .  3 7 7 1 - 3 7 7 9 .  
4 6 .   B o u r h i s ,  J . -H . ,  e t  a l . ,  R e la p s e  r i s k  a f t e r  a u to lo g o u s  t ra n sp la n ta t io n  in  p a t i e n t s  w i th  n ew l y  
d ia g n o s e d  m y e lom a  i s  n o t  r e la t e d  w i th  in fu s e d  tum o r  c e l l  lo a d  a n d  th e  o u t c om e  i s  n o t  im p ro v e d  b y  CD 3 4+  c e l l  s e l e c t io n :  lo n g  t e rm  fo l low - u p  o f  a n  EBMT  p h a s e  I I I  ra n d om i z e d  s tu d y .  H a em a to lo g i c a ,  2 0 0 7 .  9 2 ( 8 ) :  p .  1 0 8 3 - 1 0 9 0 .  
4 7 .   A t t a l ,  M .  a n d  J .L .  H a r o u s s e a u ,  Th e  ro l e  o f  h ig h - d o s e  th e ra p y  w i th  a u to lo g o u s  s t em  c e l l  
su p p o r t  in  th e  e ra  o f  n o v e l  a g e n t s .  S em in  H em a to l ,  2 0 0 9 .  4 6 ( 2 ) :  p .  1 2 7 - 3 2 .  
4 8 .   D imo p o u lo s ,  M .A .  a n d  M .  A t t a l ,  M u l t ip l e  m y e lom a  in  th e  e ra  o f  n o v e l  a g e n t s . S em in  
H em a to l ,  2 0 0 9 .  4 6 ( 2 ) :  p .  1 0 7 - 9 .  
4 9 .   P a lumb o ,  A .  a n d  S .V .  R a jk um a r ,  M u l t ip l e  m y e loma :  c h em o th e ra p y  o r  t ra n sp la n ta t io n  in  
th e  e ra  o f  n ew  d ru g s .  E u r  J  H a em a to l ,  2 0 1 0 .  8 4 ( 5 ) :  p .  3 7 9 - 9 0 .  
 
A bb r e v i a t e d  T i t l e :  HPC  f o r  AHCT  in  PCM   
V e r s io n  d a t e :  S e p t em b e r  14,  20 17  
  
                                                                                                                                          P ag e  37 o f  38  1 3  APPEND IX 2 :  DATA  COLLECT ION  ELEMENTS  REQU IRED  BY  P ROTOCOL 
A l l  o f  th e  f o l low in g  e l em e n t s  w i l l  b e  r e c o r d e d  in  th e  C3D  d a t a b a s e . 
1 3 . 1  PAT IENT  ENROLLMENT 
•  D a t e  o f  b i r th ,  ag e ,  g e n d e r ,  r a c e ,  e th n i c i ty  
•  H e ig h t •  W e ig h t •  P e r f o rm a n c e  S t a tu s •  D a t e  o f  o r ig in a l  d i ag n o s i s  •  S t a g e  a t  d i ag n o s i s 
•  S t a g e  a t  s tu dy  e n t ry 
•  T umo r  H i s to lo gy  a n d  d a t e  o f  c o n f i rm a t io n  •  D a t e  o f  I n f o rm e d  Con s e n t  s ig n a tu r e ,  c o n s e n t  v e r s io n  a n d  d a t e  o f  r eg i s t r a t ion  •  B a s e l in e  H i s to ry /Phy s i c a l •  B a s e l in e  Symp tom s •  N umb e r  p r io r  c h emo th e r a py  c o u r s e s  a n d  a n t i- my e lom a  m e d i c a t io n s  a dm in i s t e r e d   
1 3 . 2  S
TUDY  DRUG  ADM IN ISTRAT ION  
•  D o s e s  o f  f i lg r a s t im  a n d  p l e r ix a f o r 
1 3 . 3  LABORATORY  AND  DIAGNOST IC  TEST  DATA 
•  A l l  C l in i c a l  l a b o r a to ry  an d  d i a g n o s t i c  t e s t  r e su l t s  d o n e  a t  s c r e e n ing 
•  D a t a  c o l l e c t e d  by  th e  DTM  p e r t a in in g  to  th e  HPC ,  A p h e r e s i s  c o l l e c t io n  
•  A l l  t e s t s  d o n e  to  d o c um e n t  r e so lu t io n  o f  a d v e r s e  ev e n t s   
1 3 . 4  ADVERSE  EVENTS 
•  A l l  G r a d e  2  un e xp e c t ed e v e n t s  th a t  a r e  p o s s ib ly ,  p r o b a b ly  o r  d e f in i t e ly  r e l a t e d  to  th e  
r e s e a r c h .  
•  A l l  g r a d e  3  a n d  4  a d v e r s e  e v e n t s  th a t  a r e  p o s s ib ly ,  p r o b a b ly  o r  d e f in i t e ly  r e l a t e d  to  th e  
r e s e a r c h  w i l l  b e  r e c o r d e d . 
E x c e p t io n s  to  r e p o r t in g :  
T h e  f o l low in g  e v e n t s  th a t  a r e  p o s s ib ly ,  pr o b a b ly  o r  d e f in i t e ly  r e l a t e d  to  th e  r e s e a r c h  w i l l  n o t  b e  r e p o r t e d :  o O f  a ny  g r a d e :  L e u k o cy to s i s  o r  n e u t r o p h i l i a ,  e l e v a t e d  LDH ,  p a r e s th e s i a s ,  b on e  p a in ,  
f e v e r ,  f a t ig u e ,  mu s c l e  c r amp s ,  b a c k / l e g  p a in ,  sp l e nom e g a ly ,  
o O f  g r a d e  < 3 :  T h r omb o cy to p e n i a ,  a n em i a ,  hy p o c al c em i a ,  hy p om ag n e s em i a ,  e l e v a t e d  
t r a n s am in a s e s ,  d i a r r h e a ,  n a u s e a ,  v om i t in g ,  f l a tu l en c e ,  f a t ig u e ,  a r th r a lg i a ,  h e a d a c h e  a n d  d i z z in e s s ,  m i ld  in j e c t io n  s i t e  r e a c t io n s .  
1 3 . 5  C
ONCOM ITANT  MEASURES 
•  B a s e l in e  m e d i c a t io n s   
•  Th e r a py  f o r  r e c o r d e d  a d v e r s e  e v e n t s 
A bb r e v i a t e d  T i t l e :  HPC  f o r  AHCT  in  PCM   
V e r s io n  d a t e :  S e p t em b e r  14,  20 17  
  
                                                                                                                                          P ag e  38 o f  38  1 3 . 6  OFF  STUDY 
•  D a te  a n d  r e a so n  fo r  o f f  s tu dy  
•  D a t e  a n d  c a u s e  o f  d e a th 
•  P I  d e c i s io n  to  e n d  th i s  s tu dy  
 
 
 CONSENT  TO  PART IC IPATE  IN  A  CL IN ICAL  RESEARCH  STUDY 
   MED ICAL  RECORD                 •   Adu l t  P a t i e n t  o r      •   P a r e n t ,  fo r  M i no r  P a t i e n t  
  
 
INST ITUTE :  N a t i on a l  C a n c e r  In s t i t u t e   STUDY  NUMBER : 12-C - 0074 PR INC IPAL  INVEST IGATOR :   J e nn i f e r  A .  K a n a k ry ,  
M .D .   STUDY  T ITLE :   M ob i l i z a t i on  a nd  c o l l e c t i on  o f  Au t o l ogou s  S t em  c e l l  fo r  t r a n s p l a n t a t i on  (ASCT )  fo r     P l a sm a  C e l l  M y e l om a  (PCM ) 
  C on t i nu i ng R e v i ew  App rov e d  by  t h e  IRB  on  08 / 07 / 17         
Am e ndm e n t  App rov e d  by  t h e  IRB  on  09 / 23/ 17  (H )      D a t e  Po s t e d  t o  W e b :  10 / 05 / 17
 
S t a nd a rd 
PAT IENT  IDENT IF ICAT ION CONSENT TO PART IC IPATE IN  A CL IN ICAL RESEARCH STUDY 
•  Adu l t  P a t i e n t  o r •  P a r e n t ,  fo r  M i no r  P a t i en t  
N IH- 2514- 1  (07- 09 ) 
P .A . :   09- 25- 0099 F i l e  i n  S e c t i on  4 :   P ro t o c o l  C on s e n t  (1 ) 
 
 
 INTRODUCT ION  
 
W e  in v i t e  y o u  to  t ak e  p a r t  in  a  r e s e a r ch  s tu d y  a t  th e  N a t io n a l  In s t i tu t e s  o f  H e a l th  (N IH ) . 
 F i r s t ,  w e  w an t  y o u  to  k n ow  th a t :   T ak in g  p a r t  in  N IH  r e s e a r ch  i s  en t i r e ly  v o lu n t a ry .    Y o u  m ay  ch o o s e  n o t  to  t ak e  p a r t ,  o r  y o u  m ay  w i th d r aw  f rom  th e  s tu d y  a t  an y  t im e .   In  
e i th e r  c a s e ,  y o u  w i l l  n o t  lo s e  an y  b en e f i t s  to  w h i ch  y o u  a r e  o th e rw i s e  en t i t l ed .   H ow ev e r ,  to  r e c e iv e  c a r e  a t  th e  N IH ,  y o u  m u s t  b e  t ak in g  p a r t  in  a  s tu d y  o r  b e  u n d e r  ev a lu a t io n  f o r  s tu d y  p a r t i c ip a t io n .  
   Y o u  m ay  r e c e iv e  n o  b en e f i t  f rom  t ak in g  p a r t .   T h e  r e s e a r ch  m ay  g iv e  u s  k n ow l ed g e  th a t  
m ay  h e lp  p eo p l e  in  th e  f u tu r e .  
 S e co n d ,  som e  p eo p l e  h av e  p e r so n a l ,  r e l ig io u s  o r  e th i c a l  b e l i e f s  th a t  m ay  l im i t  th e  k in d s  o f  m ed i c a l  o r  r e s e a r ch  t r e a tm en t s  th ey  w o u ld  w an t  to  r e c e iv e  ( su ch  a s  b lo o d  t r an s f u s io n s ) .   I f  y o u  h av e  su ch  b e l i e f s ,  p l e a s e  d i s cu s s  th em  w i th  y o u r  N IH  d o c to r s  o r  r e s e a r ch  t e am  b e f o r e  y o u  ag r e e  to  th e  s tu d y .   N ow  w e  w i l l  d e s c r ib e  th i s  r e s e a r ch  s tu d y .   B e f o r e  y o u  d e c id e  to  t ak e  p a r t ,  p l e a s e  t ak e  a s  m u ch  t im e  a s  y o u  n e ed  to  a sk  an y  q u e s t io n s  an d  d i s cu s s  th i s  s tu d y  w i th  an y o n e  a t  N IH ,  o r  w i th  f am i ly ,  f r i en d s  o r  y o u r  p e r so n a l  p h y s i c i an  o r  o th e r  h e a l th  p ro f e s s io n a l .   
Wh y  a r e  y ou  b e in g  a sk ed  to  tak e  p a r t  in  th i s  s tud y ?  
 
Y o u  a r e  b e in g  in v i t ed  to  p a r t i c ip a t e  in  a  s tu d y  to  co l l e c t  H em a to p o i e t i c  P ro g en i to r  C e l l s  (HPC s )  f rom  y o u r  b lo o d  f o r  l a t e r  u s e  in  th e  t r e a tm en t  o f  y o u r  P l a sm a  C e l l  My e lom a  (PCM ) .      Y o u  h av e  b e en  to ld  b y  y o u r  d o c to r s  th a t  h ig h -d o s e  ch em o th e r ap y  f o l low ed  b y  A u to lo g o u s  S t em  C e l l  T r an sp l an t  (ASCT )  m ay  b e  o f  b en e f i t  in  th e  t r e a tm en t  o f  y o u r  P l a sm a  C e l l  My e lom a.   
MED ICAL RECORD CONT INUAT ION SHEET fo r  e i th e r :  
N IH  2514- 1 ,  C on s e n t  t o  P a r t i c i p a t e  i n  A  C l i n i c a l  R e s e a r c h  S t udy 
N IH  2514- 2 ,  M i no r  P a t i e n t ’ s  A s s e n t  t o  P a r t i c i p a t e  In  A  C l i n i c a l  R e s e a r c h  S t udy 
STUDY  NUMBER : 12-C - 0074 CONT INUAT ION :  p a g e  2  o f  10 p a g e s  
 
 
PAT IENT  IDENT IF ICAT ION CONT INUAT ION  SHEET  fo r  e i th e r : 
 N IH- 2514- 1  (10- 84 ) 
 N IH- 2514- 2  (10- 84 ) 
 P .A . :  09- 25- 0099 
 
  
Wh y  i s  th i s  s tud y  b e in g  d on e? 
 
T h e  m a in  g o a l  o f  th e  s tu d y  i s  to  co l l e c t  y o u r  HPC s  an d  to  ev a lu a t e  th e  b e s t  d ru g  com b in a t io n  (o n e  o r  tw o  d ru g s )  to  u s e  f o r  “m o b i l i z in g ”  th em  o u t  o f  y o u r  b o n e  m a r row  in to  y o u r  b lo o d s t r e am  wh e r e  th ey  w i l l  b e  co l l e c t ed .   HPC s  a r e  co l l e c t ed  f rom  th e  b lo o d  in  a  p ro c ed u r e  c a l l ed  ap h e r e s i s .   A f t e r  co l l e c t io n ,  th ey  w i l l  b e  s to r ed  f ro z en  u n t i l  y o u  a r e  r e ad y  to  u n d e rg o  th e  ASCT  p ro c ed u r e  f o r  th e  t r e a tm en t  o f  PCM .  
 
B o th  d ru g s ,  f i lg r a s t im  (N eu p o g en )  an d  p l e r ix a f o r  (Mo zo b i l )  a r e  ap p ro v ed  b y  th e  FDA  f o r  u s e  in  m o b i l i z a t io n  in  su b j e c t s  w i th  PCM .   T h ey  a r e  n o t  ex p e r im en t a l .   Mo b i l i z a t io n  w i th  f i lg r a s t im  a lo n e  i s  co n s id e r ed  to  b e  th e  s t an d a rd  o f  c a r e  a t  th i s  p o in t .  I t  h a s  b e en  sh ow n  th a t  ad d in g  p l e r ix a f o r  to  f i lg r a s t im  in c r e a s e s  th e  y i e ld  o f  th e  ap h e r e s i s  p ro c ed u r e .   T h i s  s tu d y  w i l l  t ry  to  d e t e rm in e  w h a t  p ro p o r t io n  o f  su b j e c t s  m ay  b e  ad eq u a t e ly  m o b i l i z ed  w i th  a  s in g l e  d ru g  (N eu p o g en )  f o r  th e  m o s t  e f f i c i en t  HPC  co l l e c t io n  an d  w h a t  p ro p o r t io n  w o u ld  b en e f i t  f rom  ad d in g  p l e r ix a f o r .    
 
D e s c r ip t ion  o f  R e s ea r ch  S tud y 
 
Y o u  w i l l  u n d e rg o  HPC  m o b i l i z a t io n  w i th  a  s t an d a rd  r eg im en  o f  f i lg r a s t im :  o n e  in j e c t io n  u n d e r  th e  sk in  f o r  5  d ay s  in  a  row .   O n  th e  m o rn in g  o f  th e  f o u r th  d ay  a  sp e c i a l  b lo o d  t e s t  w i l l  b e  p e r f o rm ed  to  d e t e rm in e  h ow  m an y  HPC s  a r e  in  y o u r  b lo o d  s t r e am .  B a s ed  on  p r ev io u s  r e s e a r ch  d o n e  a t  th e  D ep a r tm en t  o f  T r an s f u s io n  M ed i c in e  (DTM )  o f  N IH ,  t h e  r e su l t  o f  th i s  t e s t  a l low s  u s  to  m ak e  a  f a i r ly  a c cu r a t e  p r ed i c t io n  o f  w h e th e r  y o u  w o u ld  b e  l ik e ly  to  com p l e t e  y o u r  HP C  co l l e c t io n  w i th  a  s in g l e  ap h e r e s i s  p ro c ed u r e  o r  i f  i t  i s  l ik e ly  th a t  y o u  w o u ld  n e ed  s ev e r a l  p ro c ed u r e s .   I f  th e  DTM  d o c to r s  b e l i ev e ,  b a s ed  o n  th e  b lo o d  t e s t ,  th a t  y o u  a r e  l ik e ly  to  n e ed  a  s e co n d  d ay  o f  ap h e r e s i s ,  y o u  w o u ld  b e  g iv en  a  s in g l e  d o s e  o f  p l e r ix a f o r  o n  th a t  ev en in g ,  a lo n g  w i th  th e  f i f th  d o s e  o f  f i lg r a s t im th e  n ex t  d ay .  W e  b e l i ev e  th a t  th i s  w o u ld  g r e a t ly  in c r e a s e  y o u r  ch an c e s  o f  com p l e t in g  th e  HPC  co l l e c t io n  w i th  a  s in g l e  ap h e r e s i s .   
How  man y  p eop l e  w i l l  tak e  p a r t  in  th i s  s tud y ? 
 
A  to t a l  o f  6 0  p eo p l e  w i l l  b e  en ro l l ed  in  th i s  s tu d y .      
Wh a t  ar e  th e  e xp e r im en ta l  p ro c edu r e s? 
 
T h e r e  i s  n o  ex p e r im en t a l  p ro c ed u r e s  in  th i s  s tu d y .   T h e  ap h e r e s i s  p ro c ed u r e  h a s  b e en  w id e ly  a c c ep t ed  f o r  m an y  y e a r s  a s  th e  s t an d a rd  p ro c ed u r e  to  co l l e c t  HPC s  ( s e e  d e t a i l s  b e low ) .   
Wh a t  w i l l  h app en  i f  y ou  tak e  p a r t  in  th i s  r e s ea r ch s tud y ?  
 
T o  en t e r  th i s  s tu d y ,  y o u  w i l l  n e ed  to  u n d e rg o  b lo o d  t e s t s  an d  an  ECG  to  en su r e  th a t  y o u  c an  u n d e rg o  th e  ap h e r e s i s  p ro c ed u r e s  s a f e ly .   
MED ICAL RECORD CONT INUAT ION SHEET fo r  e i th e r :  
N IH  2514- 1 ,  C on s e n t  t o  P a r t i c i p a t e  i n  A  C l i n i c a l  R e s e a r c h  S t udy 
N IH  2514- 2 ,  M i no r  P a t i e n t ’ s  A s s e n t  t o  P a r t i c i p a t e  In  A  C l i n i c a l  R e s e a r c h  S t udy 
STUDY  NUMBER : 12-C - 0074 CONT INUAT ION :  p a g e  3  o f  10 p a g e s  
 
 
PAT IENT  IDENT IF ICAT ION CONT INUAT ION  SHEET  fo r  e i th e r : 
 N IH- 2514- 1  (10- 84 ) 
 N IH- 2514- 2  (10- 84 ) 
 P .A . :  09- 25- 0099 
 
 •  A  b lo o d  t e s t  w i l l  b e  d o n e  to  d e t e rm in e  i f  y o u  h av e  h ad  ex p o su r e  to  th e  h um an  
imm u n o d e f i c i en cy  v i ru s  (H IV )  a s so c i a t ed  w i th  th e  a cq u i r ed  imm u n o d e f i c i en cy  sy n d rom e  
(A IDS ) .   I f  y o u  a r e  in f e c t ed  w i th  H IV ,  y o u  w i l l  n o t  b e  ab l e  to  p a r t i c ip a t e  in  th i s  s tu d y .  W e  w i l l  t e l l  y o u  w h a t  th e  r e su l t s  m e an ,  h ow  to  f in d  c a r e ,  h ow  to  av o id  in f e c t in g  o th e r s ,  h ow  w e  r ep o r t  H IV  in f e c t io n ,  an d  th e  im p o r t an c e  o f  in f o rm in g  y o u r  p a r tn e r s  a t  p o s s ib l e  r i sk  b e c au s e  o f  y o u r  H IV  in f e c t io n .  
•  Y o u r  b lo o d  w i l l  b e  t e s t ed  f o r  m an y  o th e r  in f e c t io u s  ag en t s  (m o s t ly  v i ru s e s ) ,  in c lu d in g :  
H um an  T - lym p h o t ro p h i c  v i ru s ,  T .  C ru z i ,  an d  h ep a t i t i s  B  an d  C  v i ru s e s .   ABO  ty p in g  w i l l  a l so  b e  p e r f o rm ed .    
•  A p p ro x im a t e ly  4  t ab l e sp o o n s  o f  b lo o d  w i l l  b e  t ak en  f o r  th e s e  t e s t s .  Y o u  m ay  n o t  b e  a l low ed  
to  p a r t i c ip a t e  in  th i s  s tu d y  i f  y o u  t e s t  p o s i t iv e  f o r  som e  o f  th e s e  v i ru s e s .    
•  A l l  n o n -m en o p au s a l  w om en  en t e r in g  th e  s tu d y  w i l l  h av e  e i th e r  a  b lo o d  o r  u r in e  t e s t  f o r  
p r eg n an cy .  Y o u  w i l l  n o t  b e  a l low ed  to  p a r t i c ip a t e  in  th i s  s tu d y  i f  y o u  a r e  p r eg n an t ,  o r  i f  y o u  a r e  n o t  w i l l in g  to  s to p  b r e a s t  f e ed in g .  
 In  ad d i t io n  to  th e  t e s t s  l i s t ed  ab o v e ,  y o u  m ay n e ed  to  h av e  th e  f o l low in g  a s  p a r t  o f  th i s  s tu d y :   
•  In s e r t io n  o f  a  c a th e t e r  p l a c ed  in to  a  l a rg e  v e in  ( c en t r a l  v en o u s  c a th e t e r )  th a t  w i l l  r em a in  in  
p l a c e  th ro u g h o u t  th e  ap h e r e s i s  p ro c ed u r e s .   T h e  c a th e t e r  i s  p l a c ed  u n d e r  lo c a l  (o r  som e t im e s  g en e r a l )  an e s th e s i a  an d  y o u  w i l l  b e  a sk ed  to  s ig n  a  s ep a r a t e  co n s en t  f o r  th i s  p ro c ed u r e .    
•  T h e  DTM  s t a f f  w i l l  d e t e rm in e  b a s ed  o n  th e  s i z e  o f  th e  v e in s  in  y o u r  a rm s  i f  y o u  w i l l  n e ed  a  
c en t r a l  v en o u s  c a th e t e r .  
 
Aph e r e s i s  P ro c edu r e 
 
T h e  co l l e c t io n  o f  som e  o f  y o u r  ow n  w h i t e  b lo o d  c e l l s  (HPC s ) f rom  y o u r  b lo o d  i s  d o n e  th ro u g h  a  p ro c ed u r e  c a l l ed  ap h e r e s i s.   T h e  co l l e c t ed  HPC s m ay b e  s to r ed  f ro z en  f o r  th e  m o n th s  th a t  y o u  com p l e t e  y o u r  s t an d a rd  t r e a tm en t .   T h i s  p ro c ed u r e  i s  q u i t e  ro u t in e ;  n o rm a l  b lo o d  d o n o r  v o lu n t e e r s  ro u t in e ly  u n d e rg o  ap h e r e s i s  f o r  p l a t e l e t s  d o n a t io n  in  B lo o d  C en t e r s  (R ed  C ro s s  o r  o th e r s ) .  T h e  p ro c ed u r e  w i l l  t ak e  f rom  th r e e  to  f iv e  h o u r s  d u r in g  w h i ch  t im e  y o u  w i l l  h av e  to  r em a in  in  a  b ed  o r  a  r e c l in in g  ch a i r .  Y o u  d o  n o t  n e ed  to  b e  h o sp i t a l i z ed  f o r  th e  p ro c ed u r e .   H ow ev e r ,  i f  y o u  n e ed  a  c e r t a in  ty p e  o f  c en t r a l  v en o u s  c a th e t e r  an d  r eq u i r e  m u l t ip l e ap h e r e s i s  p ro c ed u r e s  to  com p l e t e  th e  HPC  co l l e c t io n ,  y o u  w o u ld  n e ed  to  s t ay  in  th e  h o sp i t a l  o v e rn ig h t  ( in  b e tw e en  th e  p ro c ed u r e s ) .   A p h e r e s i s  i s  d o n e  in  th e  N IH  B lo o d  B an k  (D ep a r tm en t  o f  T r an s f u s io n  M ed i c in e ;  DTM )  an d  i s  su p e rv i s ed  b y  B lo o d  B an k  p h y s i c i an s .   D u r in g  ap h e r e s i s ,  b lo o d  i s  r em o v ed  co n t in u o u s ly  th ro u g h  a  v e in  in  y o u r  a rm  (o r  y o u r  c a th e t e r ) ,  g o e s  th ro u g h  th e  m a ch in e  w h e r e  th e  w h i t e  b lo o d  c e l l s  a r e  s ep a r a t ed  f rom  th e  r ed  b lo o d  c e l l s  an d  p l a sm a  an d  th e  r ed  b lo o d  c e l l s  an d  m o s t  o f  p l a sm a  a r e  r e tu rn ed  co n t in u o u s ly  to  y o u  th ro u g h  th e  o th e r  l in e .     In  som e  c a s e s ,  th e  in t r av en o u s  c a th e t e r  p l a c ed  to  r e c e iv e  ch em o th e r ap y  c an  b e  u s ed  f o r  th e  ap h e r e s i s  p ro c ed u r e .   H ow ev e r ,  y o u  m ay  b e  a sk ed  to  h av e  tw o  in t r av en o u s  l in e s  p l a c ed ,  o n e  in  
MED ICAL RECORD CONT INUAT ION SHEET fo r  e i th e r :  
N IH  2514- 1 ,  C on s e n t  t o  P a r t i c i p a t e  i n  A  C l i n i c a l  R e s e a r c h  S t udy 
N IH  2514- 2 ,  M i no r  P a t i e n t ’ s  A s s e n t  t o  P a r t i c i p a t e  In  A  C l i n i c a l  R e s e a r c h  S t udy 
STUDY  NUMBER : 12-C - 0074 CONT INUAT ION :  p a g e  4  o f  10 p a g e s  
 
 
PAT IENT  IDENT IF ICAT ION CONT INUAT ION  SHEET  fo r  e i th e r : 
 N IH- 2514- 1  (10- 84 ) 
 N IH- 2514- 2  (10- 84 ) 
 P .A . :  09- 25- 0099 
 
 e a ch  a rm .   O n  o c c a s io n ,  y o u  m ay  b e  a sk ed  to  h av e  a  s in g l e ,  l a rg e r  t em p o r a ry  in t r av en o u s  l in e  
p l a c ed  in  a  v e in  in  y o u r  g ro in  u n t i l  th e  ap h e r e s i s  p ro c ed u r e  i s  f in i sh ed .    A p h e r e s i s  w i ll  b e  p e r f o rm ed  d a i ly  u n t i l  a  su f f i c i en t  n um b e r  o f  c e l l s  i s  co l l e c t ed .  Mo s t  p eo p l e  w i l l  n e ed  o n e  o r  tw o  ap h e r e s i s  to  co l l e c t  th e  d e s i r ed  c e l l  n um b e r .  T h e  m ax im um  n um b e r  o f  ap h e r e s i s  p ro c ed u r e s  to  b e  p e r f o rm ed  i s  4 .  
 
Th e  l en g th  o f  t r ea tm en t  
 
T h e  to t a l  l en g th  o f  th e  s tu d y  i s  ab o u t  o n e  w e ek b u t  d ep en d s  o n  th e  n um b e r  o f  ap h e r e s i s  p ro c ed u r e s  r eq u i r ed  to  co l l e c t  en o u g h  HPC s .  Y o u  w i l l  n e ed  to  b e  ev a lu a t ed  th e  d ay  a f t e r  th e  l a s t  a p h e r e s i s .     W h en  y o u  a r e  t ak en  o f f  th i s  p ro to co l ,  yo u r  c a r e  w i l l  r e tu rn  to  y o u r  r e f e r r in g  d o c to r  (o r  y o u r  NC I  t r e a tm en t  t e am  i f  y o u  a r e  o n  an  N IH  p ro to co l  o r  w i l l  en ro l l  o n  an o th e r  o n e ) .    P a r t i c ip a t io n  in  th i s  s tu d y  d o e s  n o t  co n s t i tu t e  an  ag r e em en t  f o r  N IH  to  p ro v id e  lo n g -t e rm  m ed i c a l  c a r e  f o r  y o u r  c an c e r  o r  o th e r  m ed i c a l  n e ed s  a t  th e  N IH C l in i c a l  C en t e r .  
R i sk s  o r  D i s com fo r t s  o f  P a r t i c ip a t ion 
 
M ed i ca t io n s  s id e s  e f f e c t s :  
M ed i c a t io n s P o s s ib l e  s id e  e f f e c t s 
 L ik e ly L e s s  L ik e ly Ra r e 
F i lg r a s t im •  B o n e  p a in ,  w h i ch  
c an  som e t im e s  b e  
s ev e r e .    
•  F a t ig u e  
•  Mu s c l e  c r am p s ,  
b a ck / l eg  p a in  •  H e ad a ch e   •  P a in  a t th e  n e ed l e  s i t e   •  f ev e r s   •  Ti r ed n e s s  •  T h in n in g  h a i r  •  Fi lg r a s t im  c an  
c au s e  ru p tu r e  o f  th e  
sp l e en ,  w h i ch  c an  c au s e  d e a th  
P l e r ix a f o r  (Mo zo b i l
®)  
 •  D i a r rh e a ,  n au s e a ,  
v om i t in g ,  f l a tu l en c e   
•  F a t ig u e ,  jo in t  p a in ,  
h e ad a ch e  an d  d i z z in e s s  
•  M i ld in j e c t io n  s i t e  
r e a c t io n s  
•  Tro u b l e  s l e ep in g  •  Hiv e s  
•  Sw e l l in g a ro u n d  th e  
ey e s  
•  S h o r tn e s s  o f  b r e a th ,  
an d  low  o x y g en  l ev e l s  
in  y o u r  b lo o d  (o c cu r r in g  ab o u t  3 0  m in u t e s  a f t e r  in j e c t io n ) •  L ow  b lo o d  p r e s su r e  
an d  f a in t in g  ( w i th in 1  h o u r  o f  in j e c t io n ) .  
 C en t ra l  V en o u s  C a th e t e r :   T h e  g en e r a l  r i sk s o f  p l a c in g  th i s  ty p e  o f  c a th e t e r  in c lu d e  b l e ed in g ,  in f e c t io n ,  b lo o d  c lo t s ,  a  h o l e  in  th e  lu n g  ( c a l l ed  p n eum o th o r ax ,  c au s in g  b r e a th in g  d i f f i cu l t i e s  an d  p o s s ib ly  r eq u i r in g  p l a c em en t  o f  a  tu b e  to  r e - in f l a t e  th e  lu n g ) ,  an d  th e  r i sk s  o f  lo c a l  o r  g en e r a l  an e s th e s i a .   
MED ICAL RECORD CONT INUAT ION SHEET fo r  e i th e r :  
N IH  2514- 1 ,  C on s e n t  t o  P a r t i c i p a t e  i n  A  C l i n i c a l  R e s e a r c h  S t udy 
N IH  2514- 2 ,  M i no r  P a t i e n t ’ s  A s s e n t  t o  P a r t i c i p a t e  In  A  C l i n i c a l  R e s e a r c h  S t udy 
STUDY  NUMBER : 12-C - 0074 CONT INUAT ION :  p a g e  5  o f  10 p a g e s  
 
 
PAT IENT  IDENT IF ICAT ION CONT INUAT ION  SHEET  fo r  e i th e r : 
 N IH- 2514- 1  (10- 84 ) 
 N IH- 2514- 2  (10- 84 ) 
 P .A . :  09- 25- 0099 
 
 Ap h e r e s i s : d i s com f o r t  a t  th e  in s e r t io n  s i t e s  o f  th e  c a th e t e r s ,  b l e ed in g ,  low  b lo o d  p r e s su r e ,  
f a t ig u e ,  n um b n e s s  o r  t in g l in g  in  th e  ex t r em i t i e s  o r  th e  f a c e .  N um b n e s s  o r  t in g l in g  th a t  y o u  m ay  ex p e r i en c e  d u r in g  ap h e r e s i s  w o u ld  b e  ex p e c t ed  to  g o  aw ay  a f t e r  th e  p ro c ed u r e .   B lo o d  in f e c t io n s  f rom  co n t am in a t io n  o f  th e  ap h e r e s i s  m a ch in e  a r e  a  r em o t e  p o s s ib i l i ty ,  b u t  th i s  h a s  n o t  o c cu r r ed  a t  th e  N IH .   In d iv id u a l s  w i th  b l e ed in g  d i so rd e r s  c an  b e  h a rm ed  b y  th i s  p ro c ed u r e  an d  y o u  w i l l  b e  ev a lu a t ed  f o r  su ch  a  co n d i t io n  b e f o r e  ap h e r e s i s  i s  d o n e .   A l l  a t t em p t s  w i l l  b e  m ad e  to  p ro t e c t  y o u  f rom  an y  com p l i c a t io n s .   R ep ro d u c t i v e  R i s k s :  I t  i s  u n k n ow n  w h a t  e f f e c t s  th i s  ex p e r im en t a l  p ro c ed u r e  m ay  h av e  o n  an  u n b o rn  ch i ld .   I f  y o u  a r e  a  w om an  w h o  i s  u nw i l l in g  to  s to p  b r e a s t -f e ed in g  o r  p r eg n an t ,  y o u  m ay  n o t  t ak e  p a r t  in  th e  s tu d y  b e c au s e  w e  d o n ’ t  k n ow  h ow  th i s  m ed i c in e  w o u ld  a f f e c t  y o u r  b ab y  o r  y o u r  u n b o rn  ch i ld .  I f  y o u  a r e  a  w om an  w h o  c an  b e com e  p r eg n an t ,  o r  a r e  th e  p a r tn e r  o f  a  w om an  w h o  c an  b e com e  p r eg n an t ,  y o u  w i l l  n e ed  to  pr a c t i c e  an  e f f e c t iv e  f o rm  o f  b i r th  co n t ro l  b e f o r e  s t a r t in g  s tu d y  ex p e r im en t a l  p ro c ed u r e ,  d u r in g  s tu d y  ex p e r im en t a l  p ro c ed u r e ,  an d  f o r  6  m o n th s  a f t e r  y o u  f in i sh  s tu d y  ex p e r im en t a l  p ro c ed u r e .   I f  y o u  th in k  th a t  y o u  o r  y o u r  p a r tn e r  i s  p r eg n an t ,  y o u  sh o u ld  t e l l  y o u r  s tu d y  d o c to r  o r  n u r s e  imm ed i a t e ly .     
E f f e c t iv e  f o rm s  o f  b i r th  co n t ro l  in c lu d e:  
•  a b s t in en c e   •  in t r au t e r in e  d ev i c e  ( IUD )  
•  h o rm o n a l  [ b i r th  co n t ro l  p i l l s ,  in j e c t io n s ,  o r  im p l an t s ]  •  tu b a l  l ig a t io n  •  v a s e c tom y  
 
O th e r  Po s s ib l e  Ha z a rd s  /  D i s com fo r t s   
 
B lo o d  sam p l in g : F o r  m ed i c a l  m an ag em en t ,  y o u  w i l l  b e  a sk ed  to  g iv e  b lo o d  s am p l e s  m u l t ip l e  
t im e s .  T h e  b lo o d  s am p l e s  ( ab o u t  1  to  5  t ab l e sp o o n s  e a ch  t im e )  a r e  n o t  ex p e c t ed  to  p ro d u c e  an y  im p o r t an t  d e c r e a s e  in  th e  to t a l  am o u n t  o f  b lo o d  in  y o u r  b o d y .   T h e s e  w i l l  b e  c o l l e ct ed  f rom  y o u r  c en t r a l  l in e  o r  b y  s im p l e  n e ed l e - s t i ck  f rom  a  v e in  in  y o u r  a rm  in  th e  s am e  f a sh io n  a s  ro u t in e  b lo o d  t e s t s .   V en ip u n c tu r e  c an  b e  a s so c i a t ed  w i th  p a in ,  b ru i s in g ,  an d  r a r e ly  b l e ed in g  o r  in f e c t io n .   A d d i t io n a l ly ,  som e  p a t i en t s  c an  ex p e r i en c e  l ig h t -h e ad ed n e s s  o r  f a in t in g  d u r in g  in s e r t io n  o f  th e  n e ed l e .   T h e  s am p l e s  co l l e c t ed  w i l l  b e  u s ed  to  b o th  to  m o n i to r  y o u r  m ed i c a l  co n d i t io n  an d  f o r  r e s e a r ch  p u rp o s e s .   T h e  to t a l  am o u n t  o f  b lo o d  w h i ch  m ay  b e  t ak en  f rom  y o u  w i l l  n o t  ex c e ed  4 5 0  m l  (o n e  p in t )  ev e ry s ix  w e ek s .   S om e  o f  th i s  b lo o d  m ay  b e  o b t a in ed  th ro u g h  ap h e r e s i s  ( s e e  ab o v e  “ ap h e r e s i s  p ro c ed u r e ” ) .   
 
P o t en t ia l  B en e f i t s  o f  P a r t i c ip a t ion 
 
C o l l e c t io n  o f  HPC s  f o r  l a t e r  u s e  in  a  t r an sp l an t  f o r  th e  t r e a tm en t  o f  y o u r  PCM .  
 
 
 
 
  
MED ICAL RECORD CONT INUAT ION SHEET fo r  e i th e r :  
N IH  2514- 1 ,  C on s e n t  t o  P a r t i c i p a t e  i n  A  C l i n i c a l  R e s e a r c h  S t udy 
N IH  2514- 2 ,  M i no r  P a t i e n t ’ s  A s s e n t  t o  P a r t i c i p a t e  In  A  C l i n i c a l  R e s e a r c h  S t udy 
STUDY  NUMBER : 12-C - 0074 CONT INUAT ION :  p a g e  6  o f  10 p a g e s  
 
 
PAT IENT  IDENT IF ICAT ION CONT INUAT ION  SHEET  fo r  e i th e r : 
 N IH- 2514- 1  (10- 84 ) 
 N IH- 2514- 2  (10- 84 ) 
 P .A . :  09- 25- 0099 
 
 A l t e rn a t iv e  T r ea tm en t s 
 
T h e  s tan d a rd  o f  c a r e  t r e a tm en t  th a t  y o u  sh o u ld  /  w i l l  r e c e iv e  f o r  y o u r  m u l t ip l e  m y e lom a  i s  n o t  p a r t  o f  th i s  s tu d y .     In s t e ad  o f  b e in g  in  th i s  s tu d y ,  y o u  h av e  th e s e  o p t io n s :  
•  G e t t in g  HPC  co l l e c t io n  f o r  th e  c a r e  f o r  y o u r  PCM  d o n e  a t  an o th e r  f a c i l i ty  w i th o u t  b e in g  
in  a  s tu d y  
•  T ak in g  p a r t  in  an o th e r  s tu d y  
 P l e a s e  t a lk  to  y o u r  d o c to r  ab o u t  th e s e  an d  o th e r  o p t io n s .    
R e s ea r ch  Sub j e c t ’ s  R igh t s 
 Wh a t  a r e  th e  co s t s  o f  tak in g  p a r t  in  th i s  s tud y ?   
 
I f  y o u  ch o o s e  to  t ak e  p a r t  in  th e  s tu d y ,  th e  f o l low in g  w i l l  ap p ly ,  in  k e ep in g  w i th  th e  N IH  p o l i cy : 
•  Y o u   w i l l   r e c e iv e   th e  s tu d y  t r e a tm en t   a t   n o   ch a rg e   to   y o u .   T h i s   m ay  
in c lu d e  m ed i c in e s   an d   l ab o r a to ry   t e s t in g d o n e   a t   th e   C l in i c a l   C en t e r ,  N a t io n a l  In s t i tu t e s  o f  H e a l th  (N IH ) .   
•  T h e r e   a r e   l im i t ed   f u n d s   av a i l ab l e   to   co v e r   th e   co s t   o f   som e t e s t s   an d  
p ro c ed u r e s  p e r f o rm ed  o u t s id e  th e  C l in i c a l  C en t e r ,  N IH .   Y o u  m ay  h av e  to   p ay   f o r   th e s e   co s t s   ev en   i f   th ey   a r e   n o t   co v e r ed   b y   y o u r   in su r an c e  com p an y .  
•  M ed i c in e s  th a t  a r e  n o t  p a r t  o f  th e  s tu d y  w i l l  n o t  b e  p ro v id ed  o r  p a id  f o r  
b y  th e  C l in i c a l  C en t e r ,  N IH . 
•  O n c e  y o u  h av e  com p l e t ed  t ak in g  p a r t  in  th e  s tu d y ,  m ed i c a l  c a r e  w i l l  n o  
lo n g e r  b e  p ro v id ed  b y  th e  C l in i c a l  C en t e r ,  N IH .  
 
W i l l  y ou r  m ed i ca l  in fo rma t ion  b e  k ep t  p r iv a t e? 
 
W e  w i l l  d o  o u r  b e s t  to  m ak e  su r e  th a t  th e  p e r so n a l  in f o rm a t io n  in  y o u r  m ed i c a l  r e co rd  w i l l  b e  k ep t  p r iv a t e .  H ow ev e r ,  w e  c an n o t  g u a r an t e e  to t a l  p r iv a cy .  O rg an i z a t io n s  th a t  m ay  lo o k  a t  an d /o r  co p y  y o u r  m ed i c a l  r e co rd s  f o r  r e s e a r ch ,  q u a l i ty  a s su r an c e ,  an d  d a t a  an a ly s i s  in c lu d e :  
•  T h e   N a t io n a l   C an c e r   In s t i tu t e   (NC I )   an d   o th e r   g o v e rnm en t   ag en c i e s ,   l ik e   th e   F o o d   an d  
D ru g  A dm in i s t r a t io n  (FDA ) ,  w h i ch  a r e  in v o lv ed  in  k e ep in g  r e s e a r ch  s a f e  f o r  p eo p l e .  
•  N a t io n a l  C an c e r  In s t i tu t e  In s t i tu t io n a l  R ev i ew  B o a rd 
 
A  d e s c r ip t io n  o f  th i s  c l in i c a l  t r i a l  w i l l  b e  av a i l ab l e  o n  h t tp : / /www .C l in i c a lT r i a l s . g o v ,  a s  r eq u i r ed  b y  U .S .  L aw .  T h i s  W eb  s i t e  w i l l  n o t  in c lu d e  in f o rm a t io n  th a t  c an  id en t i f y  y o u .  A t  m o s t ,  th e  W eb  s i t e  w i l l  in c lu d e  a  summ a ry  o f  th e  r e su l t s .  Y o u  c an  s e a r ch  th i s  W eb  s i t e  a t  an y  t im e .  
MED ICAL RECORD CONT INUAT ION SHEET fo r  e i th e r :  
N IH  2514- 1 ,  C on s e n t  t o  P a r t i c i p a t e  i n  A  C l i n i c a l  R e s e a r c h  S t udy 
N IH  2514- 2 ,  M i no r  P a t i e n t ’ s  A s s e n t  t o  P a r t i c i p a t e  In  A  C l i n i c a l  R e s e a r c h  S t udy 
STUDY  NUMBER : 12-C - 0074 CONT INUAT ION :  p a g e  7  o f  10 p a g e s  
 
 
PAT IENT  IDENT IF ICAT ION CONT INUAT ION  SHEET  fo r  e i th e r : 
 N IH- 2514- 1  (10- 84 ) 
 N IH- 2514- 2  (10- 84 ) 
 P .A . :  09- 25- 0099 
 
  
 
S topp in g  Th e rap y   
 
Y o u r  d o c to r  m ay  d e c id e  to  s to p  y o u r  th e r ap y  f o r  th e  f o l low in g  r e a so n s :  
•  i f  h e / sh e  b e l i ev e s  th a t  i t  i s  in  y o u r  b e s t  in t e r e s t  
•  i f  n ew  in f o rm a t io n  sh ow s  th a t  an o th e r  t r e a tm en t  w o u ld  b e  b e t t e r  f o r  y o u  •  I f  y o u  h av e  s id e  e f f e c t s  f rom  th e  t r e a tm en t  th a t  y o u r  d o c to r  th in k s  a r e  to o  s ev e r e •  i f  th e  s tu d y  d o c to r  d e c id e s  to  en d  th e  s tu d y  
 
I f  th i s  i s  th e  c a s e ,  y o u  w i l l  b e  in f o rm ed  o f  th e  r e a so n  th e r ap y  i s  b e in g  s to p p ed .  
 P a r t i c ip a t io n  in  th i s  r e s e a r ch  s tu d y  i s  v o lu n t a ry .   Y o u  m ay  s to p  y o u r  p a r t i c ip a t io n  in  th e  s tu d y  a t  an y  t im e .   T h e r e  a r e  n o  p en a l t i e s  f o r  w i th d r aw in g  f rom  th e  s tu d y .   H ow ev e r ,  i f  y o u  d e c id e  to  s to p  t ak in g  p a r t  in  th e  s tu d y ,  w e  w o u ld  l ik e  y o u  to  t a lk  to  th e  s tu d y  d o c to r  an d  y o u r  r eg u l a r  d o c to r  f i r s t .  I f  y o u  d e c id e  a t  an y  t im e  to  w i th d r aw  y o u r  co n s en t  to  p a r t i c ip a te  in  th e  t r i a l ,  w e  w i l l  n o t  co l l e c t   an y   ad d i t io n a l   m ed i c a l   in f o rm a t io n   ab o u t   y o u .   I f   y o u   w i th d r aw   y o u r   co n s en t   an d  l e av e  th e  t r i a l ,  an y  s am p l e s  o f  y o u r s  th a t  h av e  b e en  o b t a in ed  f o r  th e  s tu d y  an d  s to r ed  a t  th e  NC I  c an  b e  d e s t ro y ed   u p o n   r eq u e s t .   H ow ev e r ,   an y s am p l e s   an d   d a t a   g en e r a t ed   f rom  th e  s am p l e s  th a t  h av e  a l r e ad y   b e en   d i s t r ib u t ed   to   o th e r   r e s e a r ch e r s   o r   p l a c ed   in   th e   r e s e a r ch   d a t ab a s e s   c an n o t   b e  r e c a l l ed  an d  d e s t ro y ed .   
C on f l i c t  o f  In t e r e s t 
 
T h e  N a t io n a l  In s t i tu t e s  o f  H e a l th  (N IH )  r ev i ew s  N IH  s t a f f  r e s ea r ch e r s  a t  l e a s t  y e a r ly  f o r  co n f l i c t s  o f  in t e r e s t .   T h i s  p ro c e s s  i s  d e t a i l ed  in  a  P ro to co l  R ev i ew  G u id e.  Y o u  m ay  a sk  y o u r  r e s e a r ch  t e am  f o r  a  co p y  o f  th e  P ro to co l  R ev i ew  G u id e  o r  f o r  m o r e  in f o rm a t io n .  M em b e r s  o f  th e  r e s e a r ch  t e am  w h o  d o  n o t  w o rk  f o r  N IH  a r e  ex p e c t ed  to  f o l low  th e s e  g u id e l in e s  b u t  th ey  d o  n o t  n e ed  to  r ep o r t  th e i r  p e r so n a l  f in an c e s  to  th e  N IH .   M em b e r s  o f  th e  r e s e a r ch  t e am  w o rk in g  o n  th i s  s tu d y  m ay  h av e  u p  to  $ 1 5 , 0 0 0  o f  s to ck  in  th e  com p an i e s  th a t  m ak e  p ro d u c t s  u s ed  in  th i s  s tu d y .  T h i s  i s  a l low ed  u n d e r  f ed e r a l  ru l e s  an d  i s  n o t  a  co n f l i c t  o f  in t e r e s t .   
U s e  o f  Sp e c im en s  and  D a ta  fo r  Fu tu r e  R e s ea r ch 
T o  ad v an c e  s c i en c e ,  i t  i s  h e lp f u l  f o r  r e s e a r ch e r s  to  sh a r e  in f o rm a t io n  th ey  g e t  f rom  s tu d y in g  
h um an  s am p l e s .   T h ey  d o  th i s  b y  p u t t in g  i t  in to  o n e  o r  m o r e  s c i en t i f i c  d a t ab a s e s ,  w h e r e  i t  i s  s to r ed  a lo n g  w i th  in f o rm a t io n  f rom  o th e r  s tu d i e s .  A  r e s e a r ch e r  w h o  w an t s  to  s tu d y  th e  in f o rm a t io n  m u s t  ap p ly  to  th e  d a t ab a s e  an d  b e  ap p ro v ed .   R e s e a r ch e r s  u s e  sp e c im en s  an d  d a t a  s to r ed  in  s c i en t i f i c  d a t ab a s e s  to  ad v an c e  s c i en c e  an d  l e a rn  ab o u t  h e a l th  an d  d i s e a s e .    
W e  p l an  to  k e ep  som e  o f  y o u r  sp e c im en s  an d  d a t a  th a t  w e  co l l e c t  an d  u s e  th em  f o r  f u tu r e  
r e s e a r ch  an d  sh a r e  th em  w i th  o th e r  r e s e a r ch e r s .  W e  w i l l  n o t  co n t a c t  y o u  to  a sk  ab o u t  e a ch  o f  
MED ICAL RECORD CONT INUAT ION SHEET fo r  e i th e r :  
N IH  2514- 1 ,  C on s e n t  t o  P a r t i c i p a t e  i n  A  C l i n i c a l  R e s e a r c h  S t udy 
N IH  2514- 2 ,  M i no r  P a t i e n t ’ s  A s s e n t  t o  P a r t i c i p a t e  In  A  C l i n i c a l  R e s e a r c h  S t udy 
STUDY  NUMBER : 12-C - 0074 CONT INUAT ION :  p a g e  8  o f  10 p a g e s  
 
 
PAT IENT  IDENT IF ICAT ION CONT INUAT ION  SHEET  fo r  e i th e r : 
 N IH- 2514- 1  (10- 84 ) 
 N IH- 2514- 2  (10- 84 ) 
 P .A . :  09- 25- 0099 
 
 th e s e  f u tu r e  u s e s .   T h e s e  sp e c im en s  an d  d a t a  w i l l  b e  s t r ip p ed  o f  id en t i f i e r s  su ch  a s  n am e ,  ad d r e s s  
o r  a c co u n t  n um b e r ,  so  th a t  i t  m ay  b e  u s ed  f o r  f u tu r e  r e s e a r ch  o n  an y  to p i c  an d  sh a r ed  b ro ad ly  f o r  r e s e a r ch  p u rp o s e s .  Y o u r  sp e c im en s  an d  d a t a  w i l l  b e  u s ed  f o r  r e s e a r ch  p u rp o s e s  o n ly  an d  w i l l  n o t  b en e f i t  y o u .   I t  i s  a l so  p o s s ib l e  th a t  th e  s to r ed  sp e c im en s  an d  d a t a  m ay  n ev e r  b e  u s ed .   R e su l t s  o f  r e s e a r ch  d o n e  o n  y o u r  sp e c im en s  an d  d a t a  w i l l  n o t  b e  av a i l ab l e  to  y o u  o r  y o u r  d o c to r .   I t  m ig h t  h e lp  p eo p l e  w h o  h av e  c an c e r  an d  o th e r  d i s e a s e s  in  th e  f u tu r e .    
I f  y o u  d o  n o t  w an t  y o u r  s to r ed  sp e c im en s  an d  d a t a  u s ed  f o r  f u tu r e  r e s e a r ch ,  p l e a s e  co n t a c t  u s  in  
w r i t in g  an d  l e t  u s  k n ow  th a t  y o u  d o  n o t  w an t  u s  to  u s e  y o u r  sp e c im en s  an d /o r  d a t a .   T h en  an y  sp e c im en s  th a t  h av e  n o t  a l r e ad y  b e en  u s ed  o r  sh a r ed  w i l l  b e  d e s t ro y ed  an d  y o u r  d a t a  w i l l  n o t  b e  u s ed  f o r  f u tu r e  r e s e a r ch .  H ow ev e r ,  i t  m ay  n o t  b e  p o s s ib l e  to  w i th d r aw  o r  d e l e t e  m a t e r i a l s  o r  d a t a  o n c e  th ey  h av e  b e en  sh a r ed  w i th  o th e r  r e s e a r ch e r s .  
 
 
  
MED ICAL RECORD CONSENT TO PART IC IPATE IN  A CL IN ICAL RESEARCH STUDY 
•  Adu l t  P a t i e n t  o r  •  P a r e n t ,  fo r  M i no r  P a t i e n t 
STUDY  NUMBER : 12-C - 0074 CONT INUAT ION :  p a g e  9  o f  10 p a g e s  
 
PAT IENT  IDENT IF ICAT ION CONSENT TO PART IC IPATE IN  A CL IN ICAL RESEARCH 
STUDY  (Con t inua t i on Sh e e t ) 
•  Adu l t  P a t i e n t  o r •  P a r e n t ,  fo r  M i no r  P a t i e n t 
N IH- 2514- 1  (07- 09 ) 
P .A . :   09- 25- 0099  
F i l e  i n  S e c t i on  4 :   P ro t o c o l  C on s e n t 
 
 OTHER  PERT INENT  INFORMAT ION 
1 .  C on f id en t ia l i ty .   W h en  r esu l t s  o f  an  N IH  r e s e a r ch  s tu d y  a r e  r ep o r t ed  in  m ed i c a l  jo u rn a l s  o r  
a t  s c i en t i f i c  m e e t in g s ,  th e  p eo p l e  w h o  t ak e  p a r t  a r e  n o t  n am ed  an d  id en t i f i ed .   In  m o s t  c a s e s ,  th e  N IH   w i l l   n o t   r e l e a s e   an y   in f o rm a t io n   ab o u t   y o u r   r e s e a r ch   in v o lv em en t   w i th o u t   y o u r   w r i t t en  p e rm i s s io n .   H ow ev e r ,  i f  y o u  s ig n  a  r e l e a s e  o f  in f o rm a t io n  f o rm ,  f o r  ex am p l e ,  f o r  an  in su r an c e  com p an y ,  th e  N IH  w i l l  g iv e  th e  in su r an c e  com p an y  in f o rm a t io n  f rom  y o u r  m ed i c a l  r e co rd .   T h i s  in f o rm a t io n   m ig h t   a f f e c t   ( e i th e r   f av o r ab ly   o r   u n f av o r ab ly )   th e   w i l l i n g n e s s   o f   th e   in su r an c e  com p an y  to  s e l l  y o u  in su r an c e .   T h e   F ed e r a l   P r iv a cy   A c t   p ro t e c t s   th e   co n f id en t i a l i ty   o f   y o u r   N IH   m ed i c a l   r e co rd s .     H ow ev e r ,  y o u   sh o u ld   k n ow   th a t   th e   A c t   a l low s   r e l e a s e   o f   som e   in f o rm a t io n   f rom   y o u r   m ed i c a l   r e co rd  w i th o u t   y o u r   p e rm i s s io n ,   f o r   ex am p l e ,   i f   i t   i s   r eq u i r ed   b y   th e   F o o d   an d   D ru g   A dm in i s t r a t io n  (FDA ) ,   m em b e r s   o f   C o n g r e s s ,   l aw   en f o r c em en t   o f f i c i a l s ,   o r   au th o r i z ed  h o sp i t a l   a c c r ed i t a t io n  o rg an i z a t io n s .   
2 .  P o l i cy  R eg a rd in g  R e s ea r ch- R e la t ed  In ju r i e s .   T h e  C l in i c a l  C en t e r  w i l l  p ro v id e  sh o r t- t e rm  
m ed i c a l   c a r e   f o r   an y   in ju ry   r e su l t in g   f rom   y o u r   p a r t i c ip a t io n   in   r e s e a r ch   h e r e .     In   g en e r a l ,   n o  lo n g - t e rm  m ed i c a l  c a r e  o r  f in an c i a l  com p en s a t io n  f o r  r e s e a r ch - r e l a t ed  in ju r i e s  w i l l  b e  p ro v id ed  b y  th e  N a t io n a l  In s t i tu t e s  o f  H e a l th ,  th e  C l in ic a l  C en t e r ,  o r  th e  F ed e r a l  G o v e rnm en t .   H ow ev e r ,  y o u  h av e  th e  r ig h t  to  p u r su e  l eg a l  r em ed y  i f  y o u  b e l i ev e  th a t  y o u r  in ju ry  ju s t i f i e s  su ch  a c t io n .   
3 .  P a ym en t s .    T h e   am o u n t   o f   p aym en t   to   r e s e a r ch   v o lu n t e e r s   i s   g u id ed   b y   th e   N a t io n a l  
In s t i tu t e s  o f  H e a l th  p o l i c i e s .   In  g en e r a l ,  p a t i en t s  a r e  n o t  p a id  f o r  t ak in g  p a r t  in  r e s e a r ch  s tu d i e s  a t   th e   N a t io n a l   In s t i tu t e s   o f   H e a l th .    R e im b u r s em en t   o f   t r av e l   an d   su b s i s t en c e   w i l l   b e   o f f e r ed  co n s i s t en t  w i th  N IH  g u id e l in e s .   
4 .  P rob l em s  o r  Qu e s t ion s .   I f  y o u  h av e  an y  p ro b l em s  o r  q u e s t io n s  ab o u t  th i s  s tu d y ,  o r  ab o u t  
y o u r  r ig h t s  a s  a  r e s e a r ch  p a r t i c ip an t ,  o r  ab o u t  an y  r e s e a r ch - r e l a t ed  in ju ry ,  co n t a c t  th e  P r in c ip a l  In v e s t ig a to r :  J en n i f e r  K an ak ry ,  M .D . ,  B u i ld in g  1 0 ,  R o om  3 -3 1 3 2 ,  T e l ep h o n e :   2 4 0 -7 6 0 -6 1 7 2 .  I f  y o u  h av e  an y  q u e s t io n s  ab o u t  th e  u s e  o f  y o u r  sp e c im en s  o r  d a t a  f o r  f u tu r e  r e s e a r ch  s tu d i e s ,  y o u  m ay co n t a c t  th e  O f f i c e  o f  th e  C l in i c a l  D i r e c to r ,  NC I ,  t e l ep h o n e :  2 4 0 -7 6 0 -6 0 7 0 .   Y o u  m ay  a l so  c a l l  th e  C l in i c a l  C en t e r  P a t i en t  R ep r e s en t a t iv e  a t  3 0 1 -4 9 6 -2 6 2 6 .   
5 .  C on s en t  D o cum en t .   P l e a s e  k e ep  a  co p y  o f  th i s  d o cum en t  in  c a s e  y o u  w an t  to  r e ad  i t  ag a in .  
     
MED ICAL RECORD CONSENT TO PART IC IPATE IN  A CL IN ICAL RESEARCH STUDY 
•  Adu l t  P a t i e n t  o r  •  P a r e n t ,  fo r  M i no r  P a t i e n t 
STUDY  NUMBER : 12-C - 0074 CONT INUAT ION :  p a g e  10 o f  10 p a g e s  
 
PAT IENT  IDENT IF ICAT ION CONSENT TO PART IC IPATE IN  A CL IN ICAL RESEARCH 
STUDY  (Con t inua t i on Sh e e t ) 
•  Adu l t  P a t i e n t  o r •  P a r e n t ,  fo r  M i no r  P a t i e n t 
N IH- 2514- 1  (07- 09 ) 
P .A . :   09- 25- 0099  
F i l e  i n  S e c t i on  4 :   P ro t o c o l  C on s e n t 
 
  
  
COMPLETE  APPROPR IATE  ITEM (S )  BELOW : 
A . Adu l t  P a t i en t ’ s  C on s en t B . P a r en t ’ s  P e rm i s s ion  fo r  M in o r  P a t i en t . 
I  h av e  r e ad  th e  ex p l an a t io n  ab o u t  th i s  s tu d y  an d  h av e  b e en  g iv en  th e  o p p o r tu n i ty  to  d i s cu s s  i t  an d  to  a sk  q u e s t io n s .   I  h e r eb y  co n s en t  to  t ak e  p a r t  in  th i s  s tu d y .  I  h av e  r e ad  th e  ex p l an a t io n  ab o u t  th i s  s tu d y  an d  h av e  b e en  g iv en  th e  o p p o r tu n i ty  to  d i s cu s s  i t  an d  to  a sk  q u e s t io n s .   I  h e r eb y  g iv e  p e rm i s s io n  f o r  m y  ch i ld  to  t ak e  p a r t  in  th i s  s tu d y .    (A t t a ch  N IH  2 5 1 4 -2 ,  M in o r ’ s  A s s en t ,  i f  ap p l i c ab l e . )  
        
S ig n a tu r e  o f  A d u l t  P a t i en t / L eg a l  R ep r e s en t a t iv e D a t e S ig n a tu r e  o f  P a r en t ( s ) /  G u a rd i an D a t e 
  
P r in t  N am e   
P r in t  N am e 
C . Ch i ld ’ s  V e rb a l  A s s en t  ( I f  App l i cab l e ) 
T h e   in f o rma t io n   in   th e   ab o v e   co n s en t   w a s   d e s c r ib ed   to   m y   ch i ld   an d   m y   ch i ld   ag r e e s   to  
p a r t i c ip a t e  in  th e  s tu d y .  
       
S ig n a tu r e  o f  P a r en t ( s ) /G u a rd i an D a t e P r in t  N am e 
TH IS  CONSENT  DOCUMENT  HAS  BEEN  APPROVED  FOR  USE   
FROM  AUGUST  0 7 ,  2 0 1 7  THROUGH  AUGUST  0 6 ,  2 0 1 8 .  
 
        
S ig n a tu r e  o f  In v e s t ig a to r D a t e S ig n a tu r e  o f  W i tn e s s D a t e 
  
P r in t  N am e   
P r in t  N am e 
 
       